VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 25 (6-18 noviembre/2025)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el ojetivo de serle útil.

Usted puede realizar sugerencias sobre los contenidos y de esa forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en PATENTSCOPE sobre vacunas.
- Patentes más recientes en USPTO.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

Noticias en la Web

Next-Generation Therapeutics for Pandemic Preparedness – Global Perspectives

Nov 6. We are living through a time of significant change and disruption — and global health is feeling the strain. In 2025, shifts in international cooperation and public research funding have reshaped the landscape, with reduced investment in key technologies such as mRNA, which proved vital during the COVID-19 response.

When major players step back from global collaboration, the consequences ripple worldwide: progress slows, health inequities deepen, and public trust in science becomes harder to maintain. Yet in this moment of disruption lies opportunity — for science to lead through collaboration that transcends borders, sectors, and disciplines. The Pandemic Research Alliance exemplifies this approach, bringing together institutions across Australia, China, the United States and Singapore to drive innovation and cooperation in pandemic research.

As part of the third annual Pandemic Research Alliance International Symposium, the Cumming Global Centre for Pandemic Therapeutics hosted Next-Generation Therapeutics for Pandemic Preparedness: Global Perspectives, a panel discussion exploring the critical role of therapeutics in pandemic preparedness and response.

Moderated by The New York Times global health and science reporter Apoorva Mandavilli and opened by Victorian Minister for Medical Research The Honourable Danny Pearson, the session featured global leaders in medical science: Prof. Nanshan Zhong (Guangzhou Laboratory), Prof. David Ho (Columbia University), Prof. Linfa Wang (Duke-NUS Medical School), and Prof. Sharon Lewin (Doherty Institute & Cumming Global Centre for Pandemic Therapeutics). Together, they shared insights on how we can better prepare for the next pandemic.

- Learnings from COVID-19 – the need for speed, effective vaccines, therapeutics, and surveillance, and what the world should do differently next time.
- The role of governments – a call for pandemic preparedness investment on par with defence spending, and for the global scientific community to lead where political action lags.
- Equity and access – proposals for a global pandemic fund and tiered pricing models to ensure equitable access across low-, middle-, and high-income countries.
- Predictions for future pandemics – discussion on the pathogens most likely to cause the next global outbreak, and debate over whether host-targeted therapies or direct-acting antivirals will be more effective.

The discussion underscored both the urgency and opportunity for global collaboration in building a more resilient and equitable pandemic response system.

Fuente: DOHERTY INSTITUTE. Disponible en https://n9.cl/xwl915

Encouraging results from a first-in-human Phase 1 clinical trial of IAVI's Lassa vaccine candidate published in New England Journal of Medicine

Nov 6. Findings from a first-in-human, Phase 1 clinical trial of IAVI's Lassa virus (LASV) vaccine candidate published today in the New England Journal of Medicine demonstrate that one dose of the vaccine elicits robust and long-lasting immune responses and has an acceptable safety profile. IAVI, the study sponsor, is a nonprofit scientific research organization developing vaccines and antibodies for HIV, tuberculosis, and emerging infectious diseases (EIDs).

No vaccines or therapeutics are currently licensed against Lassa fever, an acute viral hemorrhagic illness caused by LASV that is responsible for thousands of deaths each year across West Africa, where the disease is endemic. LASV is included in the World Health Organization (WHO) Pathogens Prioritization framework as a priority pathogen needing urgent research and development, and a prototype pathogen for the Arenavirus family. It is also a priority target for the Coalition for Epidemic Preparedness Innovations (CEPI), which funded the clinical trial (IAVI C102). CEPI is a global partnership working to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need.

IAVI C102 enrolled 114 volunteers total from the Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL[1]) clinical trial site at Redemption Hospital, which is a Liberian Ministry of Health facility, as well as from Brigham and Women's Hospital, East-West Medical Research Institute, and George Washington University School of Medicine and Health Sciences in the U.S. Volunteers were randomized to receive the vaccine candidate rVSVΔG-LASV-GPC* at one of four dose levels or placebo and then monitored for 12 months post-vaccination to assess vaccine safety and induced immune responses. Investigation of immune responses in study participants was conducted by scientists based at Imperial College London, UK.

Responses activating both branches of the immune system (humoral and cellular) were detected across all dose levels up to 12 months post-vaccination. Importantly, antibodies induced by vaccination were cross-reactive to other LASV lineages known to circulate across West Africa, signaling the potential for broad protection from a single vaccine. No vaccine-related serious adverse events and no cases of hearing loss – a known risk of LASV infection – were reported during this study.

- IAVI's Lassa vaccine candidate rVSVΔG-LASV-GPC has an acceptable safety profile and elicits durable immune responses.
- Phase 1 data builds on promising preclinical results and supports the conduct of an ongoing Phase 2 clinical trial in West Africa.
- Findings are consistent with previous studies of a similarly constructed licensed Ebolavirus vaccine.

"These encouraging results add to a growing body of evidence that demonstrates the safety and immunogenicity of IAVI's single-dose Lassa vaccine candidate and further establishes IAVI and our network of partners as a leading force in the development of a vaccine to prevent future Lassa

outbreaks," said Swati Gupta, DrPH, MPH, Vice President and head of emerging infectious diseases and epidemiology, IAVI. "A vaccine is urgently needed as shifting patterns in climate, migration, and human-animal interaction may expand Lassa's footprint across West Africa and even further afield. As a nonprofit product development partnership, IAVI is committed to addressing this unmet medical need together with local governments, communities, funders, and other experts with aligned global health priorities."

"Lassa fever is a cruel disease which has plagued West Africa for decades, including a deadly outbreak in Nigeria this year," said Dr. Kent Kester, Executive Director of Vaccine R&D at CEPI. "The promising Phase 1 data for IAVI's vaccine candidate takes us one step closer towards a much-needed Lassa fever vaccine which, if successful, could save thousands of lives and avert millions of dollars of societal costs in the West African countries that bear the burden of this disease."

Dr. Mark Kieh, Principal Investigator at the PREVAIL Redemption site said, "The development of a vaccine to prevent Lassa fever will provide much needed relief to our communities impacted by the virus."

Researchers previously reported strong and durable immune responses to VSVΔG-LASV-GPC in preclinical evaluations. Based on the strength of available preclinical and Phase 1 clinical data, rVSVΔG-LASV-GPC has since advanced to an ongoing IAVI-sponsored Phase 2a clinical trial, supported by CEPI, in West Africa, and is currently the most advanced LASV vaccine candidate in the clinical development pipeline. rVSVΔG-LASV-GPC uses the same recombinant vesicular stomatitis virus, or rVSV, vector platform as ERVEBO®, Merck's single-dose vaccine against Ebolavirus, which is licensed in more than a dozen countries and has been extensively used in adults and children during Ebola outbreaks.[2] The rVSV platform underpins IAVI's broader EID vaccine development portfolio.

IAVI and members of the global Viral Hemorrhagic Fever Consortium have been collaborating since 2018 to accelerate clinical development of rVSVΔG-LASV-GPC, in studies supported and funded by CEPI and the European & Developing Countries Clinical Trials Partnership (EDCTP). Clinical evaluation of rVSVΔG-LASV-GPC is also supported by PREVAIL, a Liberia-U.S. clinical research collaboration established in 2014 by the U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases and the Liberian Ministry of Health.

In September 2025, West African Ministers of Health and the West African Health Organization held high-level talks at the Lassa fever International Conference in Abidjan, Côte d'Ivoire. There they endorsed a communiqué that reaffirmed their political endorsement of accelerating Lassa fever vaccine readiness as a regional strategic health priority and a cornerstone of pandemic preparedness.

They committed to supporting the development of IAVI's Lassa vaccine candidate through a collaborative co-funding approach and joint action to mobilize and secure resources through advocacy and regional coordination.

IAVI is committed to advancing the rVSVΔG-LASV-GPC vaccine to licensure and to ensuring affordable access should the vaccine be shown to be safe and efficacious in clinical trials.

*rVSVΔG-LASV-GPC is based on an attenuated, or weakened, strain of vesicular stomatitis virus (VSV) that has been modified to express a Lassa virus protein that plays an essential role in establishing viral infection.

Fuente: IAVI. Disponible en https://n9.cl/f1zuxb

Scientists develop first vaccine in 100 years for world's deadliest disease

Nov 8. TB remains to claim more than one million lives annually, hitting hardest in low-income countries where access to advanced antibiotics continues to be scarce or inaccessible. The bacteria's evolving resistance to available treatments has made respiratory infections the main reason for infectious deaths globally. Currently, scientists may be nearing the development of a latest vaccine to fight against tuberculosis (TB), one of the world's deadliest illnesses.

Long Road Since the BCG Vaccine

Over a century ago, the Bacillus Calmette-Guérin (BCG) vaccine significantly minimized TB cases in the U.S., from almost 80,000 each year to just a few hundred within decades. Though still used widely, BCG's protection is strongest in children and tends to reduce in adulthood, mainly in countries with elevated TB cases.

Researchers at the Massachusetts Institute of Technology (MIT) are in the phase of creating a next-generation vaccine that targets proteins produced by Mycobacterium tuberculosis, the bacteria responsible for TB.

Modern Approach to an Ancient Threat

The MIT group exposed human phagocytes, white blood cells that defend the body by engulfing harmful microbes, with M. tuberculosis. From there, they extracted MHC-II proteins from the cell surfaces and found short chains of amino acids, or peptides, that bind tightly to them.

Their findings disclosed that 24 peptides are capable of triggering an immune response from T cells, which aids the body detect and destroy infected cells. Although no single peptide activated T cells in each test, scientists believe that a combination vaccine that has many of these peptides could offer strong, broad protection for most individuals.

Bryan Bryson, an associate professor of biological engineering at MIT and a member of the Ragon Institute of Mass General Brigham in Boston, stated: "There's still a huge TB burden globally that we'd like to make an impact on."

"What we've tried to do in this initial TB vaccine is focus on antigens that we saw frequently in our screen and also appear to stimulate a response in T cells from people with prior TB infection."

Changing Face of Tuberculosis

While TB currently impacts only a few thousand Americans each year causing nearly 500 deaths—it continues to be devastating in developing nations, where it kills roughly 1.2 million people annually.

In the U.S., TB rates reduced constantly from 1993 until 2020, when they struck an all-time low of 7,170 cases. But following the pandemic, cases started climbing again, being 10,347 in 2024, an 8% rise from the year before and the highest since 2011.

The demographics of TB have also changed. Since 2001, the Centers for Disease Control and Prevention (CDC) has cited that more cases among non-U.S.-born residents than those born domestically, indicating that global travel and migration has a significant role in transmission trends.

Why Developing a New Vaccine Is So Difficult

Globally, TB prevention still depends on the BCG vaccine, launched in 1921. Since then, no fresh vaccines have received approval. One reason is the sheer complexity of M. tuberculosis, which offers over 4,000 proteins—making it riskier to determine which ones give a powerful immune response.

Fuente: THE ECONOMIC TIMES. Disponible en https://n9.cl/jkkg1u

Nicaragua inicia producción local de vacuna contra COVID-19

8 nov. El Instituto Latinoamericano de Biotecnología Mechnikov, con sede en Managua, Nicaragua, fabrica la vacuna contra la enfermedad del nuevo coronavirus (COVID-19) Convacell, desarrollada en cooperación con Rusia, informó el viernes el Gobierno.

Durante un recorrido por la institución, la ministra nicaragüense de Salud, Meyling Brenes, detalló que el personal del Instituto está a cargo del llenado, envasado y empaque del inmunizante, que será liberado para uso en Nicaragua con una producción de 4,5 millones de dosis en la primera etapa.

Según el Instituto Mechnikov, Convacell posee un diseño de biológico universal aplicable frente a diferentes variantes del virus que causa la COVID-19, lo que le ha permitido aplicarse con buenos resultados en Nicaragua desde 2023.

La ministra resaltó que la planta, la única con un antigripal precalificado por la Organización Mundial de la Salud (OMS) en Centroamérica, «está equipada con alta tecnología» y cumple estándares de calidad para fabricar un bilógico «completamente seguro».

«Tienen una sistematicidad de todos los procesos que están altamente controlados, que tienen certificaciones y, hemos podido observar, que reciben periódicamente también visitas de autoridades reguladoras», resaltó Brenes, al tiempo que felicitó al equipo conformado en su mayoría por especialistas nicaragüenses.

La funcionaria reconoció que el país ha logrado ampliar su cobertura de inmunización y ha fortalecido el acceso a vacunas a precios asequibles gracias a la cooperación con la Federación de Rusia.

«Esto nos permite tener una mayor cobertura en vacunación», reiteró.

El Instituto Mechnikov fue inaugurado en octubre de 2016 como parte de un proyecto conjunto entre Nicaragua y Rusia para investigar, desarrollar, producir y comercializar vacunas y fortalecer la autosuficiencia sanitaria regional. Desde entonces, colabora con el Ministerio de Salud en la fabricación y suministro de vacunas utilizadas en las campañas nacionales de inmunización.

Fuente: La Nación. Disponible en https://n9.cl/xacsw

Vacunas de ARNm contra Covid-19: ¿una nueva herramienta para potenciar la inmunoterapia oncológica?

10 nov. Publicado en *Nature* el 22 de octubre de 2025, un trabajo multicéntrico sugiere que las vacunas de ARNm contra SARS-CoV-2 podrían tener un efecto inesperado: sensibilizar tumores para que actúe mejor la inmunoterapia. En modelos animales y en cohortes de pacientes con cáncer de pulmón y melanoma, la combinación de vacunación reciente y tratamiento inmunoterapéutico se asoció a mayor supervivencia.

- En los últimos 20 años las inmunoterapias mejoraron el tratamiento de un gran número de pacientes con cáncer. Gracias al uso de distintas moléculas como anticuerpos monoclonales, se logra operar a distintos niveles del sistema inmune para mejorar la respuesta a las células tumorales.
- La inmunoterapia con inhibidores del punto de control inmunitario libera un freno clave del sistema inmune, pero no funciona en todos los pacientes.
- PD-L1 es una molécula que apaga a los linfocitos T para prevenir que ataquen a estructuras propias. Muchas células tumorales expresan este tipo de moléculas para evadir al sistema inmune.
- Los tumores “fríos” expresan poco PD-L1 y no responden bien a inmunoterapia. Lo contrario sucede con los tumores “calientes”.
- En una investigación publicada en Nature, encontraron que las vacunas de ARNm contra SARS-CoV-2 inducen una potente respuesta de interferón tipo I.
- Ese impulso inmune aumenta la presentación de antígenos tumorales y la infiltración por linfocitos T.
- Además, se vio que las células tumorales elevan su expresión de PD-L1, creando un blanco para los ICI.
- En pacientes con cáncer de pulmón y melanoma, la vacunación reciente se asoció a mayor supervivencia global.
- El hallazgo abre un nuevo campo de investigación: usar vacunas de ARNm como adyuvantes para convertir tumores fríos en sensibles a inmunoterapia.

El cáncer y la carrera por despertar al sistema inmune

En las últimas 2 décadas, la oncología vivió una auténtica revolución con la llegada de la inmunoterapia.

Esta estrategia no busca atacar directamente a la célula tumoral con quimioterapia o radiación, sino “despertar” al propio sistema inmune del paciente para que sea él quien reconozca y destruya al cáncer.

El corazón de esta revolución son los inhibidores de puntos de control inmunitario (ICI). Se trata de anticuerpos monoclonales dirigidos contra moléculas como PD-1, PD-L1 o CTLA-4, que normalmente funcionan como "frenos" de los linfocitos T.

Al bloquear esos frenos, los ICI permiten que los linfocitos se mantengan activos contra las células tumorales.

El problema: los tumores "fríos"

¿Por qué falla la inmunoterapia en tantos pacientes? El obstáculo principal es el tipo de microambiente tumoral.

Los oncólogos hablan de "tumores calientes" y "tumores fríos":

Los tumores calientes son ricos en infiltrado de linfocitos T, expresan PD-L1 y muestran inflamación preexistente. Estos responden mejor a los ICI.

Los tumores fríos, en cambio, tienen muy pocas células inmunes en su interior, baja expresión de PD-L1 y un entorno fuertemente inmunosupresor. Allí, el sistema inmune no logra siquiera "ver" al tumor, y por eso los ICI no tienen sobre qué actuar.

Convertir un tumor frío en caliente es uno de los grandes desafíos actuales de la inmunooncología.

¿Qué es PD-L1 y por qué es tan importante?

PD-L1 (programmed death-ligand 1) es una proteína que se encuentra en la superficie de muchas células, incluidas las tumorales.

Su función fisiológica es la de un "mecanismo de seguridad": cuando PD-L1 se une a su receptor PD-1 en los linfocitos T, envía una señal de "alto" que apaga la respuesta inmune.

En condiciones normales, esto evita que el sistema inmune ataque tejidos propios y ayuda a controlar inflamaciones excesivas.

En el cáncer, las células tumorales explotan este mecanismo: expresan grandes cantidades de PD-L1, engañando a los linfocitos T para que no los ataquen.

Por eso, la cantidad de PD-L1 que expresa un tumor se volvió un biomarcador central: cuanto más PD-L1, más probable es que el tumor responda a un inhibidor de PD-1 o PD-L1, porque hay un freno que puede bloquearse.

El desafío es que muchos tumores fríos apenas expresan PD-L1. Allí los ICI solos fracasan, porque no hay freno que liberar.

Una idea inesperada: las vacunas contra el coronavirus

En este contexto, el estudio publicado en *Nature* propone un hallazgo sorprendente: las vacunas de ARNm contra el SARS-CoV-2, desarrolladas para la pandemia, pueden actuar como moduladores inmunológicos que "encienden" al sistema inmune y hacen que los tumores fríos se vuelvan más sensibles a la inmunoterapia.

La clave es que, tras la vacunación, se produce un pico muy marcado de interferón tipo I, que activa células dendríticas y macrófagos, aumentando la presentación de antígenos, incluidos los tumorales, y despertando linfocitos T.

El resultado es doble:

1. Más linfocitos CD8+ entran en el tumor.

2. Las propias células tumorales aumentan su expresión de PD-L1, creando el escenario perfecto para que

los ICI tengan dónde actuar.

Evidencia en modelos preclínicos

En ratones con melanoma o carcinoma de pulmón, la combinación de vacuna de ARNm + ICI redujo significativamente el crecimiento tumoral en comparación con ICI solo o vacuna sola. Cuando se bloqueó el receptor de interferón tipo I (IFNAR1), el efecto desapareció.

Se observó:

- Activación de células presentadoras de antígenos.
- Expansión de linfocitos CD8+ específicos de antígenos tumorales.
- Aumento de PD-L1 en células tumorales.
- Infiltración tumoral densa por linfocitos CD8+.

Evidencia en humanos

El análisis retrospectivo en varios cientos de pacientes tratados con ICI mostró:

En cáncer de pulmón no microcítico, o NO células pequeñas (NSCLC): los vacunados en los 100 días previos al inicio de la inmunoterapia tuvieron una mediana de supervivencia de 37.3 meses, frente a 20.6 meses en los no vacunados (HR 0.51). Estos fueron 180 versus 704 pacientes respectivamente.

Melanoma metastásico: en 37 pacientes vacunados en los 100 días previos, también se observó mejor supervivencia global y mayor tiempo libre de progresión en vacunados (40 versus 27 meses).

Cohorte ampliada de distintos tumores: la vacunación reciente se asoció a mejor supervivencia, incluso en tumores con baja expresión de PD-L1.

¿Cuáles son las implicancias de estos hallazgos?

Para los pacientes, todavía no es una indicación clínica. Falta validación en ensayos controlados.

Para los investigadores, abre la puerta a usar vacunas de ARNm como “adyuvantes universales” que eleven la concentración de PD-L1 y conviertan tumores fríos en calientes.

Para la práctica futura, el aprovechar plataformas ya aprobadas y seguras podría acelerar la incorporación de esta estrategia.

Las conclusiones: ¿qué nos deja este estudio?

Este trabajo muestra que una intervención tan común como una vacuna de ARNm contra SARS-CoV-2 puede modificar el microambiente tumoral y mejorar la eficacia de los ICI.

El mecanismo pasa por un aumento de interferón tipo I, la activación inmune, la infiltración de linfocitos T y, de manera central, por el aumento de la expresión de PD-L1, la proteína que define la sensibilidad a los inhibidores de PD-1/PD-L1.

Aunque preliminar, el mensaje es claro: podemos repensar el rol de las vacunas de ARNm más allá de la infectología, como catalizadores de la inmunoterapia en oncología.

Fuente: Infomed. Disponible en https://n9.cl/ieda1

Cuba continues vaccination campaign against the human papillomavirus

Nov 11. Approximately 4,000 nine-year-old girls will be immunized in the eastern province of Holguin in the coming days with the Cecolin vaccine for the prevention of the human papillomavirus (HPV).

The campaign began on Monday at vaccination centers set up in schools, polyclinics, and certified outlying areas, after being postponed due to conditions related to Hurricane Melissa's passage through the region.

Geanela Cruz, director of the Provincial Center for Hygiene, Epidemiology, and Microbiology, emphasized to the Cubna News Agency the prior training of medical and educational personnel for administering the vaccine, which will be part of the National Immunization System starting in 2025.

She indicated that Cecolin, of Chinese origin, is safe and no adverse reactions or interactions with other antigens have been reported, although the girls' condition will be monitored for one hour at the vaccination centers, and again at 24, 48 hours, and seven days by their family doctor and nurse.

The expert added that two fundamental steps in administering the drug are a prior medical examination and informed parental consent.

Therefore, it is essential to raise family awareness about its importance in preventing cervical cancer, one of the leading causes of death in Cuba. Cecolin uses recombinant technology, meaning it does not contain HPV viral DNA.

It is administered in approximately 194 countries with high efficacy and safety and is certified for use by the World Health Organization.

Human papillomavirus (HPV) is a sexually transmitted infection caused by unprotected sex. It causes lesions in genital, anal, or oral areas and cellular changes that can trigger different types of cancer.

There are more than 630,000 new cases annually, representing five percent of all diagnoses, according to the World Health Organization.

In Cuba, a broad health promotion campaign is also underway, including talks in schools, dissemination of messages through the media, and distribution of informational brochures aimed at preventing HPV.

Fuente: Cuban News Agency ACN. Disponible en https://n9.cl/9tinu

Imperial and GSK extend collaboration to tackle global vaccine cold-chain limits

Nov 11. The initial 12-month validation study has delivered outstanding results, demonstrating successful long-term stabilisation of mRNA vaccines at room temperature. Building on these findings, GSK has renewed its commitment to find accessible technologies for Global Health, funding an additional year of development. This extension will focus on advancing in vivo testing of GSK's mRNA vaccines encapsulated in revolutionary thermostable lipid nanoparticles, developed by Professor Rongjun Chen's research group at Imperial College London's Department of Chemical Engineering.

Advancing vaccine innovation through strategic partnership

The extended collaboration will rigorously evaluate the safety, *in vivo* potency, and long-term storage stability of these innovative nanoparticle formulations encapsulating mRNA of interest at temperatures up to 40°C, conditions typical of tropical climates. This work has the potential to transform vaccine accessibility in low-income countries that frequently lack the infrastructure necessary for traditional cold-chain storage systems.

"This extension represents a crucial step towards our shared vision of making life-saving vaccines accessible to populations worldwide."

Rongjun Chen Professor, Department of Chemical Engineering.

"The success of our initial collaboration with GSK has exceeded our expectations," commented Professor Rongjun Chen, Professor of Biomaterials Engineering at Imperial College London. "This extension represents a crucial step towards our shared vision of making life-saving vaccines accessible to populations worldwide, regardless of geographical or infrastructural constraints."

Thermostable mRNA delivery technology inspired by nature

The virus-inspired nanoparticle technology, developed within Imperial's Future Vaccine Manufacturing Research Hub, mimics natural viral mechanisms to protect and deliver mRNA vaccines effectively while maintaining stability at ambient and tropical temperatures. Unlike conventional mRNA vaccines that require storage at temperatures as low as -80°C, these advanced formulations can maintain potency for extended periods at room temperature and beyond.

This technological advancement addresses one of the most significant barriers to global vaccine deployment, the cold chain, which typically accounts for up to 80% of vaccination costs and creates insurmountable logistical challenges in resource-limited settings.

Global impact potential

The implications of this technology extend far beyond individual vaccines. Successfully eliminating cold-chain requirements could revolutionize how vaccines are distributed globally, particularly benefiting underserved populations in tropical and remote regions where maintaining ultra-cold storage is impossible or prohibitively expensive. This aligns closely with GSK's commitment to change the trajectory of high burden infectious diseases in lower income countries, not only by developing new prevention and treatment options, but also by helping to improve access to life-saving innovations and interventions in the communities that need them most.

"We're proud to extend our commitment with Imperial College London to help advance thermostable mRNA vaccine technology."

Thomas Breuer Chief Global Health Officer, GSK

"This partnership highlights the strength in collaboration between academia and industry," said Thomas Breuer, Chief Global Health Officer, GSK. "We're proud to extend our commitment with Imperial College London to help advance thermostable mRNA vaccine technology, which could help overcome cold-chain barriers and in turn expand access to innovations in lower-income countries and beyond."

Research excellence foundation

The technology stems from research conducted within Imperial's Future Vaccine Manufacturing Research Hub, supported by funding from the Department of Health and Social Care using UK Aid funding and managed by the Engineering and Physical Sciences Research Council (EPSRC). This foundation underscores the UK's commitment to developing solutions for global health challenges.

The extended partnership builds upon Professor Chen's internationally recognized expertise in biomaterials engineering and his laboratory's track record of developing bio-inspired delivery systems. The research has garnered multiple awards, including the IChemE Global Team Award and Imperial College President's Award for Outstanding Research Team.

Looking forward

As the partnership enters its second phase, the focus will shift from proof-of-concept to comprehensive validation studies that could help pave the way for regulatory approval and eventual global deployment.

This collaboration represents more than a technological advancement - it embodies a commitment to health equality and the belief that geographical location should not determine access to life-saving vaccines. As the world continues to face emerging infectious disease threats, innovations like these thermostable nanoparticle systems may prove essential for rapid, equitable vaccine deployment.

Fuente: IMPERIAL. Disponible en https://n9.cl/c7dva2

Takeda says dengue vaccine provides yearslong protection

Nov 13. Takeda's dengue vaccine demonstrated strong protection against infection and hospitalization for up to 7 years, findings shared by the company showed.

The company reported data from the phase 3 TIDES trial, which assessed the vaccine — marketed as Qdenga — among more than 20,000 healthy children and adolescents in eight dengue-endemic countries in Latin America and Asia.

- Qdenga offered protection against all four dengue serotypes for 7 years, Takeda said.
- The vaccine is not available in the U.S. and Takeda has no immediate or additional next steps planned at this time.

Qdenga is authorized for use in 41 countries and is the only remaining dengue vaccine available for broad use globally, although it is not approved in the United States.

In 2023, Takeda voluntarily withdrew its application to the FDA over data the agency said were missing from the application. According to David Hamer, MD, co-core lead on climate change and emerging infectious diseases at Boston University's Center on Emerging Infectious Diseases, the concern was that the vaccine did not provide adequate protection against dengue serotypes 3 and 4.

"They just didn't have enough data," Hamer told Healio recently.

But in a press release announcing the new findings from TIDES, Takeda said the vaccine was efficacious against all four dengue serotypes through 7 years. A Takeda spokesperson told Healio there are no "immediate or additional next steps" planned regarding Qdenga's biologics license application to the FDA, although its investigational new drug application is still open and being maintained.

"While we do not have further updates to share on our regulatory plans in the U.S., keeping the investigational new drug application open allows us to continue conversations with FDA on potentially bringing Qdenga to the U.S. market," the spokesperson said.

US has no vaccine

WHO estimates that half of the world's population is at risk for dengue. In the U.S., outbreaks are mostly associated with tropical territories, including Puerto Rico and the U.S. Virgin Islands, although a few states also see locally acquired cases, including California, Florida and Texas, which all reported local cases last year.

The U.S. does not currently have an available approved dengue vaccine. The only one ever approved by the FDA was Dengvaxia, which Sanofi Pasteur has stopped making because of a lack of demand.

The remaining stock will expire next August, and because the vaccine is given in three shots over the course of a year, the time to start the series has passed.

'Longest-studied dengue vaccine'

TIDES data reported by Takeda showed that Qdenga prevented virologically confirmed dengue in 61.2% (95% CI, 56%-65.8%) of study participants 4.5 years after dosing. A booster dose given at the 4.5-year mark increased the vaccine's efficacy to 74.3% (95% CI, 66.7%-80.1%) after 2 years.



Qdenga was 61% effective at 4.5 years, which increased to 74% 2 years after a booster dose. Image: Adobe Stock

Qdenga also reduced the prevalence of dengue-related hospitalization, with an 84.1% (95% CI, 77.8%-88.6%) vaccine efficacy at 4.5 years. This efficacy remained high at 90.6% (95% CI, 78.9%-95.8%) after a booster dose.

"Qdenga is now the longest-studied dengue vaccine to date and the only approved dengue vaccine for use regardless of prior disease exposure, providing another valuable option to help reduce the growing burden of disease," the Takeda spokesperson said.

"Qdenga's ability to provide sustained protection without a booster dose is an important factor in public health planning and may offer advantages such as improving vaccination adherence and simplifying administration of the vaccine, especially in public health settings," they said.

Fuente: HEALIO. Disponible en https://n9.cl/75xp7

What it takes to build vaccine manufacturing capacity in emerging markets

Nov 15. Rwanda is progressively emerging as a hub for vaccine research and manufacturing in Africa, by building the expertise, infrastructure, and regulatory systems needed to produce vaccines locally.

Dr. Jerome Kim, the Director General of International Vaccine Institute (IVI), an organization focused on developing vaccines for global health, spoke to The New Times about the country's progress, the challenges of developing vaccines in low- and middle-income countries, and how Rwanda is preparing to meet international standards for production and regulation.

Dr. Kim, could you tell us who you are and what the International Vaccine Institute's mission is?

My name is Jerome Kim. I am the Director General of International Vaccine Institute, the only international organization fully dedicated to developing vaccines for global health. Our mission is to discover, develop, and deliver safe, effective, and affordable vaccines, and, more recently, to support vaccine equity and security.

My background is in infectious diseases. I started in HIV vaccine research, but over the years I have worked across laboratory science, clinical trials, vaccine policy, and manufacturing.

Can you explain the purpose of the recent IVI's joint symposium with University of Rwanda and how it contributes to vaccine development for the region?

We are in Rwanda for meetings with the Ministry of Health and the IVI Board of Trustees. When the board meeting was confirmed, we added a joint symposium with the University of Rwanda to advance health through research and innovation. Several IVI staff members are affiliated with the university as faculty members, and since it has been two years since our last symposium, this was a perfect moment to hold another.



Our board is made up of representatives from countries that fund IVI, two non-funding member countries, including Rwanda, represented by Professor Leon Mutesa, and 10 at-large members with backgrounds in finance, the pharmaceutical industry and global health. These include people like Helen Rees, the former chair of the WHO committee that issues global vaccine recommendations, and Seth Berkley, the former CEO of Gavi, along with senior figures from vaccine companies and main financial institutions.

Our job is to bring all these perspectives together around a single mission of developing vaccines that large companies won't pursue because the markets are in low- and middle-income countries and the profit margins are low. Big companies innovate incredibly well, but they can't justify investing heavily in products that won't generate large returns.

IVI fills that gap by advancing innovations for diseases that affect poorer countries and moving them all the way to licensure and global use, cholera being a good example.

How is IVI's regional office in Rwanda helping to build local vaccine expertise and capacity? And what did the symposium show about the country's potential for vaccine development?

When IVI sets up a regional office, we work to build strong relationships with government, universities, and industry.

The goal is to strengthen vaccine expertise in the country, support industry growth, and train the people who will eventually run research programmes, clinical trials, and manufacturing sites.

After COVID-19, everyone was talking about vaccine manufacturing. Building a factory is not the hard part; training the people who will work in it, and the scientists who will create the products for that factory, is the real challenge.

Without that human capacity, a factory doesn't mean much, and Rwanda understands this well.

The symposium was part of that long-term engagement, explaining what it takes to move a vaccine from laboratory concept, through animal studies, and clinical trials, to regulatory approval and finally WHO prequalification, which is what allows UNICEF and other UN agencies to procure it. This week's discussions also noted progress in Africa. South Africa, for example, is now testing the first oral cholera vaccine ever manufactured on the continent, produced by BioVac, using technology we transferred from IVI. If their vaccine matches the Korean version, it will be the first successful vaccine manufacturing technology transfer to Africa since the 1930s. That would be a great step toward closing the global shortage of oral cholera vaccine.

Board members also toured Rwanda's health intelligence center and were impressed by its advanced digital integration, including real-time vaccination data, disease alerts, ambulance routing, and drone deliveries.

They said openly that such systems don't exist in the U.S., Europe, or even Korea. Seeing Rwanda's capabilities firsthand boosted their confidence that vaccine development and manufacturing can succeed here.

How will IVI's Africa regional office in Rwanda benefit the country and the region?

Let me use Korea as an example. When IVI was founded in Seoul in 1997, Korea had very little biotech capacity. By 2010, during the H1N1 (swine flu) pandemic, Korea still relied on imported vaccines. At one point, the U.S. government told Korea that if supplies became tight, the U.S. could legally confiscate Korean-purchased doses because they were manufactured in the U.S. That was a wake-up call.

We helped Korea design a long-term plan to become 80 percent self-sufficient in vaccines and a top-five global manufacturer by 2030. It involved advancing research, building small-scale manufacturing facilities for clinical-trial materials, setting up a funding system to support companies through "the valley of death," and training people at every step. Korea is now halfway there and continues to grow.

For Rwanda, the approach is similar but tailored; we didn't ask the government for funding. But we asked for a partnership to attract outside resources, develop skilled people, and build the scientific and regulatory capabilities needed for independent vaccine development. Rwanda's leadership on this has been very strong.

One example is Achieve Africa, a new $100 million initiative for African-led HIV vaccine research. When the original USAID programme collapsed, we worked with African partners to rebuild it from scratch. Professor Drew Weissman, who won the Nobel Prize for mRNA technology, committed $50 million in funding plus open IP access for low- and middle-income countries.

Rwanda was one of the first countries to commit matching funds, followed by Zambia and Nigeria, with others on the way. The project headquarters will be here in Kigali. This is the model of African leadership, African ownership, and African scientific direction that everyone has talked about for years, now finally happening.

What steps is Rwanda taking to build the expertise, facilities, and regulatory capacity needed to develop and produce vaccines locally?

Vaccine development is a long chain, and discovery is only the beginning. You need facilities for high-quality animal testing, small-scale manufacturing that meets international standards, and trained clinical trial teams.

You need regulators who understand novel vaccine platforms, and funding to move products from one phase to the next. You also need a decision-making pathway. WHO's advisory group, SAGE (Strategic Advisory Group of Experts on Immunization), reviews all new vaccines and recommends whether countries should use them. Rwanda needs to be ready to generate the kind of data that SAGE and other regulators require.

Human capacity is the biggest need, but the good news is that we already run the main training programmes. IVI hosts the WHO Global Training Hub for Biomanufacturing, funded by Korea.

So far, 1,000 people from around the world have completed its two- and three-week intensive courses. Graduates then train further at the mRNA hub in South Africa, learning from an operating mRNA manufacturing facility.

Fuente: The New Times. Disponible en https://n9.cl/cxtmp

Participa el CECMED en la segunda Reunión Regional OMS/OPS/MPP de Investigación y Desarrollo de la Plataforma de ARNm en las Américas

17 nov. Sesiona la segunda Reunión Regional OMS/OPS/MPP de Investigación y Desarrollo de la Plataforma de ARNm en las Américas, en Brasilia, los días 17 y 18 de noviembre de 2025.

La delegación cubana, integrada por la directora del CECMED, MSc. Olga Jacabo Casanueva, el Dr. Vicente Vérez Bencomo y Dra. Sonsire Fernández Castillo, ambos del Instituto Finlay de Vacunas, participa en esta importante reunión regional.

Este encuentro reúne a científicos, expertos de centros de investigación, fabricantes, reguladores y representantes de la OPS y la OMS para intercambiar conocimientos y avanzar en el desarrollo de la plataforma de ARNm, una herramienta clave para asegurar la calidad, la seguridad y la eficacia de los productos médicos.

La colaboración internacional sigue siendo fundamental para fortalecer la investigación y el desarrollo de tecnologías innovadoras que beneficien a las poblaciones en las Américas.

Fuente: CECMED. Disponible en https://n9.cl/j6mbn

VacciMonitor es una revista dedicada a la vacunología y temas afines como Inmunología, Adyuvantes, Infectología, Microbiología, Epidemiología, Validación, Aspectos regulatorios, entre otros. Arbitrada, de acceso abierto y bajo la Licencia *Creative Commons* está indexada en:

Síganos en redes sociales

@vaccimonitor

@finlayediciones

Artículos científicos publicados en Medline

Filters activated: (vaccine[Title/Abstract]) AND (("2025/11/03"[Date - Publication] : "2025/11/17"[Date - Publication])) 595 records

Deep generative models design mRNA sequences with enhanced translational capacity and stability.

Zhang H, Liu H, Xu Y, Huang H, Liu Y, Wang J, Qin Y, Wang H, Ma L, Xun Z, Hou X, Lu TK, Cao J.Science. 2025 Nov 6;390(6773):eadr8470. doi: 10.1126/science.adr8470. Epub 2025 Nov 6.PMID: 40875799

Varicella **Vaccine** Effectiveness and Duration of Protection: A Systematic Review and Meta-Analysis.

Bolormaa E, Lee YH, Choe YJ, Choe SA.J Korean Med Sci. 2025 Nov 17;40(44):e286. doi: 10.3346/jkms.2025.40.e286.PMID: 41250651

Sex Differences in **Vaccine**-Induced Immunity and Protection Against Mycobacterium tuberculosis.

Harikumar Parvathy G, Hertz D, Bhandiwad D, Eggers L, von Borstel L, Behrends J, Hein M, Dreyer V, Marschner J, Orinska Z, Niemann S, Kaufmann SHE, Goldmann T, Lotter H, Flores-Valdez MA, Schneider BE.J Infect Dis. 2025 Nov 14;232(5):1187-1197. doi: 10.1093/infdis/jiaf277.PMID: 40569757

Immune Correlates and **Vaccine** Immunobridging: Statistical Innovations, Challenges, and Opportunities.

Carone M, Wolock CJ, Olivas-Martinez A, Rotnitzky A, Gilbert PB.J Infect Dis. 2025 Nov 14;232(5):1024-1028. doi: 10.1093/infdis/jiaf451.PMID: 40971983

The N terminus of H3-influenza hemagglutinin as a site-of-vulnerability to neutralizing antibody.

Rawi R, Morano NC, Cheung CS, Du H, Gorman J, Prabhakaran M, Becker JE, Bylund T, Charaf S, Chen X, Lee M, Harris DR, Olia AS, Ou L, Wang L, Wang S, Zhang B, Kanekiyo M, McDermott AB, Zhou T, Shapiro L, Kwong PD.Structure. 2025 Nov 6;33(11):1820-1830.e4. doi: 10.1016/j.str.2025.07.015. Epub 2025 Aug 14.PMID: 40816277

Peptide inhibitors: Breaking cancer code.

Coburn F, Nsereko Y, Armstrong A, Al Musaimi O.Eur J Med Chem. 2025 Nov 5;297:117961. doi: 10.1016/j.ejmech.2025.117961. Epub 2025 Jul 11.PMID: 40674852

A BCMA-mRNA **vaccine** is a promising therapeutic for multiple myeloma.

Dutta D, Liu J, Wen K, Ray A, Salatino A, Liu X, Gulla A, Hideshima T, Song Y, Anderson KC.Blood. 2025 Nov 6;146(19):2322-2335. doi: 10.1182/blood.2025028597.PMID: 40700574

The History of Measles and **Vaccine** Development.

Peltola H.Acta Paediatr. 2025 Nov 17. doi: 10.1111/apa.70370. Online ahead of print.PMID: 41246889

Allergen-specific mRNA-lipid nanoparticle therapy for prevention and treatment of experimental allergy in mice.

Rochman Y, Kotliar M, Klingler AM, Rochman M, Alameh MG, Melamed JR, Osswald GA, Caldwell JM, Felton JM, Mack LE, Hargis J, Lewkowich IP, Barski A, Weissman D, Rothenberg ME.J Clin Invest. 2025 Sep 23;135(21):e194080. doi: 10.1172/JCI194080. eCollection 2025 Nov 3.PMID: 40985871

Trained Immunity in Health and Disease.

Yao M, Zhou J, Mei J, Gao C, Ding P, Li G, Zhang C, Li Z, Gao J.MedComm (2020). 2025 Nov 6;6(11):e70461. doi: 10.1002/mco2.70461. eCollection 2025 Nov.PMID: 41211186

Influenza **vaccine** hesitancy in the elderly: Where do we stand?

Pires C.Vaccine. 2025 Nov 14;66:127831. doi: 10.1016/j.vaccine.2025.127831. Epub 2025 Oct 11.PMID: 41076809

Safety and Immunogenicity of an rVSV Lassa Fever **Vaccine** Candidate.

Malkin E, Zaric M, Kieh M, Baden LR, Fitz-Patrick D, Marini A, Yun H, Hayes P, Bromell R, Ayorinde M, Fernandez N, Varma R, Sigei F, Ward M, Pindolia H, Sewell S, Amini F, Blie J, Wilson B, Faley P, McCullough J, Tokpah F, Wisseh C, Towalid E, Hadawale S, Sayeed E, Hunt D, Keshavarzi N, Barin B, Maljkovic Berry I, Parks CL, Truter SG, Walker K, Vekemans J, Lehrman J, Engelbrecht M, Malherbe M, Laufer D, Philiponis V, Higgs E, Mutua G, Fast PE, Gupta SB; rVSVΔG-LASV-GPC Study Group.N Engl J Med. 2025 Nov 6;393(18):1807-1818. doi: 10.1056/NEJMoa2501073.PMID: 41191941

Applications of artificial intelligence and nanotechnology in **vaccine** development.

Bahrami Y, Bolideei M, Mohammadzadeh S, Gahrouei RB, Mohebbi E, Haider KH, Barzigar R, Mehran MJ.Int J Pharm. 2025 Nov 10;684:126096. doi: 10.1016/j.ijpharm.2025.126096. Epub 2025 Aug 29.PMID: 40886810

Effect of human papillomavirus (HPV) **vaccine** on HPV type replacement and sexual behaviors in the post-**vaccine** era: A cross-sectional study.

Zhang J, Chen Y, Chen S, Hua C, Cheng H.Hum Vaccin Immunother. 2025 Dec;21(1):2583577. doi: 10.1080/21645515.2025.2583577. Epub 2025 Nov 14.PMID: 41236750

Recent Advances in **Vaccine** Adjuvants: From Lab to Clinic.

Vardikar A, Prajapati MK, Gholap AD, Rojekar S, Keshari R, Jain H, Rajput A.Int J Pharm. 2025 Nov 10;684:126180. doi: 10.1016/j.ijpharm.2025.126180. Epub 2025 Sep 18.PMID: 40975446

Drug- and **vaccine** induced ANCA-associated vasculitis: An overview.

Cohen Tervaert JW.Autoimmun Rev. 2025 Nov 8:103924. doi: 10.1016/j.autrev.2025.103924. Online ahead of print.PMID: 41213309

Knowledge of the human papilloma virus and acceptance of its **vaccine** among male and female young adults in Jeddah, Saudi Arabia: A cross-sectional study.

Alghamdi R, Alghamdi M, Farsi N, Alyafi M, Alaidaroos S, Almuwalad N, Alsaeedi R, Alshobaki K, Aljabri R, Aljadani R, Bajafar R, Aljuhani J, Merdad N, Merdad R.Hum Vaccin Immunother. 2025 Dec;21(1):2583609. doi: 10.1080/21645515.2025.2583609. Epub 2025 Nov 17.PMID: 41247743

SARS-CoV-2 Variants and **Vaccine** Development: A Focused Review.

Bharadwaj A, Hiremath G, Thakur Y, Kumar K, Wahi N.Infect Disord Drug Targets. 2025 Nov 5. doi: 10.2174/0118715265359309251016105433. Online ahead of print.PMID: 41208069

Enhanced Influenza Vaccines Extend A(H3N2) Antibody Reactivity in Older Adults but Prior Vaccination Effects Persist.

Fox A, Sánchez-Ovando S, Carolan L, Hadiprodjo AJ, Chen Y, Ho F, Cheng SMS, Thompson MG, Iuliano AD, Levine MZ, Valkenburg SA, Ip DKM, Peiris JSM, Sullivan SG, Cowling BJ, Leung NHL.Clin Infect Dis. 2025 Nov 6;81(4):e192-e201. doi: 10.1093/cid/ciaf060.PMID: 40178253

Immunofocusing design of a fusion glycoprotein monomer **vaccine** for respiratory syncytial virus.

Li Q, Li Z, Chen J, He Q, Xiao H, Li H, Li H, Zhang H, Yang Y, Bi R, Li Z, Xiao S, Bi Y, Liang B, Huang L, Zhang M, Tong J, Long H, Li R, Duan J, Li Z, Wang Y.Mol Ther. 2025 Nov 5;33(11):5401-5414. doi: 10.1016/j.ymthe.2025.07.040. Epub 2025 Jul 28.PMID: 40734273

Systematic review and meta-analysis of the effectiveness of polypeptide, virus-like particles, and viral vector vaccines for foot-and-mouth disease (2020-2025).

Elrashedy A, Mousa W, Nayel M, Salama A, Zaghawa A, Elsify A, Hasan ME.Sci Rep. 2025 Nov 10;15(1):39370. doi: 10.1038/s41598-025-24078-5.PMID: 41214185

A Reminder in Every Story: The Cost of **Vaccine** Hesitancy.

Shabbir R, Shabbir Z.Ann Intern Med. 2025 Nov 11. doi: 10.7326/ANNALS-25-02508. Online ahead of print.PMID: 41213146

Current Perspectives and Future Directions in the Immunogenicity Landscape of Norovirus Vaccines.

Lee HJ, Yoon D, Jung H, Hong SY, Kim YB, Oh JW.J Microbiol Biotechnol. 2025 Nov 10;35:e2509003. doi: 10.4014/jmb.2509.09003.PMID: 41218799

Vaccine hesitancy among migrant populations in Europe: A mixed-methods systematic review.

Khuu E, Moussaoui S, Vignier N, Bonello K, Archer E.Vaccine. 2025 Nov 6;68:127954. doi: 10.1016/j.vaccine.2025.127954. Online ahead of print.PMID: 41202609

[Connection between viral infections, vaccines, and dementia].

Nadubinszky G, Székács B.Orv Hetil. 2025 Nov 9;166(45):1763-1768. doi: 10.1556/650.2025.33423. Print 2025 Nov 9.PMID: 41212043

Preemptive Mpox **Vaccine** Deployment: Aligning Strategy With Reality.

Jung SM, Miura F, Murayama H, Funk S, Wallinga J, Lessler J, Endo A.J Infect Dis. 2025 Nov 14;232(5):e867-e868. doi: 10.1093/infdis/jiaf365.PMID: 40690543

Recommendations on PCV20 **vaccine** in adults and at-risk populations.

Sotgiu G, Puci M, Bartoletti M, Blasi F, Bonanni P, Aliberti S.Eur Respir Rev. 2025 Nov 12;34(178):250016. doi: 10.1183/16000617.0016-2025. Print 2025 Oct.PMID: 41224370

Pathogenicity and virulence of *Brucella*: Strategies for metabolic adaptation and immune evasion.

Guimarães ES, Gomes MTR, de Araujo ACVSC, Ramos KKS, Oliveira SC.Virulence. 2025 Dec;16(1):2585620. doi: 10.1080/21505594.2025.2585620. Epub 2025 Nov 16.PMID: 41212588

SARS-CoV-2 variants: biology, pathogenicity, immunity and control.

Uraki R, Korber B, Diamond MS, Kawaoka Y.Nat Rev Microbiol. 2025 Nov 10. doi: 10.1038/s41579-025-01255-x. Online ahead of print.PMID: 41214236

Recent progress in enterotoxigenic Escherichia coli **vaccine** research and development.

Zhang W, Sack DA.Infect Immun. 2025 Nov 6:e0036825. doi: 10.1128/iai.00368-25. Online ahead of print.PMID: 41196327

Deciphering immunoregulatory mechanisms and structure-guided biosynthesis of β-glucans.

He W, Li Z.Carbohydr Polym. 2025 Nov 15;368(Pt 2):124254. doi: 10.1016/j.carbpol.2025.124254. Epub 2025 Aug 21.PMID: 40947233

Revisiting HPV vaccination post-COVID: geopolitical, sociocultural, and ethical disparities in global health.

Sad SA, Iftikhar L, Chamout M.Int J Equity Health. 2025 Nov 10;24(1):308. doi: 10.1186/s12939-025-02669-y.PMID: 41214693

Lipid nanoparticle mediated delivery of dsDNA to the murine retina.

Fehrman RL, Sahel D, Sahay G, Lipinski DM, Ryals RC.J Control Release. 2025 Nov 10;387:114194. doi: 10.1016/j.jconrel.2025.114194. Epub 2025 Sep 9.PMID: 40935069

Public awareness and acceptance of malaria **vaccine** in Sub-Saharan Africa: a systematic review.

Ekhator E, Essien VG, Afolabi OE, Okundaye MI, Adewonbi T.BMC Public Health. 2025 Nov 11;25(1):3890. doi: 10.1186/s12889-025-25196-5.PMID: 41219724

Misinformaion and its impact on measles **vaccine** hesitancy in the pediatric population: A scoping review.

Anson K, Patel S.J Pediatr Nurs. 2025 Nov 13;86:136-147. doi: 10.1016/j.pedn.2025.11.008. Online ahead of print.PMID: 41237560

Kyasanur Forest disease: an emerging arboviral threat.

Pandey N, Singh SK.Lancet Infect Dis. 2025 Nov 4:S1473-3099(25)00589-4. doi: 10.1016/S1473-3099(25)00589-4. Online ahead of print.PMID: 41202828

Hydroxychloroquine-functionalized ionizable lipids mitigate inflammatory responses in mRNA therapeutics.

Chen K, Li X, Feng S, Li Y, Jiang T, Liu Y, Guo N, Zeng X, Yao H, Qiu M, Lu J, Lin J.J Control Release. 2025 Nov 10;387:114267. doi: 10.1016/j.jconrel.2025.114267. Epub 2025 Sep 25.PMID: 41015258

Impact of cytomegalovirus infection on heterologous **vaccine** responsiveness.

Nicoli F, Karrer U, Appay V.Philos Trans R Soc Lond B Biol Sci. 2025 Nov 6;380(1938):20240407. doi: 10.1098/rstb.2024.0407. Epub 2025 Nov 6.PMID: 41194663

Mapping inequities in global **vaccine** sentiment research.

Balsamo D, Offeddu V, Aghamohammadi Z, Chiavenna C, Leone LP, D'Agnese E, Sharma D, Torbica A, Shayegh S, Andreu-Perez J, Melegaro A.BMJ Glob Health. 2025 Nov 3;10(11):e018587. doi: 10.1136/bmjgh-2024-018587.PMID: 41184027

mRNA cancer **vaccine**: A novel and potential immunotherapy for multiple myeloma.

Feng Y, Du Y, Zhang C, Xie F, Yan J.Biochim Biophys Acta Rev Cancer. 2025 Nov 8;1880(6):189493. doi: 10.1016/j.bbcan.2025.189493. Online ahead of print.PMID: 41213412

LRP8 is an entry receptor for tick-borne encephalitis viruses.

Li P, Hui S, Chong Z, Escaffre O, Nguyen MN, Muraro SP, Janova H, Ma H, Cao S, Kaszuba T, Imbiakha B, Palakurty S, Pearson ML, Price DA, Amarasinghe GK, Leung DW, Rossi SL, Freiberg AN, Fremont DH, Diamond MS.Proc Natl Acad Sci U S A. 2025 Nov 4;122(44):e2525771122. doi: 10.1073/pnas.2525771122. Epub 2025 Oct 30.PMID: 41166431

Childhood **vaccine** hesitancy among academics in Turkiye.

Palloş A, Yüksel Kaçan C.BMC Public Health. 2025 Nov 3;25(1):3757. doi: 10.1186/s12889-025-24976-3.PMID: 41184867

Associations between genetic variations of HLA and IGHV, vaccination schedule, and COVID-19 **vaccine** immunogenicity.

Ke L, Feng G, Lyu K, Yin B, Fang W, Di Q.NPJ Vaccines. 2025 Nov 17;10(1):235. doi: 10.1038/s41541-025-01284-w.PMID: 41249154

Vaccine-educated T cells and a CD123 bispecific T-cell engager for treatment of acute myeloid leukemia.

Liegel J, Stroopinsky D, Cheloni G, Karagkouni D, Nahas M, Ma Y, Torres D, Saldarriaga I, Wang S, Arruda de Amaral A, Ploumakis A, Clohessy J, Abirached J, Bisharat L, Fraenkel P, Yildirim O, Bonnevaux H, Guerif S, Rallis K, Chedid G, Kufe D, Vlachos IS, Avigan D, Rosenblatt J.Blood Adv. 2025 Nov 11;9(21):5585-5597. doi: 10.1182/bloodadvances.2024015449.PMID: 40811786

SitoC7A-modified lipid nanoparticles for integrated mRNA delivery and targeted STING activation.

Qiao L, Fan N, Zhang Y, Chen Y, Qin S, Song X.J Control Release. 2025 Nov 10;387:114238. doi: 10.1016/j.jconrel.2025.114238. Epub 2025 Sep 15.PMID: 40962123

Navigating Measles Treatment in 2025: A Review on Vaccines, Medications, and Supplements.

Oldham MM, Benavides S, Boylan PM.Pediatr Allergy Immunol Pulmonol. 2025 Nov 17. doi: 10.1177/2151321X251397927. Online ahead of print.PMID: 41248922

Pulmonary delivery of small circular RNA vaccines for influenza prevention.

Zhang Y, Xu Y, Tang W, Zhou S, Liu X, Wang Z, Zhu G.J Control Release. 2025 Nov 10;387:114198. doi: 10.1016/j.jconrel.2025.114198. Epub 2025 Sep 8.PMID: 40930161

Recombinant live attenuated measles virus-based vaccines inducing comprehensive protection against Ebola and Marburg viruses.

Zhou J, Zhang X, Yao Y, Xie Y, Li F, Wang W, Yan F, Peng C, Zhang B, Wu Y, Cao Z, Peng Y, Gao G, Zhang H, Gong P, Chiu S.Mol Ther. 2025 Nov 5;33(11):5470-5488. doi: 10.1016/j.ymthe.2025.08.022. Epub 2025 Aug 19.PMID: 40836428

The hidden threats posed by Japanese encephalitis virus genotype V.

Li Q, Mishra H, Kain KC, Wang R.J Virol. 2025 Nov 4:e0164425. doi: 10.1128/jvi.01644-25. Online ahead of print.PMID: 41186391

Patterns and trends in infection control nursing research: text network analysis.

Ryu D, Park H, Sok S.BMC Nurs. 2025 Nov 17;24(1):1406. doi: 10.1186/s12912-025-04054-0.PMID: 41250074

Hesitancy towards routine childhood vaccinations before and after the COVID-19 pandemic in Arkansas.

Cima MJ, Joshua C, Zohoori N, Porter A 3rd, Slagle D, Dillaha J.Vaccine. 2025 Nov 14;66:127834. doi: 10.1016/j.vaccine.2025.127834. Epub 2025 Oct 15.PMID: 41106171

Innate immune memory: The evolving role of macrophages in therapy.

Damani-Yokota P, Khanna KM.Elife. 2025 Nov 14;14:e108276. doi: 10.7554/eLife.108276.PMID: 41236793

The metabolic, microbial and immunological demands of pneumococcal colonisation.

Neill DR, Clarke TB.PLoS Pathog. 2025 Nov 13;21(11):e1013675. doi: 10.1371/journal.ppat.1013675. eCollection 2025 Nov.PMID: 41231805

Ocular manifestations of **vaccine**-preventable diseases: A comprehensive review.

McCarthy K, Silkiss RZ.Vaccine. 2025 Nov 7;68:127900. doi: 10.1016/j.vaccine.2025.127900. Online ahead of print.PMID: 41205407

Bacterial outer membrane vesicles in immune modulation: from mechanisms to applications.

Wang Y, Yang R, Luo J, Li J, Huang B, Yang J.J Mater Chem B. 2025 Nov 5;13(43):13867-13880. doi: 10.1039/d5tb01708d.PMID: 41058591

Medical Trustworthiness and COVID-19: Examining Health Beliefs and **Vaccine** Uptake in Disinvested Black Communities.

Jones HA, Campbell JM, Benoit E, Cheng AL, Windsor L.J Racial Ethn Health Disparities. 2025 Nov 14. doi: 10.1007/s40615-025-02742-w. Online ahead of print.PMID: 41239172

The social lives of the SARS-CoV-2 vaccines: A qualitative study of **vaccine** understandings and decision-making among people of Black ethnicities in London, UK.

Nicholls EJ, Onyango D, Kolodin V, Ottaway Z, Carter A, Campbell L, Post F, Tariq S.Vaccine. 2025 Nov 14;66:127802. doi: 10.1016/j.vaccine.2025.127802. Epub 2025 Oct 10.PMID: 41076806

Cyclophilins as key players in protozoan parasite infections.

Mansouri R, Granado-Aparicio E, Alcedo C, López-Abán J, Shafiei R, Muro A, Manzano-Román R, Rashidi S.Parasit Vectors. 2025 Nov 11;18(1):457. doi: 10.1186/s13071-025-07098-y.PMID: 41219799

Barriers to COVID-19 vaccination and strategies to increase trust and uptake among racial and ethnic minorities with HIV in South Florida: a qualitative study.

Ramírez-Ortiz D, Moise T, Alemohammad SY, Aymat M, Gray A, Jean-Gilles M, Sheehan DM, Ladner R, Trepka MJ.BMC Public Health. 2025 Nov 10;25(1):3885. doi: 10.1186/s12889-025-25017-9.PMID: 41214612

Evolving pneumococcal epidemiology and **vaccine** impact in the Netherlands, 2004-2024: carriage and invasive disease.

Wulffraat MT, van de Weijer NG, Wijmenga-Monsuur AJ, Badoux P, Steens A, Smit D, Mariman R, Trzciński KP, van Sorge NM, Rots NY, van Houten MA.J Infect. 2025 Nov 13:106658. doi: 10.1016/j.jinf.2025.106658. Online ahead of print.PMID: 41241235

Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based **vaccine** in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial.

Pareek M, Lassen MCH, Johansen ND, Christensen SH, Aliabadi N, Skaarup KG, Modin D, Claggett BL, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Lindholm MG, Jensen AMR, Dons M, Bernholm KF, Davidovski FS, Duus LS, Ottosen CI, Nielsen AB, Borchsenius JH, Espersen C, Köse G, Fussing FH, Køber L, Solomon SD, Jensen JUS, Martel CJ, Gessner BD, Schwarz C, Gonzalez E, Skovdal M, Zhang P, Begier E, Biering-Sørensen T.Eur Heart J. 2025 Nov 3;46(41):4291-4298. doi: 10.1093/eurheartj/ehaf679.PMID: 40884439

MPOX outbreak in Africa: the urgent need for local manufacturing of the **vaccine** and decolonized health systems.

Cynthia AN, Nchanji GT.BMC Public Health. 2025 Nov 7;25(1):3838. doi: 10.1186/s12889-025-25120-x.PMID: 41204158

Evaluation of Immunization Route in Induction of **Vaccine**-Mediated Anti-Gonococcal Immune Responses in a Murine Model of Ascending Infection.

Matthias KA, Connolly KL, Jerse AE, Kumova OK, Macintyre AN, Gray MC, Thomas KS, Criss AK, Zielke RA, Li L, Sikora AE, Ramirez-Bencomo F, Thistlethwaite A, Derrick JP, Lu WE, Bash MC.J Infect Dis. 2025 Nov 14;232(5):e765-e777. doi: 10.1093/infdis/jiaf445.PMID: 40971931

Human CD4 T cells are a functional target for lipid nanoparticle-based mRNA vaccines.

Kim SC, Felgner J, Soto MS, Hitchcock L, Silzel EK, Beares H, Hwang MJ, Yates TB, Cheng S, Joloya EM, Sureshchandra S, Sorn AM, Wagoner ZW, Tifrea D, Kabeer M, Trask D, Othy S, Felgner P, Wagar LE.mBio. 2025 Nov 12;16(11):e0225425. doi: 10.1128/mbio.02254-25. Epub 2025 Sep 22.PMID: 40980892

Incidence of Respiratory Syncytial Virus-Associated Hospitalization Among Adults in Ontario, Canada, 2017-2019.

Buchan SA, Alessandrini J, Drover SSM, Andrew MK, Bronskill SE, Brown KA, Daneman N, Deeks SL, Gubbay JB, Johnstone J, Karnauchow TM, Lee S, McGeer AJ, McNally JD, McNeil SA, Mubareka S, Murti M, Smieja M, Wilson SE, Kwong JC.J Infect Dis. 2025 Nov 14;232(5):e799-e810. doi: 10.1093/infdis/jiaf343.PMID: 40736447

Understanding measles infection and how to improve uptake of the MMR **vaccine**.

Jones R, Youlden H, McDermott C, Perry M, Norwood J.Nurs Child Young People. 2025 Nov 6;37(6):34-42. doi: 10.7748/ncyp.2025.e1562. Epub 2025 Sep 10.PMID: 40926461

Humoral SARS-CoV-2 **vaccine** responses are durable in solid organ transplant recipients with and without HIV.

Rana MM, Haydel B, Carrara G, Gleason C, Mauldin J, Srivastava K, Florman SS, Aberg J, van Kesteren M, Mischka J, Carreño JM, Singh G, Mendu DR; TITAN Study Group; Wajnberg A, Cordon-Cardo C, Krammer F, Simon V.Vaccine. 2025 Nov 14;69:127969. doi: 10.1016/j.vaccine.2025.127969. Online ahead of print.PMID: 41240586

Active immunization: A novel therapeutic strategy for treating Alzheimer's disease.

Mazahir F.Eur J Pharmacol. 2025 Nov 15;1007:178288. doi: 10.1016/j.ejphar.2025.178288. Epub 2025 Oct 24.PMID: 41138840

Human metapneumovirus: an underdiagnosed public health threat.

Sharma R, Walia A, Lakhanpal D.Infect Dis Now. 2025 Nov 14:105189. doi: 10.1016/j.idnow.2025.105189. Online ahead of print.PMID: 41242396

Long-term effectiveness of live zoster **vaccine** against herpes zoster and related complications: a nationwide emulated target trial in South Korea.

Yeo D, Lee K, Jo Y, Lee S, Jo H, Park J, Woo S, Hwang Y, Jacob L, Rahmati M, Lee J, Kim S, Lee H, Yon DK.Vaccine. 2025 Nov 14;66:127824. doi: 10.1016/j.vaccine.2025.127824. Epub 2025 Oct 11.PMID: 41082816

Public trust and mistrust of COVID-19 vaccines: A systematic meta-narrative review.

Ledderer L, Nielsen KH, Skodborg L, Fage-Butler A.Vaccine. 2025 Nov 10;69:127947. doi: 10.1016/j.vaccine.2025.127947. Online ahead of print.PMID: 41218570

Safety, Immunogenicity, and Protective Efficacy in Rhesus Macaques of a Novel Recombinant Hemagglutinin Protein Measles Virus **Vaccine**.

Rubens JH, Brockhurst JK, Ghimire S, Wu J, Liu L, Villano JS, Loomis RJ, Derrien-Colemyn A, Ruckwardt TJ, Graham BS, Watson MW, Griffin DE, Stewart-Jones GBE.J Infect Dis. 2025 Nov 14;232(5):1239-1248. doi: 10.1093/infdis/jiaf244.PMID: 40358686

Public attitudes towards intranasal and ultrasound mediated **vaccine** delivery: A cross-sectional study in the United Kingdom and United States.

Kantor J, Morrison M, Vanderslott S, Pollard AJ, Carlisle RC.Vaccine. 2025 Nov 11;69:127950. doi: 10.1016/j.vaccine.2025.127950. Online ahead of print.PMID: 41223692

Tick-borne encephalitis: Burden of disease and impact of vaccination, Austria (2000-2024).

Raffl S, Springer DN, Aberle SW, Florian DM, Kundi M, Stiasny K, Aberle JH.Vaccine. 2025 Nov 14;66:127854. doi: 10.1016/j.vaccine.2025.127854. Epub 2025 Oct 12.PMID: 41082815

Immunogenicity and safety of varicella **vaccine** co-administered with seasonal influenza **vaccine** in healthy Children Aged 7-12 years in China.

Sun X, Zhang L, Song X, Sun Y, Wang Z.Int J Infect Dis. 2025 Nov 12:108212. doi: 10.1016/j.ijid.2025.108212. Online ahead of print.PMID: 41238173

Contemporary Status and Frontiers of Cervical Cancer Screening in the United States.

Eli AV, Kasten BB, Mayer CM, Samant R, Hartman YE, Chaudhary I, Imran N, Dal Zotto VL, Kahn AG, Arend RC, Warram JM.Cancer Prev Res (Phila). 2025 Nov 3;18(11):663-675. doi: 10.1158/1940-6207.CAPR-25-0118.PMID: 40878773

High-dose vs. standard-dose inactivated influenza **vaccine** and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial.

Pareek M, Johansen ND, Modin D, Loiacono MM, Harris RC, Dufournet M, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Claggett BL, Janstrup KH, Bartholdy KV, Bernholm KF, Borchsenius JIH, Davidovski FS, Davodian LW, Dons M, Duus LS, Espersen C, Fussing FH, Jensen AMR, Landler NE, Langhoff ACF, Lassen MCH, Nielsen AB, Ottosen CI, Sengeløv M, Skaarup KG, Solomon SD, Landray MJ, Gislason GH, Køber L, Sivapalan P, Martel CJ, Jensen JUS, Biering-Sørensen T.Eur Heart J. 2025 Nov 3;46(41):4282-4290. doi: 10.1093/eurheartj/ehaf678.PMID: 40884413

Influenza **Vaccine** Effectiveness Against Medically Attended Outpatients Illness, United States, 2023-2024 Season.

Chung JR, Price AM, Zimmerman RK, Moehling Geffel K, House SL, Curley T, Wernli KJ, Phillips CH, Martin ET, Vaughn IA, Murugan V, Scotch M, Saade EA, Faryar KA, Gaglani M, Ramm JD, Williams OL, Walter EB, Kirby MK, Keong LM, Kondor R, Ellington SR, Flannery B.Clin Infect Dis. 2025 Nov 6;81(4):e184-e191. doi: 10.1093/cid/ciae658.PMID: 39761230

Optimizing **vaccine** protection for high-risk populations.

Cerqueira-Silva T, Barral-Netto M, Boaventura VS.Cell Host Microbe. 2025 Nov 12;33(11):1811-1814. doi: 10.1016/j.chom.2025.10.014.PMID: 41232512

Vaccine effectiveness against influenza A in older adults and the effect of chronic conditions: results from the I-MOVE and VEBIS multicentre European hospital case-control studies, 2015/16-2023/24.

Rose AMC, Nicolay N, Mazagatos C, Martínez-Baz I, Launay O, De Mot L, Bella A, Lazar M, Machado A, Kuliešė M, Abela S, Vučina VV, van Gageldonk-Lafeber R, Bino S, Dürrwald R, Paradowska-Stankiewicz I,

Horváth JK, Duffy R, Husa P, McMenamin J, Pozo F, Howard J, Latorre-Millán M, Castilla J, Nguyen LBL, Dauby N, Riccardo F, Ivanciuc A, Gomez V, Jančorienė L, Xuereb G, Petrović G, Marbus S, Vasili A, Tolksdorf K, Bogusz J, Oroszi B, Domegan L, Součková L, Marsh K, Bacci S, Kissling E; I-MOVE & VEBIS Hospital Network teams.BMC Med. 2025 Nov 3;23(1):602. doi: 10.1186/s12916-025-04426-y.PMID: 41185010

Novel Oral papaya-based preventive and therapeutic **vaccine** for controlling different zoonotic Taeniid parasites: Current advances.

Hernández M, Caltempa AO, Villalobos N, Elisondo MC, Guzmán C, Hernández-Aceves JA, Aguilar L, Flores-Pérez I, Martínez JJ, Elguea Zarate SD, Prieto MJP, Meneses G, Chea RH, Sifontes-Rodríguez S, Sako Y, Cardoso-Taketa A, Villarreal ML, Bobes RJ, Rosas G, Fragoso G, Sciutto E.Vaccine. 2025 Nov 14;66:127818. doi: 10.1016/j.vaccine.2025.127818. Epub 2025 Oct 8.PMID: 41066986

Trends and disparities in the research and development of infectious disease vaccines from 2015 to 2025.

Du M, Chen W, Li G, Liang W, Liu J.Hum Vaccin Immunother. 2025 Dec;21(1):2581440. doi: 10.1080/21645515.2025.2581440. Epub 2025 Nov 6.PMID: 41197019

Ageing with HIV-1: immunological challenges for effective vaccination.

Saint-Charles P, Didierlaurent AM, Appay V.Immun Ageing. 2025 Nov 4;22(1):48. doi: 10.1186/s12979-025-00544-6.PMID: 41188885

Advancing typhoid conjugate **vaccine** implementation in Asia: Regional policy priorities.

Carter AS, Steele D, John J, Saha S, Laurens MB, Minta AA, Volavola L, Moedjito I, Phounphenghack K, Mahat D, Nyein SL, Gautam A, Sespeñe MFVS, Pati T, Huong NTT, Gupta N, George LS, Jayaprakasam M, Gupta A, Garrett DO.Vaccine. 2025 Nov 14;66:127848. doi: 10.1016/j.vaccine.2025.127848. Epub 2025 Oct 14.PMID: 41092802

Immunogenicity and safety of third, fourth and subsequent COVID-19 **vaccine** doses in recipients of hematopoietic cell transplantation and cellular therapy.

Buchan CA, Agbayani G, Hueniken K, Vijenthira A, Sebag M, Wang P, Hicks LK, Hay AE, Assouline S, Fraser G, Balitsky A, Mangel J, Owen C, Reiman A, Sehn L, Sutherland H, Zhang T, Arnold C, Wilkin AM, Leite T, McCarthy E, Crawley AM, Langlois MA, Bredeson C, Kekre N, Allan D, Cooper C, Bhella S; VIP Study Investigators.Transplant Cell Ther. 2025 Nov 8:S2666-6367(25)01551-9. doi: 10.1016/j.jtct.2025.10.037. Online ahead of print.PMID: 41213500

Public trust: the **vaccine** against **vaccine** hesitancy.

The Lancet Respiratory Medicine.Lancet Respir Med. 2025 Nov 12:S2213-2600(25)00406-0. doi: 10.1016/S2213-2600(25)00406-0. Online ahead of print.PMID: 41240958

Enhancing COVID-19 **vaccine** effectiveness evidence generation using tokenized immunization registries.

Andersen KM, McGrath LJ, Allen KE, Khan FL, Yu T, Carter BT, Mateus JS, Zhou A, Lopez SMC, Puzniak L.Am J Epidemiol. 2025 Nov 13:kwaf251. doi: 10.1093/aje/kwaf251. Online ahead of print.PMID: 41230811

Cost-effectiveness of introducing a maternal **vaccine** or long-acting monoclonal antibody to prevent infant respiratory syncytial virus disease in Nepal.

Rave N, Sharma AK, Chapagain RH, Nguyen A, Pecenka C, Shaaban FL, Bont LJ, Clark A; RSV GOLD III – Health Economics Study Group.J Glob Health. 2025 Nov 14;15:04292. doi: 10.7189/jogh.15.04292.PMID: 41232121

Control of human Q fever by vaccination: the journey to Q-VAX and beyond.

Heinzen RA, Pierce KN, Voth DE, Stenos J, Graves S, Long CM.Infect Immun. 2025 Nov 6:e0028025. doi: 10.1128/iai.00280-25. Online ahead of print.PMID: 41196302

Associations between trust in public health, **vaccine** confidence, and COVID-19 vaccination among American adults.

Garvey K, Salmon DA, Dudley MZ, Brewer J, Schuh HB.Vaccine. 2025 Nov 9;68:127955. doi: 10.1016/j.vaccine.2025.127955. Online ahead of print.PMID: 41213185

A pentavalent **vaccine** targeting adhesins and metal-binding lipoproteins confers robust protection against enterococcal infections.

Lam LN, Berges A, Sedra A, Saengpet IS, Adams G, Kajfasz JK, Taylor R, Arroyo D, Huang D, Fairman J, Lemos JA.Vaccine. 2025 Nov 9;69:127965. doi: 10.1016/j.vaccine.2025.127965. Online ahead of print.PMID: 41213238

Engineering Hetero-Layered Mannodendrimers to Enhance Macrophage Receptor Binding.

Gupta MR, Zgheib A, Danalache BA, Annabi B, Roy R.Biomacromolecules. 2025 Nov 10;26(11):8246-8268. doi: 10.1021/acs.biomac.5c01692. Epub 2025 Oct 28.PMID: 41151045

Cationic nanogel-based nasal therapeutic HPV **vaccine** prevents the development of cervical cancer.

Nakahashi-Ouchida R, Mori H, Yuki Y, Machita T, Katakai Y, Umemoto S, Uchida Y, Yamanoue T, Sawada SI, Ishige K, Miyazaki T, Fujihashi K, Akiyoshi K, Yasutomi Y, Kawana K, Kiyono H.Sci Transl Med. 2025 Nov 12;17(824):eado8840. doi: 10.1126/scitranslmed.ado8840. Epub 2025 Nov 12.PMID: 41223246

Hepatitis B virus infection and **vaccine** coverage among children living with HIV, HIV-exposed uninfected, and HIV-unexposed uninfected children in the Western Cape, South Africa.

Collins C, Ratshisusu L, Modise LM, Simani OE, Selabe SG, Muloiwa R, Copelyn J, Amponsah-Dacosta E.Vaccine. 2025 Nov 14;66:127843. doi: 10.1016/j.vaccine.2025.127843. Epub 2025 Oct 14.PMID: 41092803

Safety and immunogenicity of a novel psittacine beak and feather disease **vaccine** and optimisation of a thermostable spray-dried formulation.

Das T, Nath BK, Dhar PK, Peters A, Forwood JK, Raidal SR, Das S.Vaccine. 2025 Nov 13;69:127989. doi: 10.1016/j.vaccine.2025.127989. Online ahead of print.PMID: 41237562

Immunogenicity of HLA-restricted peptide **vaccine** candidates delivered by self-assembling protein nanoparticle (SAPN) technology.

Belmonte M, Kusi KA, Kyei-Baafour E, Ofori EA, Burkhard P, Angov E, Matyas GR, Beck Z, Pfeffer-Kleemann C, Storey L, Lim P, Belmonte A, Ganeshan H, Huang J, Inoue S, Villasante E, Sedegah M.Vaccine. 2025 Nov 14;66:127832. doi: 10.1016/j.vaccine.2025.127832. Epub 2025 Oct 12.PMID: 41082812

'They're not going to tell you everything': A qualitative study with HPV **vaccine** hesitant parents and caregivers in the northeast and southeast U.S.

Cooper SC, Williams IV, Porter A, Presti C, Mikhaylov A, King A, Memaj I.Vaccine. 2025 Nov 13;68:127948. doi: 10.1016/j.vaccine.2025.127948. Online ahead of print.PMID: 41237541

Advances and prospects of respiratory mucosal vaccines: mechanisms, technologies, and clinical applications.

Li J, Wu G, Huang Z, Hu J, Tie X, Wu H, Wang Z, Chen K.NPJ Vaccines. 2025 Nov 12;10(1):230. doi: 10.1038/s41541-025-01280-0.PMID: 41224752

Leveraging the role of pharmacists in **vaccine** education and uptake among newcomers to Ontario.

Spears R, Ford C, Fullerton M, Wang HD, Faught BE.Can Pharm J (Ott). 2025 Nov 6:17151635251380866. doi: 10.1177/17151635251380866. Online ahead of print.PMID: 41209103

Monitoring strategies after the incorporation of vaccines into national immunization programs: a systematic review.

de Melo Araújo AC, Frugoli AG, de Sena Gonçalves JE, Pércio J, Da Silva TP, da Fonseca Victer TN, Matozinhos FP, Fernandes ÉG.Vaccine. 2025 Nov 14;66:127850. doi: 10.1016/j.vaccine.2025.127850. Epub 2025 Oct 11.PMID: 41076808

COVID-19 **vaccine** hesitancy continuum and its psycho-behavioral predictive models among general population: a cross-sectional study in Ethiopia.

Getachew D, Solomon N, Alie MS, Ayenew M.BMC Public Health. 2025 Nov 3;25(1):3735. doi: 10.1186/s12889-025-24470-w.PMID: 41184912

Off-Label use of vaccines may save lives and money: lessons from the province of Quebec, Canada.

De Wals P, Quach C.Expert Rev Vaccines. 2025 Dec;24(1):1-13. doi: 10.1080/14760584.2025.2589214. Epub 2025 Nov 14.PMID: 41220197

Immunotherapy in Early Parkinson's Disease: A Biomarker-Driven Trial Framework for Secondary Prevention.

Kniazev R.Cureus. 2025 Nov 4;17(11):e96090. doi: 10.7759/cureus.96090. eCollection 2025 Nov.PMID: 41195411

Exploring the effectiveness of interventions to increase uptake of measles vaccination among healthcare workers: a systematic review.

Heinze N, Martin AF, Tirion ASC, Pae R, Islam J, Smith LE, Weston D, Rubin GJ.Vaccine. 2025 Nov 14;66:127808. doi: 10.1016/j.vaccine.2025.127808. Epub 2025 Oct 9.PMID: 41072280

Progress and potential of ferritin nanocages for cancer drug delivery.

Giacobbo V, Gorgoglione F, Sevieri M, Bignami B, Tagliolini I, Corsi F, Mazzucchelli S.Expert Opin Drug Deliv. 2025 Nov 11:1-14. doi: 10.1080/17425247.2025.2584632. Online ahead of print.PMID: 41213168

Pneumococcal vaccination offer and schedules in adults in EU countries: An update.

Chiavarini M, Boccalini S, Bechini A, Barash A, Castellana E, Senape A, Bonanni P.Hum Vaccin Immunother. 2025 Dec;21(1):2563953. doi: 10.1080/21645515.2025.2563953. Epub 2025 Nov 3.PMID: 41182127

Incubation periods and mortality outcomes following rabies virus infection in mesocarnivorous reservoir hosts: implications for experimental design and veterinary policy - a review and meta-analysis.

Müller T, Denzin N, Vos A, Freuling C.Virol J. 2025 Nov 14;22(1):374. doi: 10.1186/s12985-025-02996-0.PMID: 41239379

Summary of human West Nile virus **vaccine** meeting, 2024: Investigating barriers to development.

Nett RJ, Brault AC, Lambert AJ, Agnihothram S, Barrett ADT, Barzon L, Clements DE, Durbin A, Kretschmer M, Monath TP, Mura M, Pierson TC, Prutzman K, Slifka MK, Suthar MS, Whitehead SS, Staples JE.Vaccine. 2025 Nov 5;68:127938. doi: 10.1016/j.vaccine.2025.127938. Online ahead of print.PMID: 41197444

Global expansion of lumpy skin disease: transmission trends, economic consequences, and preventive measures.

Sharma P, Kumar D.Vet Res Commun. 2025 Nov 4;50(1):22. doi: 10.1007/s11259-025-10954-y.PMID: 41186797

Monitoring **Vaccine**-Induced Antibody Levels Using Carbon Nanotube-Based Field-Effect Transistors.

Amiri A, Shao W, Zeng Z, Dhayani A, Balmert SC, Falo LD Jr, Korkmaz E, Star A.Anal Chem. 2025 Nov 3. doi: 10.1021/acs.analchem.5c03817. Online ahead of print.PMID: 41182963

Untangling choices: how awareness and socio-economic status shape malaria vaccination decisions among Ghanaian women.

Ansah RK, Tackie S, Asosega KA, Tawiah K, Danquah BA, Appiah ST, Twum RA, Omane-Adjepong M.Malar J. 2025 Nov 6;24(1):380. doi: 10.1186/s12936-025-05613-1.PMID: 41199256

A thematic analysis of flu **vaccine** hesitance in ethnically minoritised communities in Liverpool.

Powell A, Van Hout MC, Connors D, Montgomery C.PLoS One. 2025 Nov 3;20(11):e0333602. doi: 10.1371/journal.pone.0333602. eCollection 2025.PMID: 41183116

Different antigenic distance metrics generate similar predictions of influenza **vaccine** response breadth despite moderate correlation.

Billings WZ, Ge Y, Skarlupka AL, Miller SL, Hemme H, John M, Dean NE, Cobey S, Cowling BJ, Shen Y, Ross TM, Handel A.PLoS Comput Biol. 2025 Nov 14;21(11):e1013720. doi: 10.1371/journal.pcbi.1013720. Online ahead of print.PMID: 41237217

The experience of seeking & granting special medical exemptions for mandated vaccines: A scoping review.

Devsam B, Bortolussi K, Tippins J, Vasiliadis S, Danchin M, O'Neill J, Attwell K, Kaufman J.Vaccine. 2025 Nov 13;68:127935. doi: 10.1016/j.vaccine.2025.127935. Online ahead of print.PMID: 41237540

mRNA vaccines for porcine reproductive and respiratory syndrome: A new paradigm in swine health.

Khan M, Taira O, Shi X, Wang H, Cai X.Biochem Biophys Res Commun. 2025 Nov 8;791:152950. doi: 10.1016/j.bbrc.2025.152950. Online ahead of print.PMID: 41232377

Design of antibody structure-guided epitope vaccines *in silico* to induce potent immune responses against emerging viruses.

Wei X-F, Zhao L, Zhao Z, Gong Y-M, Zheng Y-Y, Cheng G-F, Wang G-X, Zhu B, Kong W-G.J Virol. 2025 Nov 11:e0068925. doi: 10.1128/jvi.00689-25. Online ahead of print.PMID: 41217174

Spatial disparities in perfluoroalkyl and polyfluoroalkyl substances exposure and immunosuppressive effects on **vaccine** induced antibody levels in Guangzhou children.

Mou Z, Zhu P, Deng F, Xu Y, Qin P, Peng R, Li J, Tan L.Environ Pollut. 2025 Nov 15;385:127066. doi: 10.1016/j.envpol.2025.127066. Epub 2025 Sep 3.PMID: 40912534

Early MMR **Vaccine** Adoption During the 2025 Texas Measles Outbreak.

Goodwin Cartwright BM, Masters NB, Gilbert KM, Rodriguez PJ, Do D, Stucky N.JAMA Netw Open. 2025 Nov 3;8(11):e2543002. doi: 10.1001/jamanetworkopen.2025.43002.PMID: 41236743

Rabies virus-vectored Lyme disease **vaccine** provides long-term protection against tick-transmitted Borrelia burgdorferi.

Rios S, Bhattachan B, Wirblich C, Chandwani A, Vavilikolanu K, Myers JF, Kitsou C, Pal U, Schnell MJ.NPJ Vaccines. 2025 Nov 13;10(1):231. doi: 10.1038/s41541-025-01294-8.PMID: 41233361

Enhancing **vaccine** acceptance: a mixed methods approach to health promotion and willingness to pay among low-income Vietnamese communities.

Tran QV, Nguyen TTH, Thanh Nguyen H, Nguyen BT, Pham VNH, Anuratpanich L, Lam Vu T, Ngoc Phuong Ta A, Nguyen HTT, Nguyen CDQ, Van Nguyen P, Vo NX, My Thuc Truong U, Tang HK, Duc Phung N, Vo TQ.Expert Rev Pharmacoecon Outcomes Res. 2025 Nov 12:1-14. doi: 10.1080/14737167.2025.2583180. Online ahead of print.PMID: 41217045

Exploring **vaccine** acceptance using Protection Motivation Theory: A study of college students' behavioral intentions in the context of COVID-19.

Gopal S, Thomas Gil M.Hum Vaccin Immunother. 2025 Dec;21(1):2582973. doi: 10.1080/21645515.2025.2582973. Epub 2025 Nov 10.PMID: 41208502

Limited **vaccine**-induced CD8+ T cell immunity in HIV-infected immunological nonresponders.

Karl V, Graeser A, Kremser A, Bauersfeld L, Emmerich F, Herkt N, Rieg S, Usadel S, Bengsch B, Boettler T, Luxenburger H, Neumann-Haefelin C, Müller MC, Thimme R, Hofmann M.JCI Insight. 2025 Nov 10;10(21):e195458. doi: 10.1172/jci.insight.195458. eCollection 2025 Nov 10.PMID: 41212052

HCV genotyping and rational computational designing of an immunogenic multiepitope **vaccine** against genotype 3a.

Sahibzada KI, Abid R, Nisar H, Rahman RAAE, Idrees M, Wei DQ, Hu Y, Sadaf S.J Comput Aided Mol Des. 2025 Nov 10;39(2):121. doi: 10.1007/s10822-025-00698-x.PMID: 41212443

A "sweeter" approach to cancer immunotherapy: Glycopolymers as diverse tools for immune modulation.

Hulugalla K, Abodunrin OD, Anderson J, Smith AE, Werfel T.J Control Release. 2025 Nov 6:114372. doi: 10.1016/j.jconrel.2025.114372. Online ahead of print.PMID: 41205704

Engineered virus-hunter **vaccine** overcomes HBV immune tolerance.

Chen X, Liu X, Xu T, Wang Y, Wang P, Liu H, Jiang Y, Qin X, Zhang L, Xiong Y, Ding J, Chen Y, Chen F, Ning W, Zeng H, Yang S, Xu L, Zhang T, Yuan Q, Liu C, Luo W, Xia N.Gut. 2025 Nov 12:gutjnl-2025-335806. doi: 10.1136/gutjnl-2025-335806. Online ahead of print.PMID: 41198172

Does human cytomegalovirus provide a novel therapeutic target for patients with glioblastoma?

Söderberg-Naucler C, Pantalone MR, Stragliotto G, Bartek J.Philos Trans R Soc Lond B Biol Sci. 2025 Nov 6;380(1938):20240403. doi: 10.1098/rstb.2024.0403. Epub 2025 Nov 6.PMID: 41194660

Cellular contributions to the pathogenesis of anti-platelet factor 4 disorders.

Treverton J, Lychacz M, Arnold DM, Nazy I.Curr Opin Hematol. 2025 Nov 4. doi: 10.1097/MOH.0000000000000900. Online ahead of print.PMID: 41185522

Safety and immunogenicity of a Nipah virus **vaccine** (HeV-sG-V) in adults: a single-centre, randomised, observer-blind, placebo-controlled, phase 1 study.

Frenck RW Jr, Naficy A, Feser J, Dickey MP, Leyva-Grado VH, Egan MA, Chen T, Eldridge JH, Sciotto-Brown S, Hermida L, Promeneur D, Luckay A, Medina H, Lazaro GA, Patel NR, Naqvi T, Broder CC, Dimitrov AS, Gast C, Mercer LD, Raine M, Andi-Lolo I, Innis BL, Aponte JJ, Hamm S, Rathi N.Lancet. 2025 Nov 14:S0140-6736(25)01390-X. doi: 10.1016/S0140-6736(25)01390-X. Online ahead of print.PMID: 41248666

A synthesis of economic data from randomized trials of recipient-focused interventions to increase **vaccine** uptake.

Hamashima Y, Breheny K, Davies SR, Dawson S, Thornton ZA, Aiton E, Caldwell DM, Christensen H, Higgins JPT, Yates J, Letley L, French CE.Vaccine. 2025 Nov 3;68:127906. doi: 10.1016/j.vaccine.2025.127906. Online ahead of print.PMID: 41192046

Recombinant AAV **vaccine** expressing PEDV S1 enhances immunity with superior neonatal protection.

Pang M, Ren M, Jiang D, Tu T, Zhou Y, Wang Y.NPJ Vaccines. 2025 Nov 6;10(1):227. doi: 10.1038/s41541-025-01248-0.PMID: 41198694

Rational Design of DNA Nanostructures as TLR9 Agonists.

Chen C, Tian C, Jin Z, Wen Y, Xia X, Ren Q, Huang CZ, Zuo H.Biomacromolecules. 2025 Nov 10;26(11):7389-7397. doi: 10.1021/acs.biomac.5c00919. Epub 2025 Oct 8.PMID: 41060642

Emergence and characterization of historically extinct virulent genotype IV Newcastle disease virus in wild and domestic birds: genetic insights, pathogenicity, and **vaccine** efficacy.

Yan W, Liu X, Jiang S, Li H, Chi W, Luo R, Peng J, Jiang F, Li H, Stoeger T, Wajid A, Dodovski A, Gao C, Mingala CN, Andreychuk DB, Yin R.J Virol. 2025 Nov 13:e0164625. doi: 10.1128/jvi.01646-25. Online ahead of print.PMID: 41231019

Influenza, pneumococcal, COVID-19 **vaccine** willingness and uptake with influencing factors in 38,184 chinese older adults in 2022: a nationwide cross-sectional study.

Liu D, Zhang Y, Lei J, Li J, Xiang C, Peng Y, Hu Y, Fang L, Feng L, Shan G, Ding Y, Gao Q, Yang T; Respiratory Disease Prevention and Control of Chinese Preventive Medicine Association.Vaccine. 2025 Nov 5;68:127961. doi: 10.1016/j.vaccine.2025.127961. Online ahead of print.PMID: 41197445

Drivers of herpes zoster **vaccine** hesitancy in adults aged 50 and above: A machine learning approach.

Wang X, Shang S, Zou T, Hu Y, Zhang E, Li Y, Zhou J, Fang Q.Vaccine. 2025 Nov 14;66:127838. doi: 10.1016/j.vaccine.2025.127838. Epub 2025 Oct 12.PMID: 41082814

The rpZDIII **vaccine** triggers vertical protection on newborn mice against zika virus infection.

Miranda-López A, Castillo CG, González-Ortega O, Romero-Maldonado A, Comas-García M, Rosales-Mendoza S.Vaccine. 2025 Nov 7;68:127941. doi: 10.1016/j.vaccine.2025.127941. Online ahead of print.PMID: 41205403

TCR bias drives development of dominant **vaccine**-induced CD8+ T cell responses which can be redirected toward cellular targets.

Iversen EF, Rahimic AHF, Frattari GS, Rosás-Umbert M, Schleimann MH, Olesen R, Gunst JD, Søgaard OS, Krogsgaard M, Tolstrup M.Vaccine. 2025 Nov 14;66:127851. doi: 10.1016/j.vaccine.2025.127851. Epub 2025 Oct 14.PMID: 41092800

Nationwide survey of municipal policies and COVID-19 vaccination uptake among older adults in Japan during 2024-2025.

Machida M, Nomachi A, Tanabe K, Ito S, Nakaya T, Matono T.Hum Vaccin Immunother. 2025 Dec;21(1):2584760. doi: 10.1080/21645515.2025.2584760. Epub 2025 Nov 12.PMID: 41222055

From Misinformation to Action: A Multi-Faceted Approach to Combating **Vaccine** Hesitancy.

Pettoello-Mantovani M, Haddad J, Kuli-Lito G, Giardino I, Vural M, Sevketoglu E, Pop TL, Pastore M, Somekh E.J Pediatr. 2025 Nov 5:114895. doi: 10.1016/j.jpeds.2025.114895. Online ahead of print.PMID: 41203113

Investigation of the sero-epidemiology of **vaccine** preventable diseases and common viral infections in French populations.

Bloch E, Baudemont G, Donnadieu F, Garcia L, Pelleau S; SeroPed Study Consortium; Milieu Intérieur Consortium; Quintana-Murci L, Duffy D, Fontanet A, White M.Commun Med (Lond). 2025 Nov 13;5(1):465. doi: 10.1038/s43856-025-01162-5.PMID: 41233587

A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate **Vaccine**, in Pneumococcal **Vaccine**-Naive Adults 18-64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8.

Scott PT, Pathirana J, Kato A, Tytus R, Perez CM, Gilchrist NL, Kanou H, Ha Yoo K, Kania G, Nissen M, Russell AF, Fernsler D, Waleed M, Li J, Buchwald UK, Platt HL.Clin Infect Dis. 2025 Nov 10:ciaf604. doi: 10.1093/cid/ciaf604. Online ahead of print.PMID: 41208546

Toward a simplified vaccination schedule in France: How can the tools we possess be put to better use?

Cohen R, Launay O, Weil-Olivier C, Bakhache P, Bégué P, Dommergues MA, Dufour V, Gaudelus J, Hau I, Pinquier D, Thiebault G, Thollot F, le Sage FV, Levy C, Lefebvre M, Haas H.Infect Dis Now. 2025 Nov 8;55(8):105186. doi: 10.1016/j.idnow.2025.105186. Online ahead of print.PMID: 41213474

Genomic insights and immunoinformatics-driven design of a multi-epitope subunit **vaccine** candidate against Shamonda virus.

Oladipo EK, Adeyemo SF, Ogunniran JA, Ajiboye BO, Alabi VA, Odemakinde DI, Ogunmodede HJ, Hammed ZO, Adebanjo MA, Arowolo SM, Ogunwale N, Remi-Aworemi FB, Odetayo JK, Ganiyu OT, Jimah EM, Senbadejo TY, Awoyelu EH, Kolawole OM, Iwalokun BA, Onyeaka H.In Silico Pharmacol. 2025 Nov 6;13(3):170. doi: 10.1007/s40203-025-00460-z. eCollection 2025.PMID: 41211467

Design of chimera **vaccine** against cutavirus using vaccinomics and immunoinformatics approaches.

Ali SL, Ali A, Khan A.In Silico Pharmacol. 2025 Nov 6;13(3):172. doi: 10.1007/s40203-025-00467-6. eCollection 2025.PMID: 41211464

Targeting asparagine and cysteine in SARS-CoV-2 variants and human pro-inflammatory mediators to alleviate COVID-19 severity; a cross-section and in-silico study.

Fadel HH, El-Esseily HA, Ahmed MAE, Khamis Mohamed MA, Roushdy MN, ElSherif A, Gharbeya KM, Abdelsalam HS.Sci Rep. 2025 Nov 3;15(1):38445. doi: 10.1038/s41598-025-19359-y.PMID: 41184328

HBsAg-tagged tumour **vaccine** system eliminates solid tumours through virus-specific memory T cells.

Wang W, Chu Y, Zhao L, Lv M, Wang L, Jin F, Hu K, Cen L, Qin S, Li X, Zhao W, Hu Y, Zuo S, Yang Y.Nat Biomed Eng. 2025 Nov 17. doi: 10.1038/s41551-025-01555-w. Online ahead of print.PMID: 41249480

The Silent Risk of Sudan Virus: A Review Addressing Global Health Vulnerabilities.

Dewan SMR, Khan SA.Health Sci Rep. 2025 Nov 12;8(11):e71522. doi: 10.1002/hsr2.71522. eCollection 2025 Nov.PMID: 41245945

Silent CD24-engineered oncolytic virus **vaccine** enhances antitumor immunity.

Xu J, Liu Y, Luo F, Zhao J.Biochem Biophys Res Commun. 2025 Nov 13;792:152975. doi: 10.1016/j.bbrc.2025.152975. Online ahead of print.PMID: 41248606

Artificial intelligence, structural, and immunoinformatics-driven multi-epitope **vaccine** design targeting non-structural proteins of West Nile Virus.

Mallick R, Sethi G, Sethi S, Hwang JH, Krishna R.In Silico Pharmacol. 2025 Nov 6;13(3):177. doi: 10.1007/s40203-025-00459-6. eCollection 2025.PMID: 41211458

A trimer ancestral spike-based mRNA **vaccine** confers cross-generational protection against SADS-CoV.

Zhang T, Yao J, Guo X, Leng C, Liu S, Chen Y, Wang J, Sun M, Ma H, Li L, Yang K, Wang Y, Zhang G, Yao L.J Nanobiotechnology. 2025 Nov 4;23(1):700. doi: 10.1186/s12951-025-03767-3.PMID: 41185028

Long-Term Protection Against Invasive Meningococcal B Disease and Gonococcal Infection 5 Years After Implementation of Funded Childhood and Adolescent 4CMenB Vaccination Program in South Australia: An Observational Cohort and Case-Control Study.

Wang B, Giles L, Andraweera P, McMillan M, Beazley R, Almond S, Lally N, Bell C, Flood L, Ward J, Marshall H.Clin Infect Dis. 2025 Nov 6;81(4):e202-e210. doi: 10.1093/cid/ciaf372.PMID: 40644358

GPC3-based circular RNA **vaccine** suppresses hepatocellular carcinoma progression by activating adaptive immune responses.

Jiang Y, Li Y, Wu T, Cao L, Xu G, Liu J, Hua C, Ding C, Yang B, Tong R, Chen D, Wu J.Hepatology. 2025 Nov 7. doi: 10.1097/HEP.0000000000001605. Online ahead of print.PMID: 41201153

Active **vaccine** safety surveillance: Experience from a prospective cohort event monitoring study of COVID-19 vaccines in Kenya.

Odhiambo DB, Akech D, Karia B, Kimani M, Sang S, Sigilai A, Voller S, Mataza C, Mang'ong'o D, Jalang'o R, Mandale M, Etyang AO, Scott JAG, Agweyu A, Kagucia EW.PLOS Glob Public Health. 2025 Nov 17;5(11):e0005080. doi: 10.1371/journal.pgph.0005080. eCollection 2025.PMID: 41248143

Effectiveness of maternal vaccines and long-acting monoclonal antibodies against respiratory syncytial virus disease burden in early life: a scoping review of dynamic modelling studies.

Bicego A, Wood JG, Newall AT, Hogan AB.Vaccine. 2025 Nov 7;68:127868. doi: 10.1016/j.vaccine.2025.127868. Online ahead of print.PMID: 41205402

Highly efficient production of HIV-1_{AD8} gp120 in mammalian cells.

Mathur T, Ahmed S, Parthasarathy D, Herschhorn A.J Virol. 2025 Nov 7:e0135925. doi: 10.1128/jvi.01359-25. Online ahead of print.PMID: 41201241

TEDD: a comprehensive database for translation efficiency dynamics.

Lei W, Li C, Zhou H, Nie Z, Wang A, Li P, Fan Z, Zhu R, Cheng H, Guo Y, Yue L, Jiang X, Gao R, Sheng Y, Niu H, Bahetibieke T, Zhang W, Zhao W, Xiao J, Chen F.Nucleic Acids Res. 2025 Nov 11:gkaf1125. doi: 10.1093/nar/gkaf1125. Online ahead of print.PMID: 41217970

The potential public health benefit of live-attenuated pertussis vaccines.

Locht C, Rubin K.Expert Opin Drug Deliv. 2025 Nov 14. doi: 10.1080/17425247.2025.2590740. Online ahead of print.PMID: 41236784

Using behavior change techniques to identify components for adapting a vaccination in pregnancy communication intervention in Canada.

Patey AM, Castrellon Pardo M, Kennedy M, Surti MS, Amarbayan MM, Myers-Stewart M, Bruce M, Kaufman J, Danchin M, Donald M, Castillo E.JBI Evid Implement. 2025 Nov 11. doi: 10.1097/XEB.0000000000000538. Online ahead of print.PMID: 41208467

Impact and **vaccine** effectiveness of PPV23 vaccination in adults aged 65 years or older in the Netherlands.

Niessen FA, Steens A, Knol MJ, Groenwold RHH, Bonten MJM, van Sorge NM, de Melker HE, van Werkhoven CH.Clin Microbiol Infect. 2025 Nov 12:S1198-743X(25)00553-1. doi: 10.1016/j.cmi.2025.09.027. Online ahead of print.PMID: 41237898

Recombinant adjuvant zoster **vaccine**-associated acute mucocutaneous toxicity.

Choma N, Kumaresan H, Haury E, Ifteqar S.Scand J Rheumatol. 2025 Nov 13:1-2. doi: 10.1080/03009742.2025.2580769. Online ahead of print.PMID: 41230657

Recommendations for estimating and reporting **vaccine** effectiveness by time since vaccination: a COVID-19 case study.

Kissling E, Nunes B, Hooiveld M, Martínez-Baz I, Monge S, Robertson C, Knol M, Sève N, Mlinarić I, Domegan L, Machado A, Whitaker H, Lazar M, Meijer A, Enkirch T, Casado I, Pérez-Gimeno G, William N, Enouf V, Filipović SK, McKenna A, Rodrigues AP, de Lusignan S, Timnea OC, Latorre-Margalef N, Castilla J, Pozo F, Hamilton M, Masse S, Ilić M, Basile L, O'Donnell J, Guiomar R, Riess M, Popescu RM, Rose AMC, Andrews N, Bacci S, Celentano LP, Valenciano M, Moren A, Beutels P, Hens N, Ecdc Primary Care Study Teams OBOI.Am J Epidemiol. 2025 Nov 17:kwaf254. doi: 10.1093/aje/kwaf254. Online ahead of print.PMID: 41246933

Lipid nanoparticle-delivered mRNA **vaccine** encoding the MOMP of Chlamydia psittaci elicits protective immune responses in BALB/c mice.

Wang B, Xiao J, Wang J, Zhang W, Jin Y, Jiang Y, Chen Y, He Z, Lei A, Lu C, Wang C.Microbiol Spectr. 2025 Nov 5:e0143825. doi: 10.1128/spectrum.01438-25. Online ahead of print.PMID: 41190885

Insights into the multifunctionality of viral glycoproteins F and HN in the lifecycle and pathogenesis of Newcastle disease virus: a systematic review.

Ma S, Xia R, Wu W, Duan Z.Vet Res. 2025 Nov 5;56(1):212. doi: 10.1186/s13567-025-01647-0.PMID: 41194263

The Effects of Chirality and Salt Addition on Phase Separation and Complexation Morphology in Mixtures of Polypeptides and Polypeptoids.

Mirlohi K, Thapa A, Zhang D, Blocher McTigue WC.Biomacromolecules. 2025 Nov 10;26(11):7646-7655. doi: 10.1021/acs.biomac.5c01165. Epub 2025 Oct 8.PMID: 41061706

Immunogenicity and safety of concomitant vaccines given with 20-valent pneumococcal conjugate **vaccine** in healthy infants.

Senders S, Korbal P, Kline M, Tamimi N, Thompson A, Drozd J, Cutler MW, Giardina PC, Trammel J, Lei L, Peng Y, Watson W, McElwee K.Vaccine. 2025 Nov 3;68:127916. doi: 10.1016/j.vaccine.2025.127916. Online ahead of print.PMID: 41187484

Correcting COVID-19 **Vaccine** Misinformation: How **Vaccine** Information, Norm Beliefs, and Relational Closeness Influence Correction Intention.

Ju I, Yel E, Song H.Health Commun. 2025 Nov 14:1-12. doi: 10.1080/10410236.2025.2587160. Online ahead of print.PMID: 41236832

The Arizona prevention research center **vaccine** confidence network: A Mobile health unit intervention and survey results of barriers and facilitators to COVID-19 vaccination.

Nuño T, Soto S, Sepulveda R, Sierra LA, Harvey B, Dillingham N, Rascon E, Wilkinson-Lee A, Carvajal S, de Zapien J, Ingram M.Vaccine. 2025 Nov 13;60 Suppl 1:127970. doi: 10.1016/j.vaccine.2025.127970. Online ahead of print.PMID: 41240547

Genetic polymorphisms in the E2 glycoprotein of chikungunya virus (2014-2023) and their potential implications for immunity and **vaccine** design.

Fogaça MMC, Souza MS, Brito RDDS, Aguiar ERGR, Luiz WB, Vidal PO, Birbrair A, Antunes PDS, Durães-Carvalho R, Amorim JH.Int J Infect Dis. 2025 Nov 12:108193. doi: 10.1016/j.ijid.2025.108193. Online ahead of print.PMID: 41238172

A glycoprotein D-targeted lipid nanoparticle-encapsulated mRNA **vaccine** elicits strong protective immunity against pseudorabies virus.

Sun Y, Xu S-J, Zhou Y, Zhang Y, Zhang H, Le T, Bai Y-Z, Rao C-H, Huo S, Zhou T, An T-Q, Yin X, Yu F, Cai X-H, Tang Y-D.J Virol. 2025 Nov 6:e0147225. doi: 10.1128/jvi.01472-25. Online ahead of print.PMID: 41196061

Genomic surveillance of Streptococcus pneumoniae in India: **vaccine**-driven serotype shifts, antimicrobial resistance, and emerging clonal lineages.

Gopalakrishnan S, Jayapal P, John J.J Appl Microbiol. 2025 Nov 4;136(11):lxaf268. doi: 10.1093/jambio/lxaf268.PMID: 41160427

IL-6 and IL-8 elevations after co-administration of COVID-19 and influenza vaccines are associated with lower anti-spike IgG titers at three and six months post-vaccination.

Schiavoni I, Muglia A, Leone P, Olivetta E, Abrignani S, Anzà D, Bandera A, Fortunato F, Gori A, Grifantini R, Lazzarotto T, Lodi V, Prato R, Restivo V, Palamara AT, Stefanelli P, Fedele G; COVAC-3 Study Group.Cytokine. 2025 Nov 5;197:157066. doi: 10.1016/j.cyto.2025.157066. Online ahead of print.PMID: 41197246

Factors influencing adolescents' attitudes towards vaccination.

Dağ P.Clinics (Sao Paulo). 2025 Nov 12;80:100824. doi: 10.1016/j.clinsp.2025.100824. Online ahead of print.PMID: 41232429

Causes and consequences of undervaccination in adults.

Gil-de-Miguel Á, Navarro-Alonso JA, Arrazola-Martínez MP, Cantarero D, Arellano M, Cremades-Bernabéu A, Fernández-Prada M, Gil-Prieto R, Gracia D, Martínez-Palancar E, Pérez-Martín JJ, Redondo-Margüello E, Sebastián N, Tolosa-Martínez N, Bouza E.Rev Esp Quimioter. 2025 Nov 11:106.2025. doi: 10.37201/req/106.2025. Online ahead of print.PMID: 41235775

Changing Attitudes and Motivations Around Coronavirus Disease 2019 Vaccination Within an Agricultural Community in Southwest Guatemala.

Rojop N, Weikel B, Lamb MM, Barrientos DM, Gomez M, Olson D.Am J Trop Med Hyg. 2025 Aug 26;113(5):1075-1078. doi: 10.4269/ajtmh.25-0149. Print 2025 Nov 5.PMID: 40858123

Genetic variation and **vaccine** match of influenza B virus in Riyadh, Saudi Arabia during three consecutive seasons, 2020-2023.

Alkubaisi NA, Aziz IM, Farrag MA, Aljowaie RM, Almajhdi FN.Virus Genes. 2025 Nov 10. doi: 10.1007/s11262-025-02198-4. Online ahead of print.PMID: 41212486

Determinants of uptake of childhood immunization in Gboko, Benue State, Nigeria.

Iba B, Zar VD, Oteng J.BMC Public Health. 2025 Nov 14;25(1):3940. doi: 10.1186/s12889-025-25355-8.PMID: 41239362

Extracellular matrix-mimicking cryogels in tissue engineering and cancer therapy: from structural design to translational applications abstract.

Liu Y, Li C, Zhu T, Li R, Zhang M, Li X, Cai D, Dai Z, Wan L, Lu H.J Mater Chem B. 2025 Nov 12;13(44):14166-14193. doi: 10.1039/d5tb01412c.PMID: 41078341

Vaccination uptake and associated factors among HIV pre-exposure prophylaxis (PrEP) users: insights from a retrospective cross-sectional study.

Shapiro Ben David S, Rahamim-Cohen D, Orvieto N, Cohen B, Adler L.BMC Public Health. 2025 Nov 17;25(1):3996. doi: 10.1186/s12889-025-25408-y.PMID: 41250089

Research progress in NSP2 of porcine reproductive and respiratory syndrome virus.

Liang F, Li J, Lan X, Ye Y, Li G, Li F, Lv C, Liu K, Yang Z, Sun R, Zheng Y, Wang L, Li H, Wang R, Zhang K, Zhao M.Virology. 2025 Nov 14;614:110743. doi: 10.1016/j.virol.2025.110743. Online ahead of print.PMID: 41242059

Respiratory immunization using antibiotic-inactivated Bordetella pertussis confers T cell-mediated protection against nasal infection in mice.

Jazayeri SD, Borkner L, Sutton CE, Mills KHG.Nat Microbiol. 2025 Nov 10. doi: 10.1038/s41564-025-02166-6. Online ahead of print.PMID: 41214155

Strengthening New **Vaccine** Introduction in Low- and Middle-Income Countries: Establishing Hospital-Based Sentinel Surveillance for **Vaccine** Safety Monitoring.

Shaum A, Blau E, Longley A, Huang WT, Gidudu J.Am J Trop Med Hyg. 2025 Sep 4;113(5):945-949. doi: 10.4269/ajtmh.25-0363. Print 2025 Nov 5.PMID: 40907498

Biosurfactants as novel antibiofilm agents: mechanisms, biomedical applications, and applications in biofilm-associated infections.

Datta D, Bhattacharjee S.Arch Microbiol. 2025 Nov 10;208(1):6. doi: 10.1007/s00203-025-04555-1.PMID: 41212219

Rhamno-oligosaccharide-based glycoconjugates as promising **vaccine** candidates against Group A Streptococcus.

Wang G, Sun C, Zhao J, Zhang Y, Gu G.Int J Biol Macromol. 2025 Nov 5;333(Pt 1):148785. doi: 10.1016/j.ijbiomac.2025.148785. Online ahead of print.PMID: 41197701

National identification and trust in institutions: understanding lower COVID-19 vaccination uptake among ethnic minorities in Europe.

Foran AM, Jetten J, Muldoon OT.Eur J Public Health. 2025 Nov 10:ckaf206. doi: 10.1093/eurpub/ckaf206. Online ahead of print.PMID: 41211740

The path to equitable respiratory syncytial virus prevention for infants: challenges and opportunities for global implementation.

Shaaban FL, Groenendijk RW, Baral R, Caballero MT, Crowe JE Jr, Englund JA, Esteban I, Hirve S, Jit M, Kalergis AM, Karron RA, Lukacs N, Martinon-Torres F, Mejias A, Nair H, Nisar MI, Nyiro JU, Pecenka C, Sparrow E, Srikantiah P, Thwaites RS, Zar HJ, Bont LJ.Lancet Glob Health. 2025 Dec;13(12):e2165-e2174. doi: 10.1016/S2214-109X(25)00379-1. Epub 2025 Nov 3.PMID: 41197645

Development and evaluation of multiepitope fusion proteins for serological diagnosis of animal brucellosis.

Guo L, Pei Q, Zhao S, Qi X, Chen Y, Yang P, Du Y, Sun M, Yin D, Zhan T.Microbiol Spectr. 2025 Nov 4;13(11):e0051625. doi: 10.1128/spectrum.00516-25. Epub 2025 Sep 30.PMID: 41025662

Designing Programmable Peptide Nucleic Acid-based Nanovaccines for Anticancer Immune Activation.

Huang Y, Huang C, Pandita S, Ieong CM, Wang Y, Wang D, Chen J, Jauregui-Matos V, Beelen AMA, Shiau YP, Tang S, Zhao J, Zong Q, Tang M, Cong Z, Li Y, Beal PA, David SS, Wang A, Wang D, Xiao Z, Lam KS.Small. 2025 Nov 7:e05605. doi: 10.1002/smll.202505605. Online ahead of print.PMID: 41201142

Protein nanoparticles assemble in plants, display antigenic viral peptides, and produce an epitope-specific immune response.

VanderBurgt JT, Strasser R, Zhu H, Kaldis A, Garnham CP, Menassa R.FEBS J. 2025 Nov 17. doi: 10.1111/febs.70288. Online ahead of print.PMID: 41247829

The resilience of **vaccine** serotypes in adult invasive pneumococcal disease in Portugal, 2018-2023.

Guerreiro-Nunes A, Silva-Costa C, Gomes-Silva J, Ramirez M, Melo-Cristino J; Portuguese Group for the Study of Streptococcal Infections.Sci Rep. 2025 Nov 17;15(1):40146. doi: 10.1038/s41598-025-23819-w.PMID: 41249230

Genetic characteristics of influenza A/H3N2 virus in Jiaxing, China (2019-2024).

Song Y, Zhang X, Ji J, Li L, Zhou Y, Li P, Ren G, Lv S, Zhang X, Yan Y, Zhu G.Virol J. 2025 Nov 4;22(1):359. doi: 10.1186/s12985-025-02974-6.PMID: 41188942

Sustained impact of bivalent HPV immunisation on CIN incidence over two rounds of cervical screening.

Palmer TJ, Kavanagh K, Cuschieri K, Cameron RL, Graham C, Wilson A, Roy K.Int J Cancer. 2025 Nov 3. doi: 10.1002/ijc.70183. Online ahead of print.PMID: 41185413

Combination Vaccines: A Comprehensive Review of Pharmacokinetics, Pharmacodynamics, Regulatory Challenges, and Clinical Evidence.

Grewal N, Narwal S, Singh G, Dushyant, Dhingra AK, Verma M, Chanalia V, Garg P, Yadav N.Rev Recent Clin Trials. 2025 Nov 3. doi: 10.2174/0115748871404248251013160024. Online ahead of print.PMID: 41185516

Cost-effectiveness analysis of different types of human papillomavirus vaccination to prevent cervical cancer in Iran.

Bashari N, Davari M, Akbarisari A, Khorasani E, Daroudi R.BMC Public Health. 2025 Nov 13;25(1):3927. doi: 10.1186/s12889-025-24916-1.PMID: 41233775

Allergic Adverse Reactions Following Measles-Mumps-Rubella Vaccination in Children with Food Allergy: A Prospective Multicenter Study.

Sipahi Cimen S, Kara Elitok G, Erbay MF, Bulbul L, Ozceker D, Yılmazbas P, Sayili U, Altinel ZU, Bulbul A.Pediatr Allergy Immunol Pulmonol. 2025 Nov 10. doi: 10.1177/2151321X251393016. Online ahead of print.PMID: 41212098

"This is not any of your business so stop your bulls**t": An abductive thematic analysis of antagonism towards others in a vaccination study.

Van Vleet B, Fuller HR, Huseth-Zosel A, Giddens A.Patient Educ Couns. 2025 Nov 12;143:109417. doi: 10.1016/j.pec.2025.109417. Online ahead of print.PMID: 41242132

Enabling global access to potent subunit vaccines with a simple and scalable injectable hydrogel platform.

Ganesh P, Prossnitz AN, Jons CK, Eckman N, Alakesh A, Song YE, Sen S, Appel EA.Biomater Sci. 2025 Nov 5. doi: 10.1039/d5bm01131k. Online ahead of print.PMID: 41190921

Post-pandemic questions in vaccination counseling: Two qualitative analyses of open-ended responses comparing hypothetical and novel vaccines.

Shamsrizi P, Eitze S, Heinemeier D, Tänzer AS, Jenny MA.Vaccine. 2025 Nov 14;66:127823. doi: 10.1016/j.vaccine.2025.127823. Epub 2025 Oct 8.PMID: 41066985

AstraMEV (AI-Guided Structural Assembly of Multi-Epitope Vaccines) Against Infectious Bronchitis Virus.

Dey S, Gates H, Salehi R, Danurdoro R, Ferdous S, Chowdhury R.J Chem Inf Model. 2025 Nov 10;65(21):12068-12087. doi: 10.1021/acs.jcim.5c01809. Epub 2025 Oct 23.PMID: 41131667

Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial.

Batmunkh T, Neal EFG, Amraa O, Mazarakis N, Altangerel B, Avaa N, Batbayar L, Batsukh K, Bright K, Burentogtokh T, Do LAH, Dorj G, Hart JD, Jamiyandorj O, Javkhlantugs K, Jigjidsuren S, Justice F, Li S, Mashbaatar K, Moore KA, Namjil N, Nguyen CD, Ochirbat B, Surenjav U, Thomson H, Tsolmon B, Licciardi

PV, von Mollendorf C, Mulholland K.Vaccine. 2025 Nov 14;66:127840. doi: 10.1016/j.vaccine.2025.127840. Epub 2025 Oct 9.PMID: 41072276

Effect of informational videos on **vaccine** perceptions among unvaccinated individuals: a randomised educational intervention.

Martinez SK, Sonderegger S, Brownback A, Cruces G, Pompeo M, Morling J.BMJ Public Health. 2025 Nov 4;3(2):e001644. doi: 10.1136/bmjph-2024-001644. eCollection 2025.PMID: 41211580

Live-attenuated influenza virus **vaccine** strain with an engineered temperature-sensitive and genetically stable viral polymerase variant.

Naito T, Ushirogawa H, Kunishio M, Yano H, Saito S, Higeuchi T, Fujita K, Saito M.J Virol. 2025 Nov 13:e0139025. doi: 10.1128/jvi.01390-25. Online ahead of print.PMID: 41231009

Live-attenuated influenza virus **vaccine** strain with an engineered temperature-sensitive and genetically stable viral polymerase variant.

Naito T, Ushirogawa H, Kunishio M, Yano H, Saito S, Higeuchi T, Fujita K, Saito M.J Virol. 2025 Nov 13:e0139025. doi: 10.1128/jvi.01390-25. Online ahead of print.PMID: 41231009

More than half of shoulder vaccinations may end up in the subacromial space.

Kutaish H, Bouché PA, Rivera PM, Cornevin A, Borgonovo A, Mombelli S, Brandariz R, De Pree B, Cunningham AL, Cunningham G.NPJ Vaccines. 2025 Nov 11;10(1):229. doi: 10.1038/s41541-025-01279-7.PMID: 41219236

Identification and characterization of a novel plaque-invisible lytic single-stranded RNA phage.

Wang Y, Tian F, Zhang J, Xu S, Li M, Tong Y.J Virol. 2025 Nov 10:e0163724. doi: 10.1128/jvi.01637-24. Online ahead of print.PMID: 41211992

Recent advances of engineered bacteria for therapeutic applications.

Xiang X, Zhou Z, Rao X, Jiang XR.Mol Ther. 2025 Nov 12:S1525-0016(25)00952-9. doi: 10.1016/j.ymthe.2025.11.013. Online ahead of print.PMID: 41234015

Advances in Cancer Vaccines for Digestive System Cancers: A Systematic Analysis of Clinical Trials.

Li J, Wang P.Cancer Manag Res. 2025 Nov 11;17:2691-2703. doi: 10.2147/CMAR.S561298. eCollection 2025.PMID: 41245584

Evaluation of immune response in BALB/c mice generated by SARS-CoV-2 membrane-envelope virus-like particles.

Kumar A, Singh ON, Surjit M, Kumar V, Parvez MK, Sinha GP, Inampudi KK, Sehgal D.Int J Biol Macromol. 2025 Nov 6;333(Pt 1):148716. doi: 10.1016/j.ijbiomac.2025.148716. Online ahead of print.PMID: 41205961

Tick-borne Encephalitis in International Travelers: A Systematic Review and **Vaccine** Recommendations.

Srinivasan R, Angulo FJ, Duench S, Davidson A, Kelly PH, Riddle MS, Halsby K, Pilz A, Steffen R, Stark JH.J Travel Med. 2025 Nov 8:taaf115. doi: 10.1093/jtm/taaf115. Online ahead of print.PMID: 41206718

Immunogenicity and safety of a SARS-CoV-2 N-terminal domain and receptor-binding domain monovalent XBB.1.5 **vaccine** in Japanese participants.

Grassi CM, Feng J, Wahid R, Kandinov B, Goel S, Wang D, Sellers K, Dixit A, Kogawara O, Das R, Chalkias S.Vaccine. 2025 Nov 11;69:127960. doi: 10.1016/j.vaccine.2025.127960. Online ahead of print.PMID: 41223690

Differential impact of porcine reproductive and respiratory virus and swine Influenza A virus infections on respiratory Lymph Nodes B cells and macrophages.

Hervet C, Perrin A, Renson P, Deblanc C, Muñoz M, Meurens F, Argilaguet J, Simon G, Bourry O, Maisonnasse P, Bertho N.Mol Immunol. 2025 Nov 10;188:98-110. doi: 10.1016/j.molimm.2025.10.010. Online ahead of print.PMID: 41218477

Energy security as a crucial component of health infrastructure: global evidence and actions.

NIHR Global Health Research Unit on Global Surgery.Lancet Planet Health. 2025 Nov 11:101329. doi: 10.1016/j.lanplh.2025.101329. Online ahead of print.PMID: 41237797

Corrigendum to "Long-term neutralization capacity of **vaccine** and breakthrough infection induced SARS-CoV-2 specific antibodies against omicron subvariants BA.2, XBB.1.5, and JN.1" [**Vaccine** 68 (2025) 127894].

Reinholm A, Khan H, Laakso T, Maljanen S, Jalkanen P, Gunell M, Kallonen T, Österlund P, Ritvos O, Nousiainen A, Häkkinen HK, Pakkanen SH, Välimaa H, Kantele A, Lempainen J, Julkunen I, Kolehmainen P, Kakkola L.Vaccine. 2025 Nov 7;68:127939. doi: 10.1016/j.vaccine.2025.127939. Online ahead of print.PMID: 41205405

Immunoinformatics-based strategies for developing DNA and mRNA vaccines against monkeypox virus (MPXV).

Khan S, Ikram Ullah, Rizwan M, Zhang Y, Zeb A, Ubaidullah, Hamza A, Zhang S, Lu X, Feng X.Virol J. 2025 Nov 14;22(1):377. doi: 10.1186/s12985-025-02982-6.PMID: 41239337

Tumor-Targeted Bacterial **Vaccine** Induces In Situ Immunogenic Cell Death for Cancer Immunotherapy.

Wu Y, Wu N, Xu Y, Yang C, Zhou H, Jiang W, Shen J, Liu H, Li M.Nano Lett. 2025 Nov 6. doi: 10.1021/acs.nanolett.5c03938. Online ahead of print.PMID: 41196813

Complications and mortality of typhoid fever: an updated global systematic review and meta-analysis.

Murthy S, Hagedoorn NN, Faigan S, Rathan MD, Marchello CS, Crump JA.Lancet Infect Dis. 2025 Nov 12:S1473-3099(25)00551-1. doi: 10.1016/S1473-3099(25)00551-1. Online ahead of print.PMID: 41240962

Enhancing O-linking oligosaccharyltransferase functionality through directed evolution.

Edwards RL, McAllister KN, McGuffey JC, Knoot CJ, Hooppaw AJ, Mackel JJ, Zhou B, Robinson LS, Scott NE, Harding CM.J Biol Chem. 2025 Nov 5:110885. doi: 10.1016/j.jbc.2025.110885. Online ahead of print.PMID: 41203123

COVID-19 vaccination and miscarriage risk: RNA-seq and bioinformatics analysis at the maternal-foetal interface.

Qu Y, Zhu C, Sun T, Jiang J, Gu Y, Jin L, Huang X, Wu B, Xu J, Chen X.J Glob Health. 2025 Nov 14;15:04129. doi: 10.7189/jogh.15.04129.PMID: 41232126

Bridging biology and therapy: translational advances of extracellular vesicles in veterinary clinical practice.

Gad WA, Ibrahim S, Nagdy H, Elsawy BSM, Aboelsoued D, Abdel-Ghany HSM, Abdel-Wareth AAA, Abd El-Razik KA, Mahmoud KGM, Soliman WTM, Taqi MO.Vet Res Commun. 2025 Nov 17;50(1):42. doi: 10.1007/s11259-025-10917-3.PMID: 41247562

Adapting the WHO Behavioural and Social Drivers of Vaccination (BeSD) tools and Vaccination Attitudes Examination (VAX) scale for pregnant women in South Africa: Insights from a mixed-methods pilot study.

Ayouni I, Githaiga JN, Amponsah-Dacosta E, Kagina BM, Muloiwa R.PLoS One. 2025 Nov 5;20(11):e0334854. doi: 10.1371/journal.pone.0334854. eCollection 2025.PMID: 41191633

IgG binding characteristics of ferret Fcγ receptors.

Ge X, Stoner M, Weiner JA, Balderas Hernández ME, Taher N, Khanwalkar US, Carpenter MC, Lee J, Ackerman ME.MAbs. 2025 Dec;17(1):2590248. doi: 10.1080/19420862.2025.2590248. Epub 2025 Nov 17.PMID: 41250609

Infodemiology of public sentiment toward the measles **vaccine** in Canada: A google trends and health belief model-based analysis, 2025.

Jokar M, Goddard Q, Nobrega D.Vaccine. 2025 Nov 14;69:127998. doi: 10.1016/j.vaccine.2025.127998. Online ahead of print.PMID: 41240587

Safety of live attenuated vaccines in immunocompromised individuals and pregnant women: a systematic literature review.

Tiozzo G, de Roo A, Hofstra HS, Gurgel Do Amaral GS, Vondeling GT, Postma MJ, Freriks RD.Expert Rev Vaccines. 2025 Nov 12. doi: 10.1080/14760584.2025.2589213. Online ahead of print.PMID: 41220274

The emergence of a highly pathogenic marek's disease virus featuring newly identified mutations in Meq oncogene in Southern China.

Luo Q, Li H, Ge Z, Chen Z, Chen R.Virol J. 2025 Nov 4;22(1):360. doi: 10.1186/s12985-025-02931-3.PMID: 41188975

Engineered migrasomes provide a robust and thermally stable vaccination platform.

Wang D, Wang H, Wan W, Zhu Z, Sho T, Zheng Y, Zhang X, Dou L, Ding Q, Yu L, Liu Z.Elife. 2025 Nov 13;13:RP97621. doi: 10.7554/eLife.97621.PMID: 41231123

Genetic characterization of measles virus circulating in Jharkhand.

Aparajita A, Sharma AK, Sinha N, Seema K, Kumar A, Boipai M, Kumar M.Indian J Med Microbiol. 2025 Nov 6;58:101006. doi: 10.1016/j.ijmmb.2025.101006. Online ahead of print.PMID: 41205652

Differentiating COVID-19 **vaccine**-related adverse events from long COVID: A comprehensive review of clinical manifestations, pathophysiology, and diagnostic approaches.

Domingo JL.Vaccine. 2025 Nov 14;66:127842. doi: 10.1016/j.vaccine.2025.127842. Epub 2025 Oct 11.PMID: 41076807

Value profile for Malaria vaccines and monoclonal antibodies.

Birkett AJ, Ansah E, Gordon S, Gyapong M, Hall S, Kelly SL, Laurens M, Penny MA, Shirey M, Slutsker L, Sparrow E, Ethelston S, Westercamp N, Wu L, Hamel MJ.Vaccine. 2025 Nov 15:127971. doi: 10.1016/j.vaccine.2025.127971. Online ahead of print.PMID: 41241619

High-Dose vs. Standard-Dose Influenza **Vaccine** and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis.

Johansen ND, Modin D, Pardo-Seco J, Rodriguez-Tenreiro-Sánchez C, Loiacono MM, Harris RC, Dufournet M, van Aalst R, Chit A, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Claggett BL, Janstrup KH, Duran-Parrondo C, Piñeiro-Sotelo M, Cribeiro-González M, Conde-Pájaro M, Mirás-Carballal S, González-Pérez JM, Solomon SD, Sivapalan P, Martel CJ, Jensen JUS, Martinón-Torres F, Biering-Sørensen T; DANFLU-2 Study Group and the GALFLU Trial Team.Circulation. 2025 Nov 10. doi: 10.1161/CIRCULATIONAHA.125.077801. Online ahead of print.PMID: 41212981

Safety profile and medium- to long-term protection of the Recombinant Zoster **vaccine** (RZV) in a cohort of high-risk patients: real-world data from a General Hospital in Southern Italy, 2021-2025.

Stefanizzi P, Moscara L, Palmieri C, Martinelli A, Di Lorenzo A, Scaltrito C, Buonvino P, Oliveto F, Pice G, Marchisella L, Spinelli G, Tafuri S.Expert Rev Vaccines. 2025 Nov 11. doi: 10.1080/14760584.2025.2589216. Online ahead of print.PMID: 41220243

Lipid nanoparticle encapsulated membrane-anchored E2 mRNA **vaccine** elicits cross-protective immune responses against bovine viral diarrhoea virus infection in calves.

Le T, Jia B, Sun C, Zhou Y, Qi Y, Liu H, Bian H, Tian C, Wang J, Xue F, Zhu Y, Chang J, Luan Y, Zhang Z, Li Z, Tai W, Jiang Z, Yin X.Vaccine. 2025 Nov 14;66:127841. doi: 10.1016/j.vaccine.2025.127841. Epub 2025 Oct 9.PMID: 41072279

Enhancing Cancer Therapy with TLR7/8 Agonists: Applications in Vaccines and Combination Treatments.

Mondal J, Prabha S, Griffith TS, Ferguson D, Panyam J.Cancers (Basel). 2025 Nov 6;17(21):3582. doi: 10.3390/cancers17213582.PMID: 41228373

Socio-economic determinants for reduced uptake of routine childhood vaccination in Afghanistan.

Saeedzai SA, Knight J, Filipe L, Moore S, Loevinsohn B.Glob Health Action. 2025 Dec;18(1):2582262. doi: 10.1080/16549716.2025.2582262. Epub 2025 Nov 13.PMID: 41230974

Potent neutralization of Marburg virus by a **vaccine**-elicited antibody.

Addetia A, Perruzza L, Sprouse K, Park YJ, McCallum M, Stewart C, Partini B, Brown JT, Donati A, Culap K, Balmelli A, Chawla B, Kar S, Gazi M, Alfson K, Goez-Gazi Y, Carrion R Jr, Corti D, Benigni F, Veesler D.Nature. 2025 Nov 12. doi: 10.1038/s41586-025-09868-1. Online ahead of print.PMID: 41225006

From Discovery to Preservation: The Changing Face of Tasmanian Devil Research.

Hogg CJ, McLennan EA, Farquharson KA, Belov K.Annu Rev Anim Biosci. 2025 Nov 12. doi: 10.1146/annurev-animal-030424-070903. Online ahead of print.PMID: 41223411

Subtractive proteomic analysis to identify highly antigenic proteins and reverse vaccinology based novel **vaccine** development against Haemophillius parainfluenzae.

Ahmad A, Zhao J, Kakakhel S, Khan SA, Aiman S, Malik A, Khan AA, Fatima S, Alshememry AK, Ul-Haq Z, Huang K.Sci Rep. 2025 Nov 12;15(1):39584. doi: 10.1038/s41598-025-98720-7.PMID: 41225176

Corrigendum to "Development of African horse sickness disabled infectious single animal (DISA)-DIVA **vaccine** platform applied for all nine serotypes" [**Vaccine** 64 (2025) 127772].

van Rijn PA, Wernery U, Feddema AJ, Maris-Veldhuis MA, Joseph S, van Gennip RGP.Vaccine. 2025 Nov 14;66:127839. doi: 10.1016/j.vaccine.2025.127839. Epub 2025 Oct 14.PMID: 41092799

Superinfection interference of alpha and orthoflavivirus pathogens by homologous non-pathogenic **vaccine** strains.

Hicks J, Brown DT, Anthony RA, Liu H-C, Hernandez R.Microbiol Spectr. 2025 Nov 3:e0336224. doi: 10.1128/spectrum.03362-24. Online ahead of print.PMID: 41181972

Long-term trends in reporting of cardiac adverse drug reactions to COVID-19 vaccines - an exploratory analysis of the EudraVigilance database.

Nazar W, Romantowski J, Nazar G, Niedoszytko M, Daniłowicz-Szymanowicz L.BMC Infect Dis. 2025 Nov 14;25(1):1584. doi: 10.1186/s12879-025-12023-w.PMID: 41239286

Trust in healthcare providers, information sources, and concerns for new maternal vaccines among pregnant and lactating women in Kenya.

Schue JL, Fesshaye B, Miller E, Singh P, Sauer M, Njogu R, Jalang'o R, Nyiro J, Karron RA, Limaye RJ.PLOS Glob Public Health. 2025 Nov 12;5(11):e0004499. doi: 10.1371/journal.pgph.0004499. eCollection 2025.PMID: 41223190

Protective efficacy of two novel Klebsiella pneumoniae **vaccine** antigens, LysM/BON and OMPP1, in a murine model.

Hou Y, Zarodkiewicz P, Cortázar JT, Stoner D, Tulauskas Z, Macori G, Valvano MA, Ingram R, McClean S.Vaccine. 2025 Nov 14;66:127844. doi: 10.1016/j.vaccine.2025.127844. Epub 2025 Oct 13.PMID: 41086758

Scaffold vaccination for prevention of orthopedic device infection.

Tatara AM, Lightbown S, Kang S, Jung WH, Ijaz H, Lee JC, Nelson SB, Super M, Mooney DJ.Proc Natl Acad Sci U S A. 2025 Nov 11;122(45):e2409562122. doi: 10.1073/pnas.2409562122. Epub 2025 Nov 3.PMID: 41183185

No compelling evidence that vaccination with streptococcus pyogenes group A carbohydrate elicits cross-reactive rheumatic fever autoantibodies.

Parks T, Cunningham MW, Saul A.NPJ Vaccines. 2025 Nov 3;10(1):224. doi: 10.1038/s41541-025-01272-0.PMID: 41184285

Evaluating the preliminary effectiveness of a video-based intervention for HPV vaccination promotion among college students aged 18-26: study protocol for a pilot randomised controlled trial.

Liu C, Chen AC, Rhodes N, Ewoldsen D, Arcoleo K.BMJ Open. 2025 Nov 16;15(11):e102235. doi: 10.1136/bmjopen-2025-102235.PMID: 41248380

Heterologous sequential immunization using chimeric mRNA and protein vaccines with HA-stem and S-RBD enhanced protective mucosal immunity against influenza and COVID-19.

Li Y, Wang X, Zeng X, Zhu B.Sci Rep. 2025 Nov 4;15(1):38639. doi: 10.1038/s41598-025-22414-3.PMID: 41188345

Genomic and pathological insights into the first identified genotype IIIb chicken anemia virus strain in Bangladesh.

Akter M, Mia R, Hasan SN, Mozumder A, Jeba N, Farazi R, Akter F, Akter S, Rahman MZ, Saha S, Islam T, Hossain MG.Microbiol Spectr. 2025 Nov 4;13(11):e0079625. doi: 10.1128/spectrum.00796-25. Epub 2025 Oct 10.PMID: 41071091

Structural and evolutionary constraints shape adaptive landscapes of immune-related genes across mammalian phylogeny.

Li Z, Hassan M, Ahmad HI, Ashraf MA, Asif AR, Qadeer I, Shahzad AH, Abbas S, Sajid M, Mateen A, Ahmed I, Muhammad J, Muhammad SA, Ataya FS.PLoS One. 2025 Nov 7;20(11):e0332734. doi: 10.1371/journal.pone.0332734. eCollection 2025.PMID: 41202012

Facts and hopes in radioimmunotherapy for localized stages of cancer.

Bosi C, Ho AY, Gregucci F, Formenti SC.Clin Cancer Res. 2025 Nov 3. doi: 10.1158/1078-0432.CCR-25-1603. Online ahead of print.PMID: 41182431

U.S. state lawmaker support for COVID-19 **vaccine** policies during the pandemic.

O'Brien TL, Johnson DR.Vaccine. 2025 Nov 7;68:127930. doi: 10.1016/j.vaccine.2025.127930. Online ahead of print.PMID: 41205401

Accessing robust **vaccine** coformulation stability by single adjuvant detection on a microelectrode.

Wagner AA, Herrera DP, Rudder AL, Kinsey C, Foley DA, Thompson DH, Payne EM, Dick JE.Proc Natl Acad Sci U S A. 2025 Nov 4;122(44):e2522044122. doi: 10.1073/pnas.2522044122. Epub 2025 Oct 28.PMID: 41150712

Structural and functional characterization of P1L, an anti-apoptotic Bcl-2-like protein from monkeypox virus.

Ye M, Chen A, Ding J, Li J.Biochem Biophys Res Commun. 2025 Nov 7;791:152939. doi: 10.1016/j.bbrc.2025.152939. Online ahead of print.PMID: 41218414

Characteristics of neuraminidase-specific immune responses in influenza vaccinated or naturally infected populations in Shenzhen, China.

Deng L, Fan X, Li J, Yin D, Zhao Y, Han Z, Jiang S, Shu Y, Yuan J, Sun C.Vaccine. 2025 Nov 10;69:127918. doi: 10.1016/j.vaccine.2025.127918. Online ahead of print.PMID: 41218569

Effector Functions of Conventional and Unconventional *Mycobacterium tuberculosis* (*Mtb*)-Specific T Cells.

Panda S, Kearns K, Lindestam Arlehamn CS.Cold Spring Harb Perspect Med. 2025 Nov 3:a041829. doi: 10.1101/cshperspect.a041829. Online ahead of print.PMID: 41184129

A phase II trial to evaluate the safety and immunogenicity of two doses of a folate receptor alpha **vaccine** in patients with triple negative breast cancer.

Knutson KL, Abu-Fares H, Keating P, Block MS, Norton N, Erskine CL, Cogen D, Assad H, Graff SL, Hamilton EP, Han HS, McIntyre KJ, Nassar A, Sparano JA, Tiersten A, Tkaczuk KH, Ward PJ, Wilson G, Garrett G, Kenney RT, Sharma P.Clin Cancer Res. 2025 Nov 10. doi: 10.1158/1078-0432.CCR-25-2763. Online ahead of print.PMID: 41213103

Impact of Influenza Vaccination during Pregnancy on Maternal Influenza Disease Severity in Rural Nepal.

Frivold C, Katz J, Lama TP, Tielsch JM, Khatry SK, LeClerq SC, Carone M, John-Stewart G, Khosropour CM, Englund JA, Chu HY.Am J Trop Med Hyg. 2025 Nov 6:tpmd250065. doi: 10.4269/ajtmh.25-0065. Online ahead of print.PMID: 41197135

HPV vaccination: analysis of acceptability among mothers - a study of 160 cases.

Bannour I, Mastouri S, Bannour R, Saoudi R, Chahed S, Bannour B.Int J Adolesc Med Health. 2025 Nov 5. doi: 10.1515/ijamh-2025-0141. Online ahead of print.PMID: 41187992

Human papillomavirus infection and vaccination among young females in rural Uganda.

Newton R, Tenet V, Mugisha J, Kimono B, Vorsters A, Bell M, Clifford GM.Int J Cancer. 2025 Nov 6. doi: 10.1002/ijc.70227. Online ahead of print.PMID: 41195830

Algae extract supplementation boosts humoral immunity induced by attenuated PRRSV-1 vaccination.

Hervet C, Bussy F, Morvan A, da Rocha Pinto F, Belloc C, Bourry O, Maisonnasse P, Nyvall P, Bertho N.BMC Vet Res. 2025 Nov 7;21(1):653. doi: 10.1186/s12917-025-05085-0.PMID: 41204351

Cloning, expression and purification of AsSGU protein and its immunogenic response analysis as target candidate for transmission blocking **vaccine** against malaria.

Singh H, Kirar M, Janjoter S, Dahiya N, Yadav M, Sehrawat N.Int Immunopharmacol. 2025 Nov 14;165:115430. doi: 10.1016/j.intimp.2025.115430. Epub 2025 Aug 31.PMID: 40889466

Vaccination versus antibody screening for measles immunity in health care workers.

Schieferdecker R, Menting T, Mankertz A, Santibanez S, Zimmermann C, Rockstroh JK, Eis-Hübinger AM, Schwarze-Zander C.Vaccine. 2025 Nov 14;66:127845. doi: 10.1016/j.vaccine.2025.127845. Epub 2025 Oct 10.PMID: 41072277

Degradable cyclic amino alcohol ionizable lipids as vectors for potent influenza mRNA vaccines.

Rudra A, Gupta A, Reed K, Deik A, Min J, Mansour HMA, Nguyen QTC, Danko A, Hu Y, Berger A, Prado M, Beck A, Clish CB, Klauda JB, Langer R, Anderson DG.Nat Nanotechnol. 2025 Nov 7. doi: 10.1038/s41565-025-02044-6. Online ahead of print.PMID: 41203968

COVID-19 **vaccine** variant target: how should we choose?

Sharff KA, Haslam A, Nealon J.Vaccine. 2025 Nov 5;68:127917. doi: 10.1016/j.vaccine.2025.127917. Online ahead of print.PMID: 41197442

Expanding the clinical spectrum of Cernunnos/XLF deficiency: a literature review of a rare cause of severe combined immunodeficiency including a novel case.

Kabadayı G, Atay Ö, Baysal Bakır D, Yağmur H, Kaşıkçı Mermer ET, Okur Acar S, Öztürk Yılmaz Ş, Hazan F, Gözmen S, Uzuner N.BMC Immunol. 2025 Nov 12;26(1):89. doi: 10.1186/s12865-025-00774-9.PMID: 41225329

Decisional needs of older adults considering COVID-19 booster vaccinations: A systematic review comparing China with other countries.

Zhang Q, Lewis KB, Phillips JC, Ma H, Kiss A, Goge S, Rader T, Stacey D.Vaccine. 2025 Nov 6;68:127949. doi: 10.1016/j.vaccine.2025.127949. Online ahead of print.PMID: 41202611

CD94/NKG2A-Qa-1(b) axis as a key modulator of **vaccine** responsiveness in aging populations.

Chen L, Bai Z, Wan D, Ren W, Que H, Wang J, Lu Y, He X, Hong W, Alu A, Peng D, Fu M, Huang Y, Ai J, Hong Q, Tan H, Gao Z, Tian X, Tang C, Zhou Y, Lu S, Tian X, Wei X.Cell Rep. 2025 Nov 3;44(11):116514. doi: 10.1016/j.celrep.2025.116514. Online ahead of print.PMID: 41191483

Recombinant Orf viral vectors: A novel **vaccine** platform.

Penaloza-MacMaster P.Mol Ther. 2025 Nov 5;33(11):5294. doi: 10.1016/j.ymthe.2025.09.039. Epub 2025 Oct 2.PMID: 41043425

Structure of the human astrovirus capsid spike in complex with the neonatal Fc receptor.

Lentz A, Lanning S, Iranpur KR, Ricemeyer L, Arias CF, DuBois RM.Nat Commun. 2025 Nov 3;16(1):9621. doi: 10.1038/s41467-025-65203-2.PMID: 41184319

STING-mediated antiviral response: insights into MVA replication control in avian cells.

Brusco T, Menci V, Caiazza C, Petrone AM, Palladino R, Faticanti M, Bignone V, Ambrosino C, Scarselli E, Mallardo M, Siani L, Ruzza V.Microbiol Spectr. 2025 Nov 4;13(11):e0007525. doi: 10.1128/spectrum.00075-25. Epub 2025 Sep 22.PMID: 40981440

T-cell responses to SARS-CoV-2 vaccinations in adults with Down syndrome - a prospective cohort study.

Hensen LCM, Streng BMM, van Wijk F, Nierkens S, van Binnendijk RS, Buisman AM, Coppus AMW, Geurts van Kessel CH, de Graaf G, van der Klis FR, Lamberts R, Vidarsson G, Ruckwardt TJ, de Vries E, de Vries RD, Weijerman ME, Weinberger DM, Wildenbeest JG, Bont LJ, Delemarre EM.Hum Vaccin Immunother. 2025 Dec;21(1):2583416. doi: 10.1080/21645515.2025.2583416. Epub 2025 Nov 6.PMID: 41196011

Sensitive detection of HEV antibodies using a blocking ELISA based on ORF2-specific monoclonal antibodies.

Wang H, Wu Y, Liu X, Shan B, Xue L, Sun Y, An T, Li C, Chen H, Yin X, Yu C, Xia C, Zhang H.Int J Biol Macromol. 2025 Nov 5;333(Pt 1):148802. doi: 10.1016/j.ijbiomac.2025.148802. Online ahead of print.PMID: 41203146

Genetic polymorphisms of merozoite surface protein-3α in Plasmodium vivax isolates from Pakistan.

Nguyễn KO, Kang JM, Võ TC, Lê HG, Akhtar S, Nguyễn TH, Nguyễn ĐTD, Cho M, Afridi SG, Na BK.Acta Trop. 2025 Nov 8;272:107904. doi: 10.1016/j.actatropica.2025.107904. Online ahead of print.PMID: 41213349

Lessons Learned in Optimizing Recruitment and Data Collection for a Pharmacy-Based Implementation Trial.

Shackley AG, Carpenter DM, Charton H, Teeter BS, Smith M, Hastings TJ, Hughes T, Curran G.J Am Pharm Assoc (2003). 2025 Nov 3:102972. doi: 10.1016/j.japh.2025.102972. Online ahead of print.PMID: 41192509

Accessibility of Ontario pharmacies offering COVID-19 vaccination by rurality, community material deprivation, and ethnic concentration: a repeated cross-sectional geospatial analysis.

Alsabbagh MW, Wieland M, Pan S, Waite NM, Houle SKD, Grindrod K.BMC Public Health. 2025 Nov 12;25(1):3915. doi: 10.1186/s12889-025-24929-w.PMID: 41225413

Recombinant fusion protein LpxC-ApxIVA elicits a protective immune response against Glaesserella parasuis and Actinobacillus pleuropneumoniae in mice.

Jia Y, Han J, Wang L, Han K, Wang H, Yin R, Ma Y, Zhou Y, Yin R.Microb Pathog. 2025 Nov 7;210:108164. doi: 10.1016/j.micpath.2025.108164. Online ahead of print.PMID: 41207542

Exploring awareness, attitudes and clinical practices of Ukrainian health professionals regarding human papillomavirus and vaccination: a qualitative study.

Tatarchuk T, Kalugina L, Antipkin Y, Tutchenko T, Regeda S, Dunaevskaya V, Tatarchuk Y.BMJ Open. 2025 Nov 12;15(11):e089968. doi: 10.1136/bmjopen-2024-089968.PMID: 41224306

Safety, tolerability, and immunogenicity of the ChAdOx1 RVF **vaccine** against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial.

Anywaine Z, Serwanga J, Ggayi AM, Abaasa AM, Wright D, Gombe B, Ejou P, Namata T, Kigozi A, Tukamwesiga N, Basajja V, Ankunda V, Mulondo DJ, Nambaziira F, Kakande A, Kakeeto W, Nabaggala P, Jenkin D, Lawrie A, Folegatti P, Tran N, Hansen C, Elliott AM, Hill AVS, Warimwe GM, Kaleebu P.Lancet Infect Dis. 2025 Nov 11:S1473-3099(25)00565-1. doi: 10.1016/S1473-3099(25)00565-1. Online ahead of print.PMID: 41237791

Pneumococcal meningitis in Mexico. Serotype distribution and antimicrobial resistance before and after the introduction of pneumococcal conjugate vaccines in pediatric patients. Results from the GIVEBPVac group.

Carnalla-Barajas MN, Soto-Noguerón A, Solórzano-Santos F, Macías-Parra M, Díaz-Jiménez V, Sánchez-González G, Jiménez-Juárez R, Parra-Ortega I, Sánchez-Francia D, Luévanos-Velázquez A, Merlo-Palomera M, Flores-Santos A, Magaña-Aquino M, Tinoco-Favila JC, Corte-Rojas RE, Garza-González E, Guajardo-Lara CE, Vázquez-Narváez JA, Hernández-Magaña R, Sánchez-Reyes BA, Pacheco-Gil L, Monroy-Colín VA, Rincón-Zuno J, Feliciano-Guzmán JM, Echániz-Aviles G.J Infect Public Health. 2025 Nov 6;19(1):103030. doi: 10.1016/j.jiph.2025.103030. Online ahead of print.PMID: 41223711

Economic evaluation of a bivalent respiratory syncytial virus prefusion F **vaccine** for older adults in Sweden: cost-effectiveness and budget impact.

Szilcz M, Naghipour P, Fridh AC, Palmborg A, Toghanian S.J Med Econ. 2025 Dec;28(1):1955-1967. doi: 10.1080/13696998.2025.2580785. Epub 2025 Nov 10.PMID: 41137859

Dysphagia after COVID-19 Vaccination: A Report of Two Cases.

Sunami E, Aoyagi Y, Ohashi M, Asano Y, Onai D, Wakita S, Kaito Y, Kitagawa T, Yoneyama T, Ikeda S, Yozu A, Li Q.Intern Med. 2025 Nov 13. doi: 10.2169/internalmedicine.5450-25. Online ahead of print.PMID: 41224265

Estimating the economic burden of invasive non-typhoidal *Salmonella* infections in low- and middle-income countries.

Lee JS, Hwang Y, MacLennan CA, Jit M, Excler JL, Kim JH.BMJ Glob Health. 2025 Nov 8;10(11):e019370. doi: 10.1136/bmjgh-2025-019370.PMID: 41206133

Western equine encephalitis virus: A comprehensive review of epidemics, transmission, hosts, and strategies for mitigation.

Wang L, Zheng R, Li Z, Zhang L.Virulence. 2025 Dec;16(1):2580162. doi: 10.1080/21505594.2025.2580162. Epub 2025 Nov 3.PMID: 41178425

Repeated vaccination with homologous influenza hemagglutinin broadens human antibody responses to unmatched flu viruses.

Deng Y, Tang M, Ross TM, Schmidt AG, Chakraborty AK, Lingwood D.Elife. 2025 Nov 13;14:e107042. doi: 10.7554/eLife.107042.PMID: 41231113

Real-World Experiences and Challenges in Rabies Post-Exposure Prophylaxis.

Soravipukuntorn T, Matsee W.J Travel Med. 2025 Nov 13:taaf117. doi: 10.1093/jtm/taaf117. Online ahead of print.PMID: 41230830

Understanding **vaccine** hesitancy: The role of fear and message framing in COVID-19 vaccination intention in adults in the UK.

Chapman S, Christodoulaki ME, Davey SA, Gaffiero D.Vaccine. 2025 Nov 15;69:127999. doi: 10.1016/j.vaccine.2025.127999. Online ahead of print.PMID: 41242288

Healthcare utilization and costs following RSV and influenza vaccination in older adults in the United States.

Bowe A, Barger C, Esterly L, Sylwestrzak G, Dixon S, Poonawalla I.Curr Med Res Opin. 2025 Nov 5:1-7. doi: 10.1080/03007995.2025.2580031. Online ahead of print.PMID: 41159254

Design of a multi-epitope recombinant BCG **vaccine** targeting Brucella OMP31, LptE and VirB2 in immunoinformatics approaches.

Li C, Zhu Y, Qi X, Chai Z, Luo J, Shang K, Tian T, Shi H, Li M, Xu R, Pu F, Kuang J, Zhang F.PLoS One. 2025 Nov 6;20(11):e0334843. doi: 10.1371/journal.pone.0334843. eCollection 2025.PMID: 41196893

Genome sequence of the Myxoma virus Borghi **vaccine** strain.

Bazzucchi M, Rossini E, Cavadini P, Bertasio C, Lavazza A.Vaccine. 2025 Nov 14;66:127835. doi: 10.1016/j.vaccine.2025.127835. Epub 2025 Oct 14.PMID: 41092801

Health system and caregiver related factors influencing measles vaccination uptake: perspectives of Chadibe village, Botswana.

Sejie GA, Diseko A, Terena MO, Dikodi K, Kebaphekotse NT, Bulawayo L, Mosarwane K.BMC Infect Dis. 2025 Nov 3;25(1):1484. doi: 10.1186/s12879-025-11966-4.PMID: 41184818

Effectiveness of SMS reminders to increase demand for HPV immunisation: a randomised controlled trial in Georgia.

Daly N, Merriam S, Tagliaferri G, Tomsa S, Bianco VM, Gamgebeli L, Lortkipanidze N.BMJ Open. 2025 Nov 13;15(11):e087080. doi: 10.1136/bmjopen-2024-087080.PMID: 41248345

Modular design of a self-amplifying mRNA **vaccine** for multivalent immunization against Neisseria meningitidis B.

Chen G, Chen G, Wang S, Xing R, Yang Y, Zhou R, Ma L, Wang X, Wang Y, Song W, Xu Z, Li Z, Zhang M, Fang W, Hu Y, Xiong C, Wang Y.Vaccine. 2025 Nov 7;68:127964. doi: 10.1016/j.vaccine.2025.127964. Online ahead of print.PMID: 41205400

Semi-Synthesis of Immunogenic Mycobacterial Lipoproteins via Aryl Selenoester-Mediated Expressed Protein Ligation.

Kambanis L, Dilly JJ, Maxwell JWC, Stockdale S, Fry SE, Harrison K, Byrne SN, Ashhurst AS, Kulkarni SS, Payne RJ.Angew Chem Int Ed Engl. 2025 Nov 10:e19647. doi: 10.1002/anie.202519647. Online ahead of print.PMID: 41208803

Low influenza, pneumococcal and herpes zoster vaccination coverage in Australian patients commencing a biologic or targeted synthetic disease modifying anti-rheumatic drug for inflammatory arthritis: a nationwide cross-sectional data linkage study.

Wong PK, O'Sullivan M, Deng L.Rheumatol Int. 2025 Nov 13;45(12):273. doi: 10.1007/s00296-025-06019-7.PMID: 41231258

Peptide **vaccine** formulations with structurally distinct STING agonist drugamers induce discrete, efficacious antitumor responses.

Song K, Nguyen DC, Wang Y, Jokonya S, Yazdani O, Sellers DL, Stayton PS, Pun SH.Proc Natl Acad Sci U S A. 2025 Nov 11;122(45):e2409978122. doi: 10.1073/pnas.2409978122. Epub 2025 Nov 3.PMID: 41183196

Controlling intracellular processing to enhance spherical nucleic acid immune stimulation.

Kang J, Teplensky MH, Dittmar JW, Evangelopoulos M, Hwang J, Mirkin CA.Proc Natl Acad Sci U S A. 2025 Nov 11;122(45):e2409554122. doi: 10.1073/pnas.2409554122. Epub 2025 Nov 3.PMID: 41183209

Systemic mRNA vaccines elicit rapid immune activation in canine brain tumors.

Carrera-Justiz S, Aghaee M, Qdaisat S, Weidert F, Garcia GA, Fagman L, Zhang D, Stover B, Moor RSF, Xie C, Goldenberg E, von Roemeling C, Doonan B, Chardon-Robles J, Elliott L, Sawyer WG, Deleyrolle LP, Sahay B, Foster TP, Seligson ND, Rahman M, Ghiaseddin A, Castillo P, Lee JH, Silver NL, Doty A, Ligon JA, Milner RJ, Mitchell D, Mendez-Gomez H, Moore H, Sayour EJ.J Immunother Cancer. 2025 Nov 11;13(11):e011817. doi: 10.1136/jitc-2025-011817.PMID: 41218853

Vaccine Incentives Harm Intrinsic Motivation: Evidence From a Priming Experiment.

Huynh J, Jacinto C, Huynh J.Health Econ. 2025 Nov 11. doi: 10.1002/hec.70061. Online ahead of print.PMID: 41217275

Proteomic and Phosphoproteomic Analysis of Adult *Taenia saginata* Revealed the Potential Importance of Cytoskeleton-Related Proteins.

Liu K, Wu K, Liu X, Xie J, Wang Y, Ngim C, Hu D, Xiao Y, Wang Z, Liu Y, Liu W, Jiang L.J Proteome Res. 2025 Nov 7;24(11):5727-5741. doi: 10.1021/acs.jproteome.5c00532. Epub 2025 Oct 29.PMID: 41159783

Awareness, uptake, and barriers to vaccination against respiratory tract infections in patients with diabetes mellitus: A multi-center study in Saudi Arabia.

Aldhahir AM, Alyami MM, Alasimi AH, Alqahtani AM, Mousa RE, Alqahtani SA, Alhalbub LM, Mohammed OA, Alosaimi SM, AlQahtani AS, Alqarni AA, Alqahtani JS, Albargi H, Almulhem MM, Siraj RA, Alwafi H.Hum Vaccin Immunother. 2025 Dec;21(1):2585544. doi: 10.1080/21645515.2025.2585544. Epub 2025 Nov 7.PMID: 41202216

The current landscape of adaptive immune receptor genomic and repertoire data: OGRDB and VDJbase.

Lees WD, Peres A, Klein V, Amos N, Jana U, Engelbrecht E, Vanwinkle Z, Malach Y, Konstantinovsky T, Polak P, Watson CT, Yaari G.Nucleic Acids Res. 2025 Nov 6:gkaf1094. doi: 10.1093/nar/gkaf1094. Online ahead of print.PMID: 41206474

Healthcare providers' preferences for pediatric pneumococcal vaccination recommendations in the United States.

Vietri J, Myers K, Huang L, Snow V, Rozenbaum MH, Arguedas A, Cane A, Tort MJ, Pierce A, Poulos C.Expert Rev Vaccines. 2025 Dec;24(1):1024-1032. doi: 10.1080/14760584.2025.2585808. Epub 2025 Nov 17.PMID: 41218918

Erratum to "Report from the World Health Organization's Immunization and Vaccines-related Implementation Research Advisory Committee (IVIR-AC) meeting, virtual gathering, 1-5 September 2025" [**Vaccine** 68 (2025) 127903].

Lambach P, Silal S, Sbarra AN, Koh M, Aggarwal R, Farooqui HH, Flasche S, Hogan AB, Kim SY, Leung K, Moss WJ, Portnoy A, Sheel M, Wang XY.Vaccine. 2025 Nov 15;69:127972. doi: 10.1016/j.vaccine.2025.127972. Online ahead of print.PMID: 41242292

Genetic Characterization and Evidence of Capsid Epitope Variation in Porcine Circovirus Type 3 Strains from Vietnamese Swine with Reproductive Disorders.

Pham LNH, Dinh PX, Ngo TNT, Le HTT, Do DT.Curr Microbiol. 2025 Nov 8;83(1):8. doi: 10.1007/s00284-025-04600-8.PMID: 41204966

Financial risk protection from vaccines in 52 Gavi-eligible low- and middle-income countries: A modeling study.

Jiao B, Sato R, Mak J, Patenaude B, de Villiers M, Deshpande A, Gamkrelidze I, Gaythorpe KAM, Hallett TB, Jit M, Li X, Lopman B, Nayagam S, Razavi-Shearer D, Tam Y, Woodruff KH, Hogan D, Mengistu T, Verguet S.PLoS Med. 2025 Nov 4;22(11):e1004764. doi: 10.1371/journal.pmed.1004764. eCollection 2025 Nov.PMID: 41187138

Atypical dengue fever in a partially vaccinated patient: a case report.

Mendes VJ, Martins EB, Lupi O, Pina-Costa A, Calvet GA, Bressan CDS, Ferreira ABTBC, Bruycker-Nogueira F, Filippis AMB, Brasil P.Rev Inst Med Trop Sao Paulo. 2025 Nov 3;67:e76. doi: 10.1590/S1678-9946202567076. eCollection 2025.PMID: 41191721

Leveraging Mycobacterium tuberculosis Rv1507A Protein for Improved Immunogenicity in Mycobacterium bovis BCG **Vaccine**.

Naqvi N, Alam A, Shariq M, Ahuja Y, Mitra DK, Hasnain SE, Ehtesham NZ.Immunology. 2025 Nov 8. doi: 10.1111/imm.70063. Online ahead of print.PMID: 41205149

Dengue virus infection reprograms baseline innate immune gene expression.

Ong EZ, Yee JX, Koh CW, Ooi JS, Tham CYL, Chan KR, Kareko BW, Lyski ZL, Tricou V, Dean H, Braun R, Kalimuddin S, Low JG, Messer WB, Sharma M, Ooi EE.Med. 2025 Nov 14;6(11):100841. doi: 10.1016/j.medj.2025.100841. Epub 2025 Sep 8.PMID: 40925380

Controlled trial of cervical cancer screening frequency among human-papillomavirus-vaccinated women.

Ortega Llobet M, Gray P, Baussano I, Elfström KM, Eriksson T, Lagheden C, Nieminen P, Söderlund-Strand A, Dillner J, Pimenoff VN, Lehtinen M.Int J Cancer. 2025 Nov 7. doi: 10.1002/ijc.70229. Online ahead of print.PMID: 41203578

Triple-TLR agonists' adjuvanted inactivated Newcastle disease virus **vaccine** promotes effective Th1/Th2 immune responses and affords protective efficacy in chickens.

Kaliappan A, Ramakrishnan S, Panwar K, Naveen D, Thomas P, Verma SK, Singh M, Chandra V, Dey S, Chellappa MM.Vaccine. 2025 Nov 14;66:127846. doi: 10.1016/j.vaccine.2025.127846. Epub 2025 Oct 11.PMID: 41082811

Large-scale randomized double-blind field clinical trial for safety and efficacy assessment of the DNA **vaccine** Neoleish against canine leishmaniasis.

Páez L, Parra A, Sotelo E, Taboada I, López R, Segade P, Boente MDM, Rivas MJ, Da Rocha L, Alonso A, Alcolea PJ, Puentes E.PLoS Negl Trop Dis. 2025 Nov 3;19(11):e0012707. doi: 10.1371/journal.pntd.0012707. eCollection 2025 Nov.PMID: 41183128

B cells targeting parasites capture spatially linked antigens to secure T cell help.

Gao X, McNamara HA, Lee J, Lo AF, Chatterjee D, Spensberger D, Fernandez-Ruiz D, Walz K, Wang K, Kelly HG, Pohl K, Carreira PE, Do A, Xiong L, Beattie L, Spencer AJ, Gray DHD, Frischknecht F, Rug M, Cockburn IA.Sci Immunol. 2025 Nov 7;10(113):eadw0415. doi: 10.1126/sciimmunol.adw0415. Epub 2025 Nov 7.PMID: 41202148

Nanocorona-engineered gold nanostars orchestrate photothermal augmented immunotherapy and durable cancer vaccination.

Park JY, Lim SH, Kim G, Park JY, Lee BG, Park SJ, Lee Y, Khang D.J Nanobiotechnology. 2025 Nov 3;23(1):697. doi: 10.1186/s12951-025-03781-5.PMID: 41177903

Hantavirus Gn^{H} Nanoparticle Immunogen Elicits a Cross-Neutralizing Antibody Response in Mice.

Ramos KE, Mariano MC, Mittler E, Pardo R, Zylberman V, Guardado-Calvo P, Chandran K, Lai JR.ACS Infect Dis. 2025 Nov 14;11(11):3061-3070. doi: 10.1021/acsinfecdis.5c00415. Epub 2025 Oct 12.PMID: 41077721

Community interpretation of a consent form and willingness to participate in a Nipah virus **vaccine** trial in Bangladesh.

Nahar N, Parveen S, Gurley ES, Ghosh PK, Jabeen I, Haidar MR, Jahan F, Munim MS, Ali MW, Shirin T, Banu S, Chowdhury AI, Alam A, Dawes BE, Fusco J, Monath TP, Heppner G, Luby SP.Vaccine. 2025 Nov 12;68:127953. doi: 10.1016/j.vaccine.2025.127953. Online ahead of print.PMID: 41232456

Nanomedicine in the development of vaccines against Herpesviridae: a narrative review.

Lee DH, Lee W, Bach H.Nanomedicine (Lond). 2025 Nov 11:1-21. doi: 10.1080/17435889.2025.2587714. Online ahead of print.PMID: 41217254

VP1 region-based molecular characterization of foot-and-mouth disease virus serotype O from clinical cases in Haryana, India.

Dalal P, Dahiya S, Lather A, Sheoran D, Sangwan P, Rani N, Pannu A, Kumar P, Kumar P, Subramaniam S, Singh RP.BMC Vet Res. 2025 Nov 6;21(1):649. doi: 10.1186/s12917-025-05112-0.PMID: 41199288

Correction: Risk perception and trust in the relationship between knowledge and HPV **vaccine** hesitancy among female university students in China: a cross-sectional study.

Chen X, Wang L, Huang Y, Zhang L.BMC Public Health. 2025 Nov 12;25(1):3908. doi: 10.1186/s12889-025-25130-9.PMID: 41225374

Long-term trends and the role of health resources in under-5 mortality rates: a 2000-2021 longitudinal analysis at the global level.

Zang Z, Yu L, Li S, Xu X, Zhou H, Yue Q, Yang L.BMJ Open. 2025 Nov 16;15(11):e102980. doi: 10.1136/bmjopen-2025-102980.PMID: 41248390

Development of a recombinant adenovirus-vectored **vaccine** against Pseudomonas plecoglossicida in large yellow croaker (Larimichthys crocea).

Li S, Li Z, Wang M, Zhou J, Wang Y, Qin C, Li XC.Fish Shellfish Immunol. 2025 Nov 11;168:110991. doi: 10.1016/j.fsi.2025.110991. Online ahead of print.PMID: 41232633

Serotype distribution and antimicrobial susceptibility patterns of Streptococcus pneumoniae isolates in the post-pneumococcal conjugate **vaccine** era in Nigeria: a hospital-based cross-sectional study.

Joy N, Ebere O, Tochukwu N, Onochie-Igbinedion I, Harrison A, Charles E, Ikegbunam M.BMC Infect Dis. 2025 Nov 4;25(1):1487. doi: 10.1186/s12879-025-11936-w.PMID: 41188720

Estimating Influenza **Vaccine** Effectiveness Against Laboratory-Confirmed Influenza Using Linked Public Health Information Systems, California, 2023-2024 Season.

Zhu S, Quint J, León TM, Sun M, Li NJ, Yen C, Tenforde MW, Flannery B, Jain S, Schechter R, Hoover C, Murray EL.J Infect Dis. 2025 Nov 14;232(5):1249-1257. doi: 10.1093/infdis/jiaf248.PMID: 40359401

Real-world immune response to SARS-CoV-2 vaccination in Thai patients with systemic lupus erythematosus: a cross-sectional observational study.

Pongkulkiat P, Foocharoen C, Nanthapisal S, Phanthanawiboon S, Meesing A, Suwannaroj S, Mootsikapun P, Mahakkanukrauh A.Lupus Sci Med. 2025 Nov 10;12(2):e001631. doi: 10.1136/lupus-2025-001631.PMID: 41213821

Electronic health record analysis reveals no association between COVID-19 vaccines and ischemic stroke.

Makkar SR, Hansen K, Hotaling N, Sidky H; N3C Consortium.J Neurol Sci. 2025 Nov 15;478:123681. doi: 10.1016/j.jns.2025.123681. Epub 2025 Aug 29.PMID: 41100968

Epidemiology and Management of Intussusception Among Children Aged Under 2 Years in Gujarat, India.

Shah NR, Vyas B, Buch P, Thakkar PA, Ramji J, Patel N, Chudasama R, Ganatra J, Solanki JR, Joshi RS, Chaudhary VS, Kharat N, Machathi A, Lingam R.Indian J Pediatr. 2025 Nov 11. doi: 10.1007/s12098-025-05806-1. Online ahead of print.PMID: 41214394

Impact of oral *Chlamydia* vaccination on host gut microbiome and metabolite composition.

Huang Y, Wan J, Shu C, Yan X, Ma J, Zhang T, He J, Wan Z, Li G, Zhang Q, Zhou Z, Sun X, Zhao J, Zhang P, Wang L, Zhang T, Tian Q.mSystems. 2025 Nov 10:e0128525. doi: 10.1128/msystems.01285-25. Online ahead of print.PMID: 41211986

Effect of influenza vaccination on post-admission outcomes for influenza patients in England: a population-based cohort study.

Jeffery C, Cheyne CP, Buchan I, Garcia-Finana M, Green MA, Bonnett L, Hughes DM, French N, Hungerford D.Vaccine. 2025 Nov 9;68:127933. doi: 10.1016/j.vaccine.2025.127933. Online ahead of print.PMID: 41213184

Randomized, double-blind, placebo-controlled, phase 3 trial to demonstrate lot-to-lot consistency of 3 lots of the simplified formulation of Butantan-dengue **vaccine**.

Peixoto de Miranda ÉJF, de Sousa Moreira JA, da Silva Braga R, Silveira DHR, Infante V, de Oliveira Alves LB, de Camargo Vieira Tenorio J, Dos Santos Silva GF, Patiño EG, de Mesquita Pacheco PHT, Ramos F, Oliveira DS, Kallás EG, Boulos FC.Vaccine. 2025 Nov 14;66:127836. doi: 10.1016/j.vaccine.2025.127836. Epub 2025 Oct 14.PMID: 41092804

Cancer Prevention at Work (CPW) project: Rationale, framework and research protocol.

Kostrzewa M, Sadat Seyyedsalehi M, Godono A, Collatuzzo G, Fiorini G, Moscato S, Santello A, Roth C, Wensing M, Massimino G, Cella MT, Biagioli V, Magaña M, Pinto-Vidal FA, Klöslová Z, Oravec Bérešová J, Bruno D, Giordani S, Kočtúchová Blažinová M, Vilček R, Otelea MR, Popescu FG, Crull I, Gili R, Gorra E, Fernandez-Tardon G, Rodriguez-Suarez MM, Calota V, Askegaard S, Honrado Á, Tardon A, Fabiánová E, Vencovsky D, Schneider-Kamp A, Mates D, Mellone S, Boffetta P.PLoS One. 2025 Nov 3;20(11):e0335752. doi: 10.1371/journal.pone.0335752. eCollection 2025.PMID: 41183072

Development and evaluation of recombinant Varicella-Zoster virus glycoprotein E protein microneedles for enhanced pediatric **vaccine** delivery.

Lee DE, Cha HR, Lee YL, Chung HW, Park S, Oh YJ, Jung E, Baek SK, Ahn BC, Yum JS, Lee JM, Park JH.Drug Deliv Transl Res. 2025 Nov 11. doi: 10.1007/s13346-025-02012-6. Online ahead of print.PMID: 41217681

Dendritic cell-derived biomimetic vesicles as cancer **vaccine** platforms for melanoma immunotherapy.

Liu J, Lu J, Miao F, Wu L, Ding L, Ma T, Wang R, Yan H, Cui Z, Chen Z, Tai Z, Zhu Q.J Control Release. 2025 Nov 14:114405. doi: 10.1016/j.jconrel.2025.114405. Online ahead of print.PMID: 41242665

Exploring the predictors for the uptake of Respiratory Syncytial Virus (RSV) **vaccine** under the immunization programme in India.

Hora R, Ray A, Kumari A, Dutta M, Mehra R, Kaur A, Quadri SF, Koshal SS, Singh SK, Sultana A, Roy AD.Vaccine. 2025 Nov 14;66:127827. doi: 10.1016/j.vaccine.2025.127827. Epub 2025 Oct 10.PMID: 41072278

Immunogenicity and protective efficacy of Vibrio vulnificus outer membrane vesicles in zebrafish: Implications for fish immunization.

Chen D, Zheng C, Wang J, Li Z, Dong C, Liang Y, Huang Y, Chen Y, Xue T, Lin C.Fish Shellfish Immunol. 2025 Nov 6;168:110981. doi: 10.1016/j.fsi.2025.110981. Online ahead of print.PMID: 41205783

Navigating the Mpox Outbreak: Insights on Vaccination Decisions and Psychosocial Impacts Among Gay, Bisexual, and Other Men Who Have Sex with Men in Los Angeles.

Yonko EA, Wright CG, Rabbottini L, Aminzadeh K, Mayer KH, Biello KB, Mimiaga MJ.AIDS Behav. 2025 Nov 9. doi: 10.1007/s10461-025-04916-3. Online ahead of print.PMID: 41206825

Proposal of a Vaccination Needs Index to Prioritise Municipal Interventions in Brazil.

Diaz-Quijano FA, Schrarstzhaupt IN, Fantinato FFST, Guzmán-Barrera LS, Croda J.Trop Med Int Health. 2025 Nov 13. doi: 10.1111/tmi.70059. Online ahead of print.PMID: 41230725

A Narrative Review of Human Papillomavirus (HPV) Vaccination in Ecuador: A Crisis of Inequity and an Evidence-Based Roadmap for Elimination.

Redrobán JDS, López D, Santillan C.J Epidemiol Glob Health. 2025 Nov 17;15(1):135. doi: 10.1007/s44197-025-00480-0.PMID: 41247608

Advancing vaccines justice through international regulatory pathways.

Perehudoff K, Parwani P, Bruinsma S.Glob Public Health. 2025 Dec 31;20(1):2566730. doi: 10.1080/17441692.2025.2566730. Epub 2025 Nov 13.PMID: 41230656

Cost-effectiveness of maternal vaccination against respiratory syncytial virus in Hong Kong: a decision-analytical analysis.

Wang Y, Rui M, Wei Q, Leung TF, Leung TY, You JHS.Expert Rev Vaccines. 2025 Dec;24(1):1015-1023. doi: 10.1080/14760584.2025.2589208. Epub 2025 Nov 16.PMID: 41232956

Anti-Pneumococcal Properties of the Native Human Milk Oligosaccharide Fraction: A Concentration-Dependent Study.

Makarewicz O, Tchatchiashvili T, Jasef L, van der Linden MPG, Jarzynka S, Strom K, Ueberschaar N, Mazur M, Oledzka G, Pletz MW.Int J Mol Sci. 2025 Nov 6;26(21):10781. doi: 10.3390/ijms262110781.PMID: 41226817

Are individuals with persistently high conspiracy mentality also persistently **vaccine**-hesitant? Findings from a three-wave panel study.

Lamot M, Kirbiš A, Kerman K.Soc Sci Med. 2025 Nov 10;388:118770. doi: 10.1016/j.socscimed.2025.118770. Online ahead of print.PMID: 41240658

Incorporation of 5-methylcytidine alleviates RIG-I-mediated innate immune responses to a self-amplifying RNA **vaccine**.

Akahata W, Komori M, Morey AL, Quiñones-Molina AA, Hood JB, Fofana J, Romero L, Peters E, Webber JD, Meeks T, Przygonska PA, Steinberg I, Ober E, Kim T, Rogan DC, Matsuda K, Smith JF, Gummuluru S, Connors M, Akiyama H.Sci Transl Med. 2025 Nov 12;17(824):eadz2276. doi: 10.1126/scitranslmed.adz2276. Epub 2025 Nov 12.PMID: 41223248

An intranasal adjuvanted, recombinant influenza A/H5 **vaccine** primes against diverse H5N1 clades: a phase I trial.

Deming ME, Toapanta FR, Pasetti M, Golding H, Khurana S, Hamouda T, Fattom A, Liang Y, Tennant SM, McGilvray MF, Bernal PJ, Oshinsky JJ, Datta S, Booth JP, Coughlan L, Neuzil KM, Costley CD, Kotloff KL, Sztein MB, Ortiz JR; rH5 Writing Group.Nat Commun. 2025 Nov 6;16(1):9321. doi: 10.1038/s41467-025-64686-3.PMID: 41198655

Development of a whole cell **vaccine** to activate dendritic cells using polyvalent CpG.

Han H, Yu D, Shi P, Zhang H, Jia H.Mater Horiz. 2025 Nov 12. doi: 10.1039/d5mh01849h. Online ahead of print.PMID: 41221596

Immunological characteristics of inactivated vaccines after vaccination and short-term concentrated BA.4/5 exposure: A prospective cohort study in Henan, China.

Cui K, Xu M, Zhang X, Kang Y.Microb Pathog. 2025 Nov 10;210:108170. doi: 10.1016/j.micpath.2025.108170. Online ahead of print.PMID: 41224161

Development of monoclonal antibody based SPCE logistic regression model to predict the protective status of animals vaccinated against FMD virus type A.

Hema Sayee R, Hosamani M, Krishnaswamy N, Shanmuganathan S, Sri Sai Charan M, Vignesh DR, Bhanuprakash V.J Virol Methods. 2025 Nov 7;340:115299. doi: 10.1016/j.jviromet.2025.115299. Online ahead of print.PMID: 41205762

Tregitopes derived from canine proteins can enhance T regulatory lymphocytes frequency in dog peripheral blood mononuclear cells (PBMC) culture in vitro.

Szydłowski P, Grabowski T, Chełmońska-Soyta A.J Leukoc Biol. 2025 Nov 4;117(11):qiaf143. doi: 10.1093/jleuko/qiaf143.PMID: 41067721

Classification bias and impact of COVID-19 vaccination on all-cause mortality: the case of the Italian region Emilia-Romagna.

Alessandria M, Trambusti G, Malatesta GM, Polykretis P, Donzelli A.Autoimmunity. 2025 Dec;58(1):2562972. doi: 10.1080/08916934.2025.2562972. Epub 2025 Nov 3.PMID: 41182849

Successful prophylactic against Brucella melitensis using a **vaccine** candidate consisting of recombinant antigens OMP19 and L7/L12 loaded in a nanoliposomal adjuvant system in a mouse model.

Pirhajati R, Chiani M, Habibi M, Emami T, Shahrokhi N, Asadi Karam MR.Int J Pharm. 2025 Nov 9;687:126372. doi: 10.1016/j.ijpharm.2025.126372. Online ahead of print.PMID: 41218729

Martini 3 Coarse-Grained Model for Chitosan with Tunable Acetylation.

Cambiaso S, Razmazma H, Shrestha R, Bochicchio D, Rossi G, Monticelli L.Biomacromolecules. 2025 Nov 10;26(11):7319-7330. doi: 10.1021/acs.biomac.5c00683. Epub 2025 Oct 29.PMID: 41159902

A video-based educational intervention to improve **vaccine** acceptance for Schistosomiasis japonicum: A pre-post study using the 5C model in rural China.

Yang Q, Wang J, Du C, Lee HY, Wong LP.Hum Vaccin Immunother. 2025 Dec;21(1):2585557. doi: 10.1080/21645515.2025.2585557. Epub 2025 Nov 11.PMID: 41215694

Strengthening the mpox response: how do we balance pragmatism and equity in resource-constrained settings?

Lokossou VK, Ogunyemi KO, Usman AB, Kamdem S, Ahanhanzo CD, Agbla F, Aïssi MA, Sombié I.J Glob Health. 2025 Nov 14;15:03036. doi: 10.7189/jogh.15.03036.PMID: 41232125

Estimated impact of 2022-2023 influenza vaccines on annual hospital burden in the United States.

Bi K, Bandekar SR, Bouchnita A, Cramer A, Fox SJ, Borchering RK, Biggerstaff M, Meyers LA.Proc Natl Acad Sci U S A. 2025 Nov 18;122(46):e2505175122. doi: 10.1073/pnas.2505175122. Epub 2025 Nov 11.PMID: 41218113

Intersectional stigma and resilience in the uptake of cervical cancer prevention services in Nigeria: a qualitative study.

Wapmuk AE, Obionu I, Obiezu-Umeh C, Gbaja-Biamila TA, Kokelu E, Nwaozuru U, Kpokiri EE, Airhihenbuwa CO, Smith JS, Zaidat M, Obi-Jeff C, Azuogu BN, Ajenifuja K, Tucker JD, Iwelunmor J, Ezechi OC.BMJ Glob Health. 2025 Nov 16;10(11):e020065. doi: 10.1136/bmjgh-2025-020065.PMID: 41248939

Supporting Informed **Vaccine** Decision-Making and Communication in Pregnancy Through the Vaccines in Pregnancy Canada Intervention: Multi-Method Co-Design.

Castillo E, Patey AM, Myers-Stewart M, Surti MS, Castrellon Pardo M, Bruce M, Jamal Z, Kennedy M, Bettinger JA, Kaufman J, Danchin M, Donald M.J Med Internet Res. 2025 Nov 12. doi: 10.2196/77446. Online ahead of print.PMID: 41232072

"This Is Something Every Woman Needs. . .So Why Is It That Expensive?": Examining Privileges and Inequities in Access to a Privately Funded HPV Vaccination Program in Ghana.

Marfo EA, Adjei CA, Salami BO, MacDonald SE.Glob Qual Nurs Res. 2025 Nov 13;12:23333936251391556. doi: 10.1177/23333936251391556. eCollection 2025 Jan-Dec.PMID: 41245073

Cross-species blood transcriptional correlates of BCG-mediated protection against tuberculosis include innate and adaptive immune processes.

Bridges K, Awany D, Gela A, Mwambene TD, Kurtz SL, Baker RE, Elkins KL, Sassetti CM, Scriba TJ, Lauffenburger DA.JCI Insight. 2025 Nov 11:e194450. doi: 10.1172/jci.insight.194450. Online ahead of print.PMID: 41217848

Understanding Determinants of Parental HPV **Vaccine** Hesitancy Under a Municipal Free Vaccination Program in Guangzhou, China.

Li A, Wang P, Li J, Chen W, Chang J.Health Policy Plan. 2025 Nov 10:czaf087. doi: 10.1093/heapol/czaf087. Online ahead of print.PMID: 41213869

Optimizing the schedule of BNT162b2 COVID-19 against long COVID and associated quality of life losses.

Kuodi P, Shibli H, Zayyad H, Wertheim O, Wiegler KB, Jabal KA, Dror AA, Nazzal S, Glikman D, Charlett A, Edelstein M.Commun Med (Lond). 2025 Nov 7;5(1):462. doi: 10.1038/s43856-025-01160-7.PMID: 41204001

Unbiased cell clustering analysis of **vaccine**-induced T cell responses in the Imbokodo HIV-1 **vaccine** trial.

Voillet V, van Duijn J, Vanshylla K, Dintwe OB, Pattacini L, Omar FL, Khuzwayo S, Euler Z, Schwedhelm K, MacMillan HR, Gilbert PB, Fiore-Gartland A, Newell EW, Hendriks J, McElrath MJ, Stieh DJ, De Rosa SC, Andersen-Nissen E.EBioMedicine. 2025 Nov 13;122:106017. doi: 10.1016/j.ebiom.2025.106017. Online ahead of print.PMID: 41237667

Risk factors for loss of Varicella immunity after pediatric kidney transplantation.

Pizzo H, Soni PR, Nadipuram S, Mirocha J, Garrison J, Hilario S, Puliyanda D.Pediatr Nephrol. 2025 Nov 13. doi: 10.1007/s00467-025-07022-7. Online ahead of print.PMID: 41225196

Corrigendum to "Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM" [**Vaccine** 68 (2025) 127897].

Mukhopadhyay ES, Bellamy DG, Tinto H, Hamaluba M, Truby A, Salman AM, Hill AVS.Vaccine. 2025 Nov 15;69:127973. doi: 10.1016/j.vaccine.2025.127973. Online ahead of print.PMID: 41242289

Immune persistence and safety of the AS01(E)-adjuvanted respiratory syncytial virus prefusion F protein-based **vaccine** in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial.

Ferguson M, Schwarz TF, Núñez SA, Rodríguez-García J, Mital M, Zala C, Pek B, Schmitt B, Toursarkissian N, Ochoa Mazarro D, Großkopf J, Voors-Pette C, Mehta H, Amare Hailemariam H, Gérard C, Damaso S, David MP, Descamps D, Hill J, Vandermeulen C, Hulstrøm V.Hum Vaccin Immunother. 2025 Dec;21(1):2579335. doi: 10.1080/21645515.2025.2579335. Epub 2025 Nov 5.PMID: 41194599

Effectiveness of the RTS,S/AS01(E) malaria **vaccine** in a real-world setting over 1 year of follow-up after the three-dose primary schedule: an interim analysis of a phase 4 study in Ghana, Kenya, and Malawi.

Ndeketa L, Haine V, Debois M, Asante KP, Agyapong PD, Kaali S, Devadiga R, Harrison SBE, Boahen O, French N, Kayan K, Ogutu B, Adeniji E, Kariuki S, Owusu-Agyei S, Olewe F, Jere TM, Maleta K, Mategula D, Mzanga P, Phiri VK, Ansah PO, Orimbo J, Ansah NA, Orsini M, Ong'echa JM, Oduro AR, Sifuna PM, Azongo DK, Otieno W, Bangre O, Kaburise MB, Ababio LO, Oyieko JN, Sing'oei V, Amoit SK, Nyangulu W, Schuerman L, Awuni D, Ochieng BO, Onyango I, Odera-Ojwang P, Oguk EA, Mendoza YG, Cherop RY, Okoth GO, Cravcenco C, Chipatala R, Roman F, Oneko M, Savic M; RTS,S Epidemiology EPI-MAL-003 Study Group.Lancet Glob Health. 2025 Nov 6:S2214-109X(25)00415-2. doi: 10.1016/S2214-109X(25)00415-2. Online ahead of print.PMID: 41207319

Recombinant rSF toxoid enhances efficacy of bacterin-inactivated **vaccine** against F18+ Escherichia coli-induced edema disease in swine.

Liu Y, Wu H, Zhang F, Yang X, Huang T, Wu B, Liu G.BMC Vet Res. 2025 Nov 6;21(1):647. doi: 10.1186/s12917-025-05034-x.PMID: 41194063

Resurgent COVID-19 Wave in India and South Asia: Is the NB.1.8.1 Variant a Renewed Global Health Concern?

Pranto AH, Promi AT, Islam S, Islam MR.Health Sci Rep. 2025 Nov 10;8(11):e71453. doi: 10.1002/hsr2.71453. eCollection 2025 Nov.PMID: 41229566

A Stable RNA **Vaccine** Against the Regulatory Peptide Adrenomedullin Reduces Angiogenesis and Tumor Burden in a Subcutaneous Melanoma Model Without Inducing an Immunosuppressive Tumor Microenvironment.

Tadic S, García-Sanmartín J, Narro-Íñiguez J, Martínez A.Int J Mol Sci. 2025 Nov 5;26(21):10745. doi: 10.3390/ijms262110745.PMID: 41226782

Use of shotgun immunoproteomics for the development of protein vaccines against Edwardsiella piscicida.

Jacobsen KL, Griffin MJ, Phinney BS, Salemi M, Yazdi Z, Balami S, Older CE, Ware CC, Yamamoto FY, Huda NU, Rodriguez-Ramos T, Dixon B, Ma J, LaFrentz BR, Soto E.Fish Shellfish Immunol. 2025 Nov 8;168:110992. doi: 10.1016/j.fsi.2025.110992. Online ahead of print.PMID: 41213346

Changing epidemiology of SARS-CoV-2 positivity rates in a diverse population of children and adults during variant evolution and progressive vaccination eligibility in New York City.

Velu PD, Thomas C, Rand S, Imada E, Zanettini C, Han JY, Grinspan Z, Abramson EL, Marchionni L, Cushing MM, Acker KP.BMC Infect Dis. 2025 Nov 11;25(1):1548. doi: 10.1186/s12879-025-11990-4.PMID: 41219859

Development of the rationale of a personalized cancer **vaccine** based on the in situ **vaccine** effect of radiotherapy: a mechanistic study of the POLARSTAR trial.

Pang K, Sun P, Liu X, Yang D, Zhao P, Huang Y, Cao S, Gao Y, Chen G, Yu H, Duan L, Yang Y, Zhang Z.Cancer Immunol Immunother. 2025 Nov 12;74(12):369. doi: 10.1007/s00262-025-04229-3.PMID: 41222702

Targeted Sequencing Identifies SNPs Associated with Antimalarial Drug Resistance and the CSP **Vaccine** Antigen in Plasmodium falciparum from Southwest Cameroon.

Efeti MT, Fankem SN, Diallo MT, Lahngong MS, Acha NL, Shey RA, Demeyer K, Souopgui J, Ghogomu SM, Njemini R.Int J Mol Sci. 2025 Nov 5;26(21):10764. doi: 10.3390/ijms262110764.PMID: 41226800

Identification of two novel linear B-cell epitopes in p27 of feline leukemia virus using monoclonal antibodies.

Zhu S, Tang A, Zhu Y, Zhang D, Zhu M, Zhang M, Li N, Pang S, Zhang Q, Tan X, Zhu J, Li C, Meng C, Liu G.Int J Biol Macromol. 2025 Nov 10:148439. doi: 10.1016/j.ijbiomac.2025.148439. Online ahead of print.PMID: 41218517

Changing epidemiology of respiratory pathogens since 2020: Shenzhen case study and global perspectives.

Chen C, Liu H, Liu J, Chen P, Lu H.Drug Discov Ther. 2025 Nov 15;19(5):277-284. doi: 10.5582/ddt.2025.01108. Epub 2025 Oct 23.PMID: 41125353

Gc glycoprotein trimer **vaccine** elicits robust neutralizing antibodies against severe fever with thrombocytopenia syndrome virus in mice.

Liu X, Li Q, Zhang H, Zhang M, Yang Y, Xiao H, He Q, Li H, Wang Y, Li Z.Int Immunopharmacol. 2025 Nov 14;165:115470. doi: 10.1016/j.intimp.2025.115470. Epub 2025 Sep 11.PMID: 40939432

Wang Y, Li M, Yang X, Yin Y, Liu J, Qu J, Bao Y, Qi J, Han X, Wang S, Tian M.Vet Res. 2025 Nov 7;56(1):214. doi: 10.1186/s13567-025-01658-x.PMID: 41204344

Pfs230 domain 12 is a potent malaria transmission-blocking **vaccine** candidate.

Inklaar MR, de Jong RM, Da DF, Hubregtse LL, Meijer M, Teelen K, Bekkering ET, Grievink S, van de Vegte-Bolmer M, van Gemert GJ, Stoter R, Nagaoka H, Tsuboi T, Takashima E, Spruijt CG, Vermeulen M, Dabire RK, Arinaitwe E, Cohuet A, Bousema T, Jore MM.Sci Adv. 2025 Nov 7;11(45):eadw8216. doi: 10.1126/sciadv.adw8216. Epub 2025 Nov 7.PMID: 41202138

Pulmonary Surfactant Protein-Hitchhiking Inhalable Vaccines Augment Mucosal and Systemic Antiviral Immunity.

Guo M, Sun J, Guo Y, Chen Z, Gao S, Mei J, Fu W, Zhou X, Wang X, Cui Y, An Y, Dai L, Xu K, Gao GF, Wang H, Zhao Y, Wang Y, Chen C.ACS Nano. 2025 Nov 4;19(43):37895-37909. doi: 10.1021/acsnano.5c11682. Epub 2025 Oct 24.PMID: 41133467

Distinct trajectories of humoral immune responses after SARS-CoV-2 mRNA vaccination in autoimmune inflammatory rheumatic diseases: A group-based trajectory analysis.

Yamaguchi Y, Amiya S, Inokuchi S, Nagao S, Kosaka K, Nameki S, Murakami T, Yoshimine Y, Okita Y, Kawasaki T, Morita T, Tsujimoto K, Fujimoto J, Nishide M, Nishida S, Narazaki M, Kato Y, Kumanogoh A.Vaccine. 2025 Nov 14;66:127771. doi: 10.1016/j.vaccine.2025.127771. Epub 2025 Oct 12.PMID: 41083320

Outpatient antibiotic prescribing for medically attended respiratory syncytial virus, influenza, or human metapneumovirus illness among high-risk adults in rural Wisconsin, United States.

Jorgensen SCJ, McClure DL, Alonge OD, Sundaram ME.J Antimicrob Chemother. 2025 Nov 4:dkaf412. doi: 10.1093/jac/dkaf412. Online ahead of print.PMID: 41187946

Impact of vaccination on shingles-related hospitalisations in 70-79-year-olds in Scotland between 2000 and 2023: A retrospective cohort study.

Kouzeli A, Hasan T, Smith K, Metelmann S, Gibbons C, Ghebrehewet S.Vaccine. 2025 Nov 7;68:127951. doi: 10.1016/j.vaccine.2025.127951. Online ahead of print.PMID: 41205404

Using machine learning models to predict **vaccine** hesitancy: a showcase of COVID-19 **vaccine** hesitancy in rural populations during the pandemic.

Ge Y, Zahid A, Kuchur R, Martinez L, Wang B, Zhang L, Aras S, Raynee P, Dike A, Navarro C, Lawrick C, Greer T, Twum F, Shen Y, Gipson J, Lemacks J.Vaccine. 2025 Nov 14;66:127799. doi: 10.1016/j.vaccine.2025.127799. Epub 2025 Oct 10.PMID: 41075400

An analysis of causality assessed serious and severe adverse events following COVID-19 vaccines administered from January 2021 to September 2022 in India.

Singh AK, Feren N, Thapar R, Boulton ML.Expert Rev Vaccines. 2025 Dec;24(1):992-1001. doi: 10.1080/14760584.2025.2589203. Epub 2025 Nov 13.PMID: 41222029

Precision design of an HLA-I-targeted multiepitope **vaccine** against human papillomavirus 16 oncoproteins E6/E7: integrated immunoinformatic and immunogenicity profiling.

Dai J, Yang R, Cun Y, Zhang X, Li J, Shi L, Zhou L, Tao Y, Shi L, Yao Y, Liu S.Anticancer Drugs. 2025 Nov 5. doi: 10.1097/CAD.0000000000001790. Online ahead of print.PMID: 41191800

Vaccine hesitancy is anything but homogeneous: The social representations of COVID-19 vaccines among not hesitant and slightly hesitant vaccinated adults.

Rochira A, Fasanelli R, Prati G, Gatti F, Gattino S, Marzana D, Procentese F, De Simone E.J Health Psychol. 2025 Nov 3:13591053251375321. doi: 10.1177/13591053251375321. Online ahead of print.PMID: 41185094

Tolerability, safety, and preliminary immunogenicity assessment of different dosages of Quadrivalent inactivated influenza **vaccine** in healthy subjects aged 6-35 months: A single-center, dose-escalation, open-label phase I clinical trial.

Zhu Y, Si M, Wang L, Zhang Y, Zhu T, Wu J, Zhang Y, Shuai Q, Lu W, Ma W, Zhao M, Zhu S, Tang Y, Yu J.Vaccine. 2025 Nov 8;68:127962. doi: 10.1016/j.vaccine.2025.127962. Online ahead of print.PMID: 41207071

A virus-like-particle-producing DNA **vaccine** triggers specific humoral immunity against hepatitis C virus in mice.

Hussein NA, Azouz RAM, El-Shenawy R, Helmy NM, Tabll AA, El-Abd YS, Ali AA.Arch Virol. 2025 Nov 10;170(12):244. doi: 10.1007/s00705-025-06419-x.PMID: 41212307

Optimizing Aeromonas hydrophila **Vaccine** Efficacy in Common Carp: The Role of Free vs. Microencapsulated Lactiplantibacillus plantarum and Lactobacillus delbrueckii bulgaricus.

Alishahi M, Aakool MAK, Peyghan R, Khosravi M, Gharibi D.Fish Shellfish Immunol. 2025 Nov 12:110996. doi: 10.1016/j.fsi.2025.110996. Online ahead of print.PMID: 41238066

Incidence of Respiratory Infections after the COVID-19 Pandemic (2023-2024) and Its Association of Vaccination Among Entire Populations in Korea.

Song J, Jeong S, Chun AY, Jung J, Park SJ, Park SM.Int J Infect Dis. 2025 Nov 7:108194. doi: 10.1016/j.ijid.2025.108194. Online ahead of print.PMID: 41207370

Assessing factors associated with one-year antibody waning in participants with repeated influenza vaccinations: A six-year cohort study.

Cheng C, Chen X, Ge Y, Sung MH, Zhang Y, Ogunyemi K, Carlock MA, Hanley HB, Handel A, Ross TM, Shen Y.Vaccine. 2025 Nov 6;68:127904. doi: 10.1016/j.vaccine.2025.127904. Online ahead of print.PMID: 41202613

Vaccine advice based on science: US centre fills gaps in public-health information.

Lenharo M.Nature. 2025 Nov 10. doi: 10.1038/d41586-025-03625-0. Online ahead of print.PMID: 41214315

Human papillomavirus (HPV) vaccination coverage among adults aged 27-45 years in the United States, 3 years after the recommendation for shared clinical decision-making.

Lu PJ, Hung MC, Lewis RM, Srivastav A, Brewer SK, Black CL, Singleton JA, Markowitz LE.Am J Prev Med. 2025 Nov 4:108180. doi: 10.1016/j.amepre.2025.108180. Online ahead of print.PMID: 41197975

Intranasal CD40-targeted recombinant MERS-CoV S1 protein is superior to intramuscular immunization in eliciting systemic and mucosal immune responses in mice.

Khan MY, Aljehani ND, Abdulal RH, Ghazwani A, Alsulaiman RM, Eyouni M, Shebbo S, Basabrain M, Sanki MA, Alsharef AA, Abdulaal WH, Albukhari A, Qadri I, Alluhaybi KA, Altorki T, Alhabbab R, Alghanmi M, Zawawi A, Abujamel TS, Algaissi A, Thulasi Raman SN, Alfaleh MA, Alghamdi BS, Azhari AA, Li X, Mahmoud

AB, Hashem AM.Vaccine. 2025 Nov 12;69:127975. doi: 10.1016/j.vaccine.2025.127975. Online ahead of print.PMID: 41232171

Free Nucleic Acids in the ChAdOx1 nCov-19-S Adenovirus Vector **Vaccine** Contribute to an Anti-platelet Factor 4 Antibody Response.

Siegerist F, Reder A, Palankar R, Wesche J, Müller L, Michalik S, Brandt JVD, Hoppen J, Schönborn L, Thiele T, Völker U, Endlich N, Greinacher A.Thromb Haemost. 2025 Nov 13. doi: 10.1055/a-2736-5418. Online ahead of print.PMID: 41183547

Limitations of serological screening for measles immunity in young health care workers in New Zealand.

Saha S, van Binnendijk R, Ussher J, Ten Hulscher H, Millier M, McIntyre P.Vaccine. 2025 Nov 3;68:127931. doi: 10.1016/j.vaccine.2025.127931. Online ahead of print.PMID: 41187485

Multi-epitope recombinant chimera and inactivated Escherichia coli expressing chimeric gene of Corynebacterium pseudotuberculosis as vaccines for caseous lymphadenitis.

de Oliveira Silva MT, Barbosa TN, de Pinho RB, Moron LD, Scholl NR, Borsuk S.Res Vet Sci. 2025 Nov 4;197:105956. doi: 10.1016/j.rvsc.2025.105956. Online ahead of print.PMID: 41202659

Determinants of non-compliance with additional booster doses of the SARS-CoV-2 **vaccine** in people living with HIV (PWH): An observational study based on a behavioral and epidemiological survey in Rome (Italy).

Del Duca G, Sperduti I, Cozzi Lepri A, Mazzotta V, Drobniewski F, Gagliardini R, Fusto M, Plazzi MM, Paulicelli J, Vergori A, De Ponte C, Faccendini P, Gallì P, Girardi E, Antinori A.Hum Vaccin Immunother. 2025 Dec;21(1):2582964. doi: 10.1080/21645515.2025.2582964. Epub 2025 Nov 6.PMID: 41195641

Differences in symptoms and clinical outcomes of COVID-19 infection across vaccination status and age groups during the national pandemic from December 2022 to February 2023 in China: a cross-sectional study.

Hua N, Wang A, Zheng F, Gao W, Zhang Q, Chen J.BMC Infect Dis. 2025 Nov 11;25(1):1542. doi: 10.1186/s12879-025-11733-5.PMID: 41219943

Negative-sense RNA virus nucleocapsid as a versatile platform for gene delivery, **vaccine** development, and antiviral screening.

Rehman S, Chavan PM, Chaturvedi A, Nayak D.Sci Rep. 2025 Nov 3;15(1):38367. doi: 10.1038/s41598-025-22282-x.PMID: 41184450

Structural basis for a potent human neutralizing antibody targeting a conserved epitope on the H7 hemagglutinin head.

Li J, Wang M, Yang Y, Zhang L, Liu L, Yang W, Peng Y, Zhang X, Yuan B, Peng Q, Yang X, Chen Y, Gao GF, Shi Y, Wan X.Proc Natl Acad Sci U S A. 2025 Nov 11;122(45):e2503008122. doi: 10.1073/pnas.2503008122. Epub 2025 Nov 6.PMID: 41196357

HCMV infection of terminally differentiated neurons disrupts microtubule organization, resulting in neurite retraction.

Adelman JW, Sukowaty AT, Partridge KJ, Gawrys JE, Akins A, Terhune SS, Ebert AD.Microbiol Spectr. 2025 Nov 4;13(11):e0119825. doi: 10.1128/spectrum.01198-25. Epub 2025 Oct 8.PMID: 41059695

Immunopeptidomics can inform the design of mRNA vaccines for the delivery of *Mycobacterium tuberculosis* MHC class II antigens.

Leddy O, Ogongo P, Huffaker J, Gan M, Milligan R, Mahmud S, Ni HM, Yuki Y, Bobosha K, Wassie L, Carrington M, Liu Q, Ernst JD, White FM, Bryson BD.Sci Transl Med. 2025 Nov 5;17(823):eadw9184. doi: 10.1126/scitranslmed.adw9184. Epub 2025 Nov 5.PMID: 41191777

Evaluation of Suitability, Efficacy, and Safety of Zinc Hydroxide Adjuvant System Adsorbed on Tetanus Toxoid **Vaccine**.

Khan HA, Haq R, Awan AA, Mehmood K, Ghazanfar S, Debnath B, Ashique S, Mondal M, Sridhar SB, Ansari MY, Hussain MS.Mol Biotechnol. 2025 Nov 6. doi: 10.1007/s12033-025-01527-0. Online ahead of print.PMID: 41196532

The cervical cancer screening program in the North of Portugal: Outcomes after nearly two decades of coexistence with the human papillomavirus **vaccine**.

Sá P, Monteiro P, Henrique R, Lunet N.Int J Cancer. 2025 Nov 3. doi: 10.1002/ijc.70196. Online ahead of print.PMID: 41181943

Efficacy of intradermal plus intramuscular Recombinant hepatitis B vaccination in **vaccine** nonresponders.

Tabak F, Sahin Ozdemir M.Ir J Med Sci. 2025 Nov 3. doi: 10.1007/s11845-025-04146-5. Online ahead of print.PMID: 41182584

Determinants of parental readiness for childhood vaccination: experiences, information, sociodemographics and adherence.

Hansen BT, Østlie IB, Greve-Isdahl M, Gleditsch RN.Vaccine. 2025 Nov 14;66:127809. doi: 10.1016/j.vaccine.2025.127809. Epub 2025 Oct 11.PMID: 41082813

Determinants of parental readiness for childhood vaccination: experiences, information, sociodemographics and adherence.

Hansen BT, Østlie IB, Greve-Isdahl M, Gleditsch RN.Vaccine. 2025 Nov 14;66:127809. doi: 10.1016/j.vaccine.2025.127809. Epub 2025 Oct 11.PMID: 41082813

Adverse childhood experiences and COVID-19 vaccination uptake: Examining the intersection of sex and urban-rural residence.

Fu K, Jackson DB, Testa A.PLoS One. 2025 Nov 7;20(11):e0336390. doi: 10.1371/journal.pone.0336390. eCollection 2025.PMID: 41202059

The development of a pan-genotypic T cell **vaccine** against hepatitis C virus using heterologous prime-boost strategies.

Strain R, Edmans M, Montalvo Zurbia-Flores G, Frumento N, Brown A, Hutchings C, Board C, Knight C, Flyak AI, Bailey J, Lauer G, Cox A, Klenerman P, Barnes E.Hepatology. 2025 Nov 14. doi: 10.1097/HEP.0000000000001599. Online ahead of print.PMID: 41236497

A pediatric case of anti-PF4 antibody-induced cerebral venous sinus thrombosis and thrombocytopenia following adenovirus infection: a literature review.

Nagai K, Mitani T, Kawahara Y, Oguma H, Gomi A, Yasumoto A, Tajima T, Muramatsu K, Osaka H.Brain Dev. 2025 Nov 9;47(6):104483. doi: 10.1016/j.braindev.2025.104483. Online ahead of print.PMID: 41213226

Nasal delivery of *Lacticaseibacillus rhamnosus* GG modulates respiratory immune responses and attenuates *Mycoplasma pneumoniae* pneumonia in a murine model.

He J, Tian W, Feng P, Du T, Long H, He G, Wei H, Zhu X, Jiang X, Zhu C.Microbiol Spectr. 2025 Nov 14:e0077125. doi: 10.1128/spectrum.00771-25. Online ahead of print.PMID: 41236498

Evolutionary dynamics of Influenza A(H3N2) virus in India from 2009 to 2023.

Potdar V, Dhawlarker A, Vipat V, Gaikwad S, Kelkar P, Jadhav S, Choudhary ML, Bhardwaj S, Vijay N, Gupta N; VRDL Laboratory network.Gene. 2025 Nov 5;971:149798. doi: 10.1016/j.gene.2025.149798. Epub 2025 Oct 9.PMID: 41067552

Self-amplifying mRNA nanovaccine encoding GM-CSF-fused HPV16 E7 enhances immunogenicity and therapeutic efficacy against cervical cancer.

Lin G, Guo X, Fu Z, Liu Z, Gu F, Yan H, Chen R, Liu Y, Kuang X, Xu Y, Zhang Y.Int J Biol Macromol. 2025 Nov 10;333(Pt 2):148933. doi: 10.1016/j.ijbiomac.2025.148933. Online ahead of print.PMID: 41224055

Safety and immunogenicity of a tetravalent dengue **vaccine** (CYD-TDV) in HIV-positive adults aged 18-50 years in Brazil: Results from a phase II, randomized, observer-blind, placebo-controlled trial.

Perroud A, Madruga JVR, Fernandes L, Luz K, Lukic N, Bourée S, Sanchez-Ruiz M, Pegoraro F, Petit C, Zambrano B, Dayan G.Hum Vaccin Immunother. 2025 Dec;21(1):2582237. doi: 10.1080/21645515.2025.2582237. Epub 2025 Nov 10.PMID: 41213642

Maternal and Neonatal Outcomes in Pregnant Women Vaccinated Against COVID-19 Compared to an Unvaccinated Group.

Nourian T, Sarandili S, Mousavi S, Mirmohammadkhani M, Rahmanian M.Int J Womens Health. 2025 Nov 5;17:4131-4142. doi: 10.2147/IJWH.S548444. eCollection 2025.PMID: 41220619

Transient lung eosinophilia during breakthrough influenza infection in vaccinated mice is associated with protective and balanced Type 1/2 immune responses.

Chang LA, Yeung ST, Warang P, Noureddine M, Singh G, Webb BT, Burgess E, Schotsaert M.J Virol. 2025 Nov 5:e0096525. doi: 10.1128/jvi.00965-25. Online ahead of print.PMID: 41190814

Genomic characteristics, antimicrobial resistance profiles and virulence factors of Gallibacterium anatis isolates from layer chickens in Northern China.

Guo F, Wang D, Wu H, Zhao X, Xu F, Cui Y, Shao Y, Zhang Y, Bu W, Wen T.BMC Microbiol. 2025 Nov 3;25(1):706. doi: 10.1186/s12866-025-04440-3.PMID: 41184760

Job's not done: BCG-itis as the first manifestation of hyper-IgE syndrome. A case report and review of the literature.

Staines-Boone AT, Venegas-Montoya E, Campos JAG, García JAO, Marmolejo Bjirsdorp JC, Gálvez YS, Cruz-Muñoz ME, Galicia LB, Medina-Torres EA, Espinosa-Padilla SE, Calderón DO, Berrón-Ruiz L, Lugo Reyes SO.Clin Immunol. 2025 Nov 14:110639. doi: 10.1016/j.clim.2025.110639. Online ahead of print.PMID: 41242409

Severe flare of genital warts after intralesional nonvalent HPV **vaccine** and development of multiple nodules at the sites of injection.

Stefanaki C, Karousos G, Sachanas S.Int J STD AIDS. 2025 Nov 11:9564624251394549. doi: 10.1177/09564624251394549. Online ahead of print.PMID: 41216745

BNT162b2 mRNA COVID-19 **vaccine** effectiveness in pregnancy: Emulating trial NCT04754594 using observational data from Norwegian health registries.

Zidan M, Trinh NTH, Desalegn A, Smith LH, van Gelder MMHJ, Nordeng H, Lupattelli A.Vaccine. 2025 Nov 6;68:127908. doi: 10.1016/j.vaccine.2025.127908. Online ahead of print.PMID: 41202612

Assessing effects of pneumococcal vaccination (PCV13) and rotavirus vaccination (RV) on colonization with extended-spectrum cephalosporin-resistant Enterobacterales (ESCrE) in Guatemalan children.

Ramay BM, Yoder J, Castillo C, Fahsen N, Grajeda L, Santos LF, Romero JC, Lopez MR, Palmer GH, Cordon-Rosales C, Call DR.Vaccine. 2025 Nov 14;66:127852. doi: 10.1016/j.vaccine.2025.127852. Epub 2025 Oct 13.PMID: 41086757

Seeking positive connection: Is inflammation associated with anticipated and experienced shared positive affect with close versus non-close others?

West TN, Jolink TA, Feldman MJ, Alvarez GM, Cardenas MN, Fredrickson BL, Muscatell KA.Emotion. 2025 Nov 3. doi: 10.1037/emo0001594. Online ahead of print.PMID: 41182732

Analysis and comparison of chickenpox outbreaks in two schools at different educational stages: a mixed retrospective observational study.

Lyu H, Chen M, Zhou H, Zhang Z, Zeng Y, Xiong H.BMC Infect Dis. 2025 Nov 11;25(1):1543. doi: 10.1186/s12879-025-11981-5.PMID: 41219850

A tumor-selective mRNA system enables precision cancer treatment.

Żak MM, Yoo J, Utrero-Rico A, Walter W, Mainkar G, Adjmi M, Kurian AA, Rahaman A, Ojalvo DL, Ochando J, Haferlach T, Parsons RE, Swirski FK, Zangi L.Mol Ther. 2025 Nov 15:S1525-0016(25)00954-2. doi: 10.1016/j.ymthe.2025.11.015. Online ahead of print.PMID: 41243282

Engineered MS2 Virus Capsids for Cellular Display of Peptide Antigens.

Martin HS, Huang P, Leifer IC, Pratakshya P, Francis MB.ACS Chem Biol. 2025 Nov 15. doi: 10.1021/acschembio.5c00700. Online ahead of print.PMID: 41240063

Trichinella spiralis serine protease mediates larval invasion of gut epithelium via binding to CK8 and activating RhoA/ROCK1 pathway.

Zheng WW, Zhang XZ, Cong PK, Zhang R, Long SR, Zhang X, Liu RD, Wang ZQ, Cui J.PLoS Negl Trop Dis. 2025 Nov 13;19(11):e0013725. doi: 10.1371/journal.pntd.0013725. Online ahead of print.PMID: 41231913

Insights from the Study of B-Cell Epitopes of a Microbial Pathogen by Phage Display.

Silverman GJ.Cold Spring Harb Protoc. 2025 Nov 7. doi: 10.1101/pdb.top107777. Online ahead of print.PMID: 41203422

Protein nanoparticles assemble in plants, display antigenic viral peptides, and produce an epitope-specific immune response.

VanderBurgt JT, Strasser R, Zhu H, Kaldis A, Garnham CP, Menassa R.FEBS J. 2025 Nov 17. doi: 10.1111/febs.70288. Online ahead of print.PMID: 41247829

Randomised controlled field trial to assess the safety and efficacy of a killed autologous **vaccine** against Streptococcus dysgalactiae subspecies dysgalactiae in a sheep flock.

Angell JW, Ahmed N, Jackson LP, Kasiora K, Ballingall K, Duncan JS.Vet Rec. 2025 Nov 15;197(10):e256-e263. doi: 10.1002/vetr.5667. Epub 2025 Oct 10.PMID: 41071169

Long-term oral administration of inactivated Vibrio harveyi **vaccine** triggers immunosuppression in Penaeus vannamei.

Kuang B, Yang W, Li C, Lee CW, Liu BY, Bong CW, Wang W, Chen S.Fish Shellfish Immunol. 2025 Nov 5;168:110983. doi: 10.1016/j.fsi.2025.110983. Online ahead of print.PMID: 41202998

Parallel HIV-1 fitness landscapes shape viral dynamics in humans and macaques that develop broadly neutralizing antibodies.

Shimagaki KS, Lynch RM, Barton JP.Elife. 2025 Nov 10;14:RP105466. doi: 10.7554/eLife.105466.PMID: 41212071

Purification of Quillaja saponins QS-21$_{Xyl}$ and QS-21$_{Api}$ by hydrophilic interaction chromatography.

Yue S, Shi J, Cai C, Ke Y.Carbohydr Res. 2025 Nov 8;559:109741. doi: 10.1016/j.carres.2025.109741. Online ahead of print.PMID: 41223814

High Case Fatality Rate of Human Adenovirus Type 7 Infections in Children: A Meta-Analysis and Phylogenetic Study of HAdV-7 Epidemics Over the Past Seven Decades.

Li Y, Deng S, Yang P, Wu J, Zhao T, Chen D, Duan B, Xin N, Mo L, Xiao H, Seto D, Chodosh J, Ou J, Zhang Q.Emerg Microbes Infect. 2025 Nov 3:2582911. doi: 10.1080/22221751.2025.2582911. Online ahead of print.PMID: 41182032

Could more adults than just those aged 75-79 years potentially benefit from vaccination against RSV: insights from UK data.

Vyse A, Hockey C, Wright H, Ellsbury G.J Pharm Policy Pract. 2025 Nov 4;18(1):2576618. doi: 10.1080/20523211.2025.2576618. eCollection 2025.PMID: 41199924

Immune imprinting toward SARS-CoV-2 XBB: implications for **vaccine** strategy and variant risk assessment.

Yang X, Li G, Wang Y, Song T, Cui T, Luo J, Chen S, Cao J, Zhong J, Zhong N, Zhao Z, Wang Z.Signal Transduct Target Ther. 2025 Nov 13;10(1):372. doi: 10.1038/s41392-025-02484-5.PMID: 41233323

Weekly azithromycin for 48 weeks impacts nasopharyngeal microbial prevalence and Streptococcus pneumoniae serotypes in children with HIV-associated chronic lung disease.

Mushunje PK, Sovershaeva E, Olwagen CP, Madhi S, Odland JØ, Ferrand RA, Nicol MP, Abotsi RE, Dube FS.Sci Rep. 2025 Nov 7;15(1):39175. doi: 10.1038/s41598-025-23693-6.PMID: 41203736

H1N1 challenge results in rapid recall of stem-specific immunity in HA stem nanoparticle-vaccinated newborn monkeys.

Crofts KF, Holbrook BC, Page CL, Sangesland M, Kanekiyo M, Alexander-Miller M.JCI Insight. 2025 Nov 10;10(21):e194932. doi: 10.1172/jci.insight.194932. eCollection 2025 Nov 10.PMID: 41212054

Fungal vaccines: so needed, so feasible, and yet so far off.

Casadevall A.J Clin Invest. 2025 Nov 17;135(22):e199451. doi: 10.1172/JCI199451. eCollection 2025 Nov 17.PMID: 41243962

Digital Nudges to Increase Influenza Vaccination in Patients with Chronic Diseases.

Johansen ND, Vaduganathan M, Bhatt AS, Modin D, Claggett BL, Janstrup KH, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Køber L, Solomon SD, Sivapalan P, Jensen JUS, Martel CJ, Krause TG, Biering-Sørensen T.NEJM Evid. 2025 Nov 10:EVIDoa2500265. doi: 10.1056/EVIDoa2500265. Online ahead of print.PMID: 41213006

Coverage of the influenza and pneumococcal vaccinations among immigrant and non-immigrant older adults in Canada: a cross-sectional analysis of data from the Canadian Longitudinal Study on Aging (CLSA).

Kim JY, Sulis G, Russell A, Yang S, Papenburg J, Banerjee A, Li P.BMC Public Health. 2025 Nov 4;25(1):3775. doi: 10.1186/s12889-025-25005-z.PMID: 41188807

Applying spectral analysis to the arterial pulse to discriminate cardiovascular side effects following administration of Moderna's mRNA-1273 **vaccine**.

Chen CC, Chang WT, Chiu CC, Yang TY, Hao WR, Huang TW, Lin KJ, Fang YA, Hsu MH, Yang TL, Lai YH, Jong HC, Liu JC, Hsiu H.Eur J Pharmacol. 2025 Nov 15;1007:178269. doi: 10.1016/j.ejphar.2025.178269. Epub 2025 Oct 17.PMID: 41110748

Economic Incentives for COVID-19 Vaccination Among Employees of a Safety-Net Health System and Medical Center in Southern California: A Cross-Sectional Study.

Khurana D, Garcia L, Freund D, Firek A, Gatto NM.Health Sci Rep. 2025 Nov 9;8(11):e71454. doi: 10.1002/hsr2.71454. eCollection 2025 Nov.PMID: 41221419

Protection conferred by the Omicron XBB.1.5-adapted monovalent COVID-19 mRNA **vaccine** to patients hospitalized with COVID-19 in Greece in 2023-2024.

Maltezou HC, Rapti V, Petrakis V, Gamaletsou MN, Voulgaraki E, Giannouchos TV, Antoniadou E, Kounouklas K, Basoulis D, Karapanou A, Karantoni E, Chini M, Poulakou G, Panagopoulos P, Hatzigeorgiou D, Syrigos KN, Sipsas NV.Infect Dis Now. 2025 Nov 4:105183. doi: 10.1016/j.idnow.2025.105183. Online ahead of print.PMID: 41197803

Supporting equitable booster strategies: one-year real-world immunogenicity data in people with HIV (PWH) receiving different variant-adapted COVID-19 vaccines.

Vergori A, Matusali G, Lepri AC, Cimini E, Colavita F, Mariotti D, Esvan R, Gili S, Cristofanelli F, Mazzotta V, Maggi F, Antinori A.Int J Infect Dis. 2025 Nov 7:108189. doi: 10.1016/j.ijid.2025.108189. Online ahead of print.PMID: 41207367

The future impact of zero-dose children in inaccessible conflict-affected areas of Somalia: aligned with the immunization agenda 2030.

Hussein SA, Osman MM, Hassan MM, Hassan YSA, Hussein AA, Mohamed AH, Adem R, Fuje MM, Mohamud KH, Ali AN, Ibrahim AM, Ali AA.Trop Med Health. 2025 Nov 12;53(1):162. doi: 10.1186/s41182-025-00833-2.PMID: 41225680

Simultaneous efficacy of IL-15 and the HSP70 fragments in increasing immunostimulatory effects of a HIV-1 DNA **vaccine** candidate against SCR HIV-1.

Fekri M, Bolhassani A, Movahedi M, Rahmati F.PLoS One. 2025 Nov 6;20(11):e0336042. doi: 10.1371/journal.pone.0336042. eCollection 2025.PMID: 41196843

Local control of T cell fate in lymph nodes safely and durably reverses myelin-driven autoimmunity.

Kapnick SM, Gosselin EA, Tsai SJ, Oakes RS, Habibabady ZA, Ackun-Farmmer MA, Carey ST, Shah SA, Shen R, Froimchuk E, Eppler HB, Bridgeman CJ, Yanes AA, McIlvaine RA, Noshin M, Tostanoski LH, Black SK, Zeng X, Azimzadeh A, Pierson RN 3rd, Bromberg JS, Jewell CM.Proc Natl Acad Sci U S A. 2025 Nov 11;122(45):e2409563122. doi: 10.1073/pnas.2409563122. Epub 2025 Nov 3.PMID: 41183200

Unravelling parental decision-making for adolescent HPV vaccination in China by COM-B framework: a discrete choice experiment.

Shi N, Xiu S, Wang J, Yang L, Zhang Y, Shen Y, Jin H.Expert Rev Vaccines. 2025 Nov 17. doi: 10.1080/14760584.2025.2591111. Online ahead of print.PMID: 41247187

mRNA-Based Vaccination Drives in Vivo Dendritic Cell Reprogramming and Selective Cytotoxic T Lymphocyte Modulation for Enhanced Antitumor Immunity.

Zhang C, Stewart W, Teng Y, Hu B, Xu X, Zhang XQ.ACS Nano. 2025 Nov 11;19(44):38267-38283. doi: 10.1021/acsnano.5c09365. Epub 2025 Oct 28.PMID: 41151069

Reverse genetics study disclaims the role of African swine fever virus gene I196L in the pathogenesis in pigs.

Yoshimoto A, Kitamura T, Ikezawa M, Kokuho T, Masujin K.J Vet Med Sci. 2025 Nov 10;87(11):1355-1361. doi: 10.1292/jvms.25-0245. Epub 2025 Oct 1.PMID: 41034131

Provider setting for influenza and COVID-19 vaccination among Australian adults in 2023 and 2024.

Reekie J, Stepien S, Hendry A, Dalton L, Macartney K, Liu B.Vaccine. 2025 Nov 6;68:127945. doi: 10.1016/j.vaccine.2025.127945. Online ahead of print.PMID: 41202610

Comparison of the immunogenicity of adjuvanted and conventional egg-based quadrivalent influenza vaccines among healthcare personnel in Lima, Peru: A randomized controlled trial.

Marcenac P, Soto G, Yau T, Carreon JD, Romero C, Gonzales M, La Rosa S, Arriola CS, Prouty M, Díaz RAH, Romero FA, Llanos-Cuentas A, Prado EDM, Silva M, Fowlkes A, Levine MZ, Azziz-Baumgartner E, Duca LM, Neyra J.Int J Infect Dis. 2025 Nov 11:108205. doi: 10.1016/j.ijid.2025.108205. Online ahead of print.PMID: 41232749

The enhanced cancer nanovaccine by bidirectionally blocking CXCL12/CXCR4 axis to inhibit the recurrence and metastasis of triple-negative breast cancer.

Liu M, Ye W, Ji Q, Zhang B, Yang Z, Liu D, Zhou S.Mol Cancer. 2025 Nov 13;24(1):290. doi: 10.1186/s12943-025-02496-3.PMID: 41233789

Rotasiil **vaccine** effectiveness against rotavirus-associated hospitalizations in the Democratic Republic of the Congo: comparison of multivariate logistic regression and inverse probability treatment weighting methods in a test-negative design.

Luhata Lungayo C, Burnett E, Mulumba A, Milabyo A, Nasaka P, Adhaku R, Volatier E, Tate JE, Parashar U, Diallo AO, Burke RM, Otomba JS, Dommergues MA, Pukuta E, Mwenda JM, Ngoy F, Ngoy M, Mosala N, Muteba D, Domingo DD, Ditekemena J, Launay O, Jouffroy R.Vaccine. 2025 Nov 10;68:127944. doi: 10.1016/j.vaccine.2025.127944. Online ahead of print.PMID: 41218304

Comment on 'COVID-19 **vaccine** wastage in private and public healthcare facilities in KwaZulu-Natal, South Africa'.

Kleebayoon A, Wiwanitkit V.Int Health. 2025 Nov 4;17(6):1048. doi: 10.1093/inthealth/ihaf009.PMID: 39887022

Beyond the Words: How Physicians' Verbal and Nonverbal Communication Shape Patients' Intentions to Seek Health Information.

Liao D, Yan J, Wilson SR.Health Commun. 2025 Nov 10:1-11. doi: 10.1080/10410236.2025.2585307. Online ahead of print.PMID: 41214434

Biomimetic Organic Nanozyme as Tumor Vaccines for Targeted Suppression of Ammonia-Induced T Lymphocyte Death to Augment Breast Cancer Immunotherapy.

Suo M, Yang D, Yang M, Wang J, Zhang D, Zhu D, Xu Q, Song Y.Adv Sci (Weinh). 2025 Nov 7:e18037. doi: 10.1002/advs.202518037. Online ahead of print.PMID: 41201121

Genetic Manipulation Tools in Leishmania: From CRISPR/Cas9 to **Vaccine** Strategies for Disease Control.

Gundogdu M, Islek Z.Acta Parasitol. 2025 Nov 14;70(6):217. doi: 10.1007/s11686-025-01161-5.PMID: 41238927 Review.

Long-term protection and response to a booster dose after primary hepatitis B vaccination in people under pre-exposure prophylaxis for HIV infection.

Raccagni AR, Morsica G, Reali P, Lolatto R, Bertoni C, Hasson H, Siribelli A, Bruzzesi E, Passini F, Canetti D, Castagna A, Nozza S.Vaccine. 2025 Nov 14;66:127825. doi: 10.1016/j.vaccine.2025.127825. Epub 2025 Oct 10.PMID: 41075401

Glycoengineering the Pseudomonas exotoxin a for multi-sequon integration and enhanced bioconjugation efficiency by PglS.

Knoot CJ, Pomper N, Robinson LS, Harding CM.Glycobiology. 2025 Nov 8:cwaf075. doi: 10.1093/glycob/cwaf075. Online ahead of print.PMID: 41206735

Plasmodium vivax cysteine-rich protective antigen (PvCyRPA), an important element for **vaccine** strategies targeting P. vivax, interacts with human erythrocyte surface.

Cebrián-Carmona J, Arévalo-Pinzón G, Barreto-Santamaria A, Gutiérrez-Ortegón DE, Gómez M, Sánchez-Mirón A, Mesa-Valle CM, Molina-Miras A, Garrido-Cárdenas JA, Patarroyo MA.Acta Trop. 2025 Nov 7;272:107903. doi: 10.1016/j.actatropica.2025.107903. Online ahead of print.PMID: 41205844

Efficacy of genetically modified Mycoplasma hyopneumoniae strains and their effect on local and cell-mediated immune responses in pigs.

Beuckelaere L, Boyen F, Auray G, Haspeslagh M, De Coensel E, Trueeb BS, Meyer E, Haesebrouck F, De Spiegelaere W, Devriendt B, Summerfield A, Kuhnert P, Maes D.Vet Res. 2025 Nov 17;56(1):217. doi: 10.1186/s13567-025-01653-2.PMID: 41250130

Lipid-free, thermostable mRNA vaccines prepared using atomic layer deposition.

Coleman HJ, Rauch A, Langsfeld E, Anderson K, Parlikar U, Funke HH, Garcea RL, Randolph TW.J Pharm Sci. 2025 Nov 13:104066. doi: 10.1016/j.xphs.2025.104066. Online ahead of print.PMID: 41241219

Inverted H1 hemagglutinin nanoparticle vaccines protect mice against challenges with human H1N1 and bovine H5N1 influenza viruses.

Biswas A, Loeffler K, Kim D, Eisfeld AJ, Duffy A, Hammond H, Sangappa A, Abozeid HH, Neumann G, Moreno A, Kawaoka Y, Kane RS.NPJ Vaccines. 2025 Nov 3;10(1):225. doi: 10.1038/s41541-025-01276-w.PMID: 41184296

Maintain **vaccine** mandates to save children's lives.

Epee-Bounya A.BMJ. 2025 Nov 13;391:r2386. doi: 10.1136/bmj.r2386.PMID: 41232964

Genetic diversity, natural selection, and immunological features of the Plasmodium vivax CyRPA protein: Implications for **vaccine** development.

Garzón-Ospina D, Buitrago SP, Cepeda-Riaño N, Castro-Cavadía CJ, Yasnot-Acosta MF.Gene. 2025 Nov 12:149894. doi: 10.1016/j.gene.2025.149894. Online ahead of print.PMID: 41238047

Genetic differences in the HLA region contribute to the variability in SARS-CoV-2 **vaccine** responsiveness of older persons: the Doetinchem Cohort Study.

Kuijpers Y, Rietman ML, Picavet HSJ, Engelfriet P, Verschuren WMM, Buisman AM.Clin Transl Immunology. 2025 Nov 5;14(11):e70058. doi: 10.1002/cti2.70058. eCollection 2025.PMID: 41199751

Cure of experimental *Trypanosoma vivax* infection with a single dose of an unmodified antibody-based drug targeting the invariant flagellum cell surface protein IFX.

Autheman D, Viola C, Rhodes G, Clare S, Brandt C, Harcourt K, Wright GJ.mBio. 2025 Nov 12;16(11):e0206425. doi: 10.1128/mbio.02064-25. Epub 2025 Oct 20.PMID: 41114596

Genome sequence of fowlpox virus from a field outbreak in Bangladesh.

Mozumder A, Akter S, Mia R, Hasan SMN, Das A, Tasmin J, Mondal ABMHR, Rahman MS, Bhuiyan MIU, Akter S, Saha S, Hossain MG.Microbiol Resour Announc. 2025 Nov 17:e0088125. doi: 10.1128/mra.00881-25. Online ahead of print.PMID: 41247027

Assessment of cellular and humoral immunity against varicella-zoster virus in adult allogeneic hematopoietic cell transplant recipients: a cross-sectional study assessing cellular immunity after administration of an adjuvanted recombinant zoster **vaccine**.

Konuma T, Hamatani-Asakura M, Nagai E, Kato S, Andoh S, Adachi E, Monna-Oiwa M, Takahashi S, Yotsuyanagi H, Nannya Y.J Infect Chemother. 2025 Nov 6;31(12):102857. doi: 10.1016/j.jiac.2025.102857. Online ahead of print.PMID: 41205809

Impact of infection timing before vaccination on the effectiveness of COVID-19 mRNA **vaccine** in healthcare workers.

Takatori M, Nemoto A, Hirotsu Y, Mikawa T, Honda R, Ono M, Endo A, Shibamori K, Shiozawa R, Maejima M, Shibusawa M, Natori Y, Nagakubo Y, Hosaka K, Hoshiai M, Miyashita Y, Wakasugi M, Mochizuki H, Omata M.Microbiol Spectr. 2025 Nov 12:e0128825. doi: 10.1128/spectrum.01288-25. Online ahead of print.PMID: 41222268

Vaccination coverage against HPV in a national representative sample of schoolgirls aged 12-18 years in Greece and core knowledge factors in parents' decision to vaccinate their daughters.

Efkarpidis A, Koulierakis G, Papastilianou A, Paschali A, Merakou K.J Public Health Res. 2025 Nov 6;14(4):22799036251388594. doi: 10.1177/22799036251388594. eCollection 2025 Oct.PMID: 41211226

Intracavitary infusion of FOLactis Lactobacillus leads to disappearance of MPE in patient with advanced lung adenocarcinoma.

Zhou M, Zhang J, Zhu S, Zhao Y, Liu B, Shen J.Discov Oncol. 2025 Nov 3;16(1):2016. doi: 10.1007/s12672-025-03727-1.PMID: 41182492

Longitudinal monitoring of cellular immunity by the ex vivo activation of genes in leukocytes (EAGL) assay highlights potential markers of mRNA COVID-19 **vaccine** efficacy against breakthrough symptoms.

Saito T, Couzinet A, Suzuki T, Shimomura M, Ryo A, Miyakawa K, Katayama Y, Nakatsura T.Vaccine. 2025 Nov 6;68:127942. doi: 10.1016/j.vaccine.2025.127942. Online ahead of print.PMID: 41202608

Pre-Existing Th1 Immunity Outperforms Age in Predicting Antibody Responses to SARS-CoV-2 Inactivated Vaccines.

Ye C, Zhang X, Qiu L, Ji J, Gu J, Jia H, Lu Y, Chen J, Meng Z, Lian J, Yao H, Zeng X, Yang Y.Adv Sci (Weinh). 2025 Nov 16:e14147. doi: 10.1002/advs.202514147. Online ahead of print.PMID: 41243198

Replication in human cells supersedes serum antigenic match for the in vivo efficacy of an A/H1N1pdm09 LAIV virus.

Llewellyn S, Schewe KE, Ayaz S, Burbidge D, Cooper S, Crowe J, Dodd S, Shapanis J, Tudor K, Ryan K, Parker L, Dibben O.NPJ Vaccines. 2025 Nov 17;10(1):236. doi: 10.1038/s41541-025-01281-z.PMID: 41249826

Corrigendum to "Monitoring strategies after the incorporation of vaccines into national immunization programs: a systematic review" [**Vaccine** 66 (2025) 127850].

de Melo Araújo AC, Frugoli AG, de Sena Gonçalves JE, Pércio J, Rangel PSC, da Fonseca Victer TN, Matozinhos FP, Fernandes ÉG.Vaccine. 2025 Nov 5;68:127929. doi: 10.1016/j.vaccine.2025.127929. Online ahead of print.PMID: 41197441

Neutralizing Antibodies and the Pathogenesis of HTLV-1: Insights from Clinical Cohorts.

Blanco S, Lingua G, Del Pilar Gómez L, Mangeaud A, Gallego SV.Microb Pathog. 2025 Nov 14:108190. doi: 10.1016/j.micpath.2025.108190. Online ahead of print.PMID: 41242568

Resolving the mRNA Encapsulation-Release Trade-off via Compensatory Forces in Engineered Ionizable Lipids.

Gao W, An K, Ma Y, Xu X, Wang Z, Liu J, Shan X, Liu Y, Chen W, Wang P, Zhou C, Ren Y, Huang X, Xia Y.Adv Mater. 2025 Nov 16:e12235. doi: 10.1002/adma.202512235. Online ahead of print.PMID: 41243603

Ben_0691 functions as an IRG-47 mycoplasma stimulator that mediates host cell resistance to Mycoplasma mycoides subsp. mycoides infection.

Liu T, Zhao H, Wang X, Xu Q, Li Y, Wu Q, Wei Y, Xin J, Pan Q.Commun Biol. 2025 Nov 14;8(1):1571. doi: 10.1038/s42003-025-08950-8.PMID: 41238896

Brucella secreted effector BspH stimulates intracellular ion flux and confers anti-Brucella immunity.

Shi C, Li Q, Wang S, Li R, Cui Y, Hao J, Zhang J, Jia X, Zhang H, Li Z.Vaccine. 2025 Nov 14;69:127992. doi: 10.1016/j.vaccine.2025.127992. Online ahead of print.PMID: 41240584

The intramolecular stabilizing effects of *O*-benzoyl substituents as a driving force of the acid-promoted pyranoside-*into*-furanoside rearrangement.

Gerbst AG, Nikogosova SP, Rastrepaeva DA, Argunov DA, Krylov VB, Nifantiev NE.Beilstein J Org Chem. 2025 Nov 7;21:2456-2464. doi: 10.3762/bjoc.21.187. eCollection 2025.PMID: 41220838

Short report: association between self-reported COVID-19 experience and contemptuous beliefs about pandemic management among German citizens and healthcare professionals.

Wegwarth O, Hertwig R.J Public Health (Oxf). 2025 Nov 8:fdaf144. doi: 10.1093/pubmed/fdaf144. Online ahead of print.PMID: 41206715

Rapid increase in serotype 4 invasive pneumococcal disease among vulnerable young male adults in Belgium (2020-2024).

Lize C, J SG, Paulo HAJ, Reinout N, Thomas AM, Sophie H, Xavier H, Philippe C, Gilles D, Brice L, Fabrizio B, Laetitia B, Henry P, Maya H, Katrien L, Nicolas D, Stefanie D.Int J Infect Dis. 2025 Nov 12:108216. doi: 10.1016/j.ijid.2025.108216. Online ahead of print.PMID: 41238171

Comparative analysis of a flexible novel **vaccine** platform based on cell permeable chimeric HBV capsids for mucosal vaccination.

Raupach J, Housria Y, Hein S, Schnierle B, Durmaz H, Zahn T, Hildt E.Vaccine. 2025 Nov 15;69:127987. doi: 10.1016/j.vaccine.2025.127987. Online ahead of print.PMID: 41242290

A single-center, randomized, double-blind, positive-controlled, phase IV clinical trial to assess the immunogenicity and safety of adsorbed tetanus toxoid **vaccine** in individuals aged 16 years.

Guan Q, Liu J, Tang M, Li Q, Yang H, Zhang Z, Liu S, Wang X, Wu C, Zeng T, Zhou Y, Gao Y, Chen H, Yang Y, Chen W, Meng S, Zhang R.Hum Immunol. 2025 Nov 14;86(6):111612. doi: 10.1016/j.humimm.2025.111612. Online ahead of print.PMID: 41240607

Seroprevalence of nine human papillomavirus types included in the nonavalent **vaccine** in unvaccinated women living in Puerto Rico: A population-based study.

Cruz A, Ramos-Cartagena JM, Panicker G, Pérez CM, Suárez E, Romaguera J, Unger ER, Rivera T, Ortiz AP.Int J Infect Dis. 2025 Nov 10:108195. doi: 10.1016/j.ijid.2025.108195. Online ahead of print.PMID: 41224106

Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans.

Williams WB, Alam SM, Ofek G, Erdmann N, Montefiori DC, Seaman MS, Wagh K, Korber B, Edwards RJ, Mansouri K, Eaton A, Cain DW, Martin M, Hwang J, Arus-Altuz A, Lu X, Cai F, Jamieson N, Parks R, Barr M, Foulger A, Anasti K, Patel P, Sammour S, Parsons RJ, Huang X, Lindenberger J, Fetics S, Janowska K, Niyongabo A, Janus BM, Astavans A, Fox CB, Mohanty I, Evangelous T, Chen Y, Berry M, Kirshner H, Van Itallie E, Saunders KO, Wiehe K, Cohen KW, McElrath MJ, Corey L, Acharya P, Walsh SR, Baden LR, Haynes BF.Cell. 2025 Nov 13;188(23):6688-6689. doi: 10.1016/j.cell.2025.10.023. Epub 2025 Nov 1.PMID: 41177155

Evaluation of protective effect of infectious hematopoietic necrosis (IHN) oral DNA **vaccine** wrapped with 4 different delivery vectors against IHN virus (IHNV) infection in rainbow trout (Oncorhynchus mykiss).

Shao Y, Zhao J, Li T, Liu W, Lu T, Xu L.Fish Shellfish Immunol. 2025 Nov 14:111003. doi: 10.1016/j.fsi.2025.111003. Online ahead of print.PMID: 41242626

Bivalent SARS-CoV-2 spike immunization with non-replicative antibiotic resistance-free DNA **vaccine** induces immunity to multiple virus variants.

Larraga J, Nogales-Altozano P, Gomez-Marcos L, Ruiz S, Loayza FJ, Rivera-Rodríguez A, Louloudes-Lázaro A, Carlon AB, Rodríguez-Martín D, Alonso A, Martín V, Alcolea PJ, Rojas JM, Larraga V, Sevilla N.Sci Rep. 2025 Nov 14;15(1):40039. doi: 10.1038/s41598-025-23919-7.PMID: 41238792

Plasmodium falciparum gene expression signatures and antibody profiling implicate the fikk, phist, and surf multigene families in severe malaria syndromes.

Cummings BE, Stucke EM, Coulibaly D, Lawton JG, Sobota RS, Kone AK, Kane B, Guindo B, Tangara B, Sissoko M, Maiga F, Traore K, Diawara A, Traore A, Thera A, Dara A, Niangaly A, Daou M, Diarra I, Tolo Y, Sebastian S, Jain A, Nakajima R, Jasinskas A, Silzel EK, Shrestha B, Ouattara A, Munro JB, Laurens MB, Lyke KE, Tebben K, Bogale H, Plowe CV, Sissoko MS, Kouriba B, Takala-Harrison S, Felgner PL, Silva JC, Doumbo OK, Thera MA, Travassos MA.J Infect. 2025 Nov 12:106655. doi: 10.1016/j.jinf.2025.106655. Online ahead of print.PMID: 41238081

NOUS-209 off-the-shelf immunotherapy has the potential to hit primary and metachronous colorectal and urothelial cancer in Lynch syndrome.

De Marco L, Micarelli E, Panula J, Nikkola J, Moilanen L, Annala M, Härkönen J, Hokkanen KE, D'Alise AM, Pylvänäinen K, Peltomäki PT, Ahtiainen M, Böhm J, Mecklin JP, Scarselli E, Seppälä TT.Mol Cancer Ther. 2025 Nov 13. doi: 10.1158/1535-7163.MCT-25-0864. Online ahead of print.PMID: 41232028

Congenital measles: a case highlighting challenges in clinical interventions in a developing country.

Koumba Maniaga R, Bang Ntamack JA, Mintsa-Mi-Nkama E, Lembet Mikolo A, Lekana-Douki SE, Lekana-Douki JB, Ategbo S, Kuissi Kamgaing E, Djoba Siawaya JF.Int J Infect Dis. 2025 Nov 12:108215. doi: 10.1016/j.ijid.2025.108215. Online ahead of print.PMID: 41238169

Temporal single-cell landscape suggests infection-induced IgM plasma cells as a correlate of durable influenza immunity.

Li X, Yuan L, Li M, Liao Q, Jia T, Wu Z, Wen S, Luo H, Wang D, Miao Z, Chen Y, Shu Y.Int J Infect Dis. 2025 Nov 14:108227. doi: 10.1016/j.ijid.2025.108227. Online ahead of print.PMID: 41242688

Giving the respiratory syncytial virus F protein a precision cut: A step toward a rational **vaccine** design for focused immune responses.

Ahmed AU.Mol Ther. 2025 Nov 5;33(11):5292-5293. doi: 10.1016/j.ymthe.2025.10.018. Epub 2025 Oct 21.PMID: 41118762

Day-old vaccination with the Vaxsafe MG304 live-attenuated **vaccine** protects chickens from tracheal transcriptional changes induced by chronic infection with Mycoplasma gallisepticum.

Kamathewatta KI, Kanci Condello A, Ekanayake D, Noormohammadi AH, Young ND, Browning GF, Tivendale KA, Wawegama NK.Vaccine. 2025 Nov 6;68:127915. doi: 10.1016/j.vaccine.2025.127915. Online ahead of print.PMID: 41202614

PPE18 protein of Mycobacterium tuberculosis functions as a virulence factor and is a potential novel therapeutic target.

Manikoth AG, Sontyana B, Shrivastava R, Ghosh S, Mukhopadhyay S.J Immunol. 2025 Nov 15:vkaf146. doi: 10.1093/jimmun/vkaf146. Online ahead of print.PMID: 41240377

Retraction notice to "Based on T-spherical fuzzy environment: A combination of FWZIC and FDOSM for prioritising COVID-19 **vaccine** dose recipients" [J Infect Public Health 14 (2021) 1513-1559].

Alsalem MA, Alsattar HA, Albahri AS, Mohammed RT, Albahri OS, Zaidan AA, Alnoor A, Alamoodi AH, Qahtan S, Zaidana BB, Aickelin U, Alazab M, Jumaah FM.J Infect Public Health. 2025 Nov 14;19(1):103047. doi: 10.1016/j.jiph.2025.103047. Online ahead of print.PMID: 41240424

Retraction Note: Neoantigen **vaccine** nanoformulations based on Chemically synthesized minimal mRNA (CmRNA): small molecules, big impact.

Imani S, Tagit O, Pichon C.NPJ Vaccines. 2025 Nov 14;10(1):233. doi: 10.1038/s41541-025-01306-7.PMID: 41238581

Safety and immunogenicity of the Hendra virus recombinant soluble glycoprotein G Nipah virus **vaccine** in adults.

Yadav PD, Sahay RR.Lancet. 2025 Nov 14:S0140-6736(25)02277-9. doi: 10.1016/S0140-6736(25)02277-9. Online ahead of print.PMID: 41248668

The effectiveness of two doses of Hecolin **vaccine** in response to outbreaks in resource-limited settings.

Zhang F, Xia J, Wang L.Virol Sin. 2025 Nov 11:S1995-820X(25)00155-5. doi: 10.1016/j.virs.2025.11.001. Online ahead of print.PMID: 41232604

Response to Anticipated impact of novel adult-specific pneumococcal conjugate **vaccine** by Joshi et al.

McLaughlin JM, Wassil J.Vaccine. 2025 Nov 15:127988. doi: 10.1016/j.vaccine.2025.127988. Online ahead of print.PMID: 41241620

What is actually the emerging evidence about non-specific **vaccine** effects in randomized trials from the Bandim Health Project?

Støvring H, Ekstrøm CT, Schneider JW, Strøm C.Vaccine. 2025 Nov 13:127937. doi: 10.1016/j.vaccine.2025.127937. Online ahead of print.PMID: 41233263

RETRACTION: A Novel In Situ Dendritic Cell **Vaccine** Triggered by Rose Bengal Enhances Adaptive Antitumour Immunity.

Immunology Research JO.J Immunol Res. 2025 Nov 13;2025:9834758. doi: 10.1155/jimr/9834758. eCollection 2025.PMID: 41245396

Letter to the Editor regarding to Effectiveness of 13-Valent Pneumococcal Conjugate **Vaccine** Against Pneumonia Hospitalization Among Medicare Beneficiaries Aged 65 in Long-Term Care.

Zhao W, Yan X, Yang Y.J Infect Dis. 2025 Nov 15:jiaf581. doi: 10.1093/infdis/jiaf581. Online ahead of print.PMID: 41237830

Correction: A protocol for modeling the factors influencing the deployment of the COVID-19 **vaccine** across African countries.

Ezezika O, Kotsaftis TS, Amponsah-Dacosta E, Demi S, Omwenga EO, Mong'are S, Zaranyika T, Ariyo O, Ngianga-Bakwin K, Ameyaw EK.PLoS One. 2025 Nov 10;20(11):e0336507. doi: 10.1371/journal.pone.0336507. eCollection 2025.PMID: 41212847

Development of a Promising Ferritin-Based Bioconjugate Nanovaccine Candidate against Brucellosis.

Li W, Li J, Cao X, Song N, Li T, Ye J, Chen Z, Lyu Y, Zhu L, Liu Z, Yang X, Wang H, Pan C, Wang Y.ACS Infect Dis. 2025 Nov 14;11(11):3050-3060. doi: 10.1021/acsinfecdis.5c00260. Epub 2025 Oct 31.PMID: 41171198

High Specific Real-Time Tracking of Single Virus Particles.

Hong E, Jang G, Lin C, Rao S, Wang Q.ACS Nano. 2025 Nov 4;19(43):37837-37846. doi: 10.1021/acsnano.5c11017. Epub 2025 Oct 21.PMID: 41117904

Cryo-EM structure of endogenous Pfs230:Pfs48/45 complex with six antibodies reveals mechanisms of malaria transmission-blocking activity.

Bekkering ET, Yoo R, Hailemariam S, Heide F, Ivanochko D, Jackman M, Proellochs NI, Stoter R, van Gemert GJ, Maeda A, Yuguchi T, Wanders OT, van Daalen RC, Inklaar MR, Andrade CM, Jansen PWTC, Vermeulen M, Bousema T, Takashima E, Rubinstein JL, Kooij TWA, Jore MM, Julien JP.Immunity. 2025 Nov 11;58(11):2899-2916.e10. doi: 10.1016/j.immuni.2025.09.014. Epub 2025 Oct 9.PMID: 41072404

Tick-borne encephalitis: An ancient pathology, but a current emergence in Europe.

Hoellinger B, Parfut A, Grisard M, Martin-Latil S, Denis J, Augereau O, Gregorowicz G, Martinot M, Hansmann Y, Velay A.Infect Dis Now. 2025 Nov 14:105187. doi: 10.1016/j.idnow.2025.105187. Online ahead of print.PMID: 41242395

Construction and immunological characterization of two chimeric proteins built from the Mycoplasma bovis genome.

Gomes CP, da Silva LSC, Guimarães BCB, Santos Júnior MN, Barbosa MS, Sampaio BA, Timenetsky J, Bastos BL, Marques LM.Vet Microbiol. 2025 Nov 11;312:110793. doi: 10.1016/j.vetmic.2025.110793. Online ahead of print.PMID: 41237746

Use of personal protective equipment among nurses in the pre- and post-COVID-19 vaccination periods.

Nogueira WPS, Gir E, Menegueti MG, Freire MEM, Barroso BIL, Oliveira E Silva AC.Rev Lat Am Enfermagem. 2025 Nov 10;33:e4731. doi: 10.1590/1518-8345.7510.4731. eCollection 2025.PMID: 41221921

Pandemic-Era Shifts in Life Expectancy in Hawai'i, 2018-2022.

Wu Y, Ching L, Prieto C, Phillips MM, Braun KL.Asia Pac J Public Health. 2025 Nov 11:10105395251384117. doi: 10.1177/10105395251384117. Online ahead of print.PMID: 41217001

Red blood cells as probes for determining free QS21 in liposomal adjuvant formulations to support product safety and stability.

Komla E, Rochelle C, Carreon A, Torres OB, Matyas GR, Abucayon EG.Anal Methods. 2025 Nov 6. doi: 10.1039/d5ay00854a. Online ahead of print.PMID: 41196220

Comparative pathogenicity of wild-type and E3-deleted canine adenovirus type 2 in experimental canine infections.

Cao D, Zhang H, Wang P, Sun F, Zhou Y, Peng L, Zhou H, Qin Y, Ouyang K, Yin Y, Wei Z, Huang W, Long J, Chen Y.Microb Pathog. 2025 Nov 14:108189. doi: 10.1016/j.micpath.2025.108189. Online ahead of print.PMID: 41242570

Biohybrid nanocarriers for targeted drug delivery by integrating biological interfaces with synthetic platforms for site-specific therapeutics.

Chennamsetty S, Keerikkadu M, Shetty A, Bangera PD, Tippavajhala VK, Rathnanand M.Int J Pharm. 2025 Nov 14:126400. doi: 10.1016/j.ijpharm.2025.126400. Online ahead of print.PMID: 41242353

Preparation of monoclonal antibodies against pyruvate dehydrogenase E1 component beta subunit (PDHB) protein of Mycoplasma bovis and the identification of its two novel B-cell epitopes.

Shu J, Wu Y, Wu C, Wang X, Ma Y, Lu Y, Zhang Z, Sun X, Pan Z, Yao H.Int J Biol Macromol. 2025 Nov 11;333(Pt 2):148995. doi: 10.1016/j.ijbiomac.2025.148995. Online ahead of print.PMID: 41232890

Unsupervised classification of influenza virus surface spikes from cryo-EM reconstructions using head-to-stem width ratio.

Benkarroum Y.Virol J. 2025 Nov 10;22(1):368. doi: 10.1186/s12985-025-02969-3.PMID: 41214782

Dual-Nanocomplex Delivery of Neoantigen Vaccines and Doxorubicin for Synergistic Chemo-Immunotherapy against Colorectal Cancer.

Zhao W, Noor KS, Sun S, Xu H, Meng J, He X, Sheng W.Adv Healthc Mater. 2025 Nov 10:e03947. doi: 10.1002/adhm.202503947. Online ahead of print.PMID: 41208771

Are people noticing excessive mistrust in others and how do they understand it? A survey of a UK representative adult population.

Slaoui G, Beckwith H, Lambe S, Kabir T, Sokunle G, Ahmed M, Freeman D.Psychol Med. 2025 Nov 3;55:e331. doi: 10.1017/S0033291725102365.PMID: 41177562

Targeted degradation of the HPV oncoprotein E6 reduces tumor burden in cervical cancer.

Smalley TB, Nicolaci AA, Tran KC, Lokhandwala J, Obertopp N, Matlack JK, Miner RE 3rd, Teng MN, Pilon-Thomas S, Binning JM.Mol Ther. 2025 Nov 5;33(11):5415-5426. doi: 10.1016/j.ymthe.2025.08.033. Epub 2025 Aug 26.PMID: 40873032

A Review on Emerging Technologies in Pharmaceutical Packaging: From Anti-Counterfeiting to Green Solutions.

Sikaria K, Sreedevi A, Srivastava N, Ligade VS, Muragundi P, D S.AAPS PharmSciTech. 2025 Nov 11;27(1):22. doi: 10.1208/s12249-025-03230-4.PMID: 41219636

From Salves to Sulzberger: The Emergence of the American Approach to Acne Treatment.

Woźna J, Woźna W, Mojs E, Grzybowski A, Żaba R.Clin Dermatol. 2025 Nov 13:S0738-081X(25)00294-9. doi: 10.1016/j.clindermatol.2025.11.001. Online ahead of print.PMID: 41241206

Mass spectrometry-based metabolomics uncovers distinct metabolic signatures and potential therapeutic targets in Plasmodium knowlesi.

Uthailak N, Chotirat S, Anatjitsupha A, Thongyod W, Tipthara P, Sattabongkot J, Tarning J, Nguitragool W, Reamtong O.PLoS One. 2025 Nov 13;20(11):e0337058. doi: 10.1371/journal.pone.0337058. eCollection 2025.PMID: 41231891

Durations of fever and other symptoms among COVID-19 outpatients administered ensitrelvir during the 2023 Japanese XBB epidemic period.

Kawai N, Bando T, Goto T, Matsuura S, Nagao S, Tanaka O, Kawashima T, Chong Y, Ikematsu H.J Infect Chemother. 2025 Nov 4;31(12):102852. doi: 10.1016/j.jiac.2025.102852. Online ahead of print.PMID: 41197954

Reprogramming tumor microenvironment via systemic delivery of TLR3 agonist and manganese nanoparticle.

Cho YS, Zhou X, Sun X, Wan Z, Crowther J, Takahashi M, Kodamasimham S, Wu Q, Phoo MT, Na Y, Han K, Li Z, Schwendeman A, Schwendeman SP, Lei YL, Moon JJ.Proc Natl Acad Sci U S A. 2025 Nov 11;122(45):e2409559121. doi: 10.1073/pnas.2409559121. Epub 2025 Nov 3.PMID: 41183207

From sequence to scaffold: Computational design of protein nanoparticle vaccines from AlphaFold2-predicted building blocks.

Haas CM, Jasti N, Dosey A, Allen JD, Gillespie R, McGowan J, Leaf EM, Crispin M, DeForest CA, Kanekiyo M, King NP.Proc Natl Acad Sci U S A. 2025 Nov 11;122(45):e2409566122. doi: 10.1073/pnas.2409566122. Epub 2025 Nov 3.PMID: 41183183

The reduced expression and decreased stability of RNA polymerase core proteins are implicated in the virulence attenuation of Brucella abortus strain A19.

Zhan T, Guo L, Chen Y, Zhao S, Qi X, Pei Q, Xie Y, Yang P, Yin D.Int J Biol Macromol. 2025 Nov 13:149015. doi: 10.1016/j.ijbiomac.2025.149015. Online ahead of print.PMID: 41241348

Development of a Porcine Cell Line Stably Expressing Ephrin-B2 for Nipah Virus Research and Diagnostic Testing.

Zhang H, Saito A.Microbiol Immunol. 2025 Nov 17. doi: 10.1111/1348-0421.70022. Online ahead of print.PMID: 41243593

Loop structure in poly(A) tail of mRNA **vaccine** enhances antigen translation efficiency and mRNA stability.

Oh A, Lee S, Park HJ, Yoon S, Ha D, Lee J, Lee S, Roh G, Cho Y, Lee SY, Choi EJ, Lee Y, Bae SH, Cho S, Choi H, Jo S, Kim J, Park HJ, Nam JH.NPJ Vaccines. 2025 Nov 17;10(1):234. doi: 10.1038/s41541-025-01287-7.PMID: 41249784

Septic shock in pigs infected, vaccinated and challenged with Actinobacillus pleuropneumoniae: A clinicopathological study.

Elvira SM, Pérez JT, Ortega MET, Gallardo SG, Puente JHL, Guerrero DQ, Torres MG, Carrasco AC.Vet J. 2025 Nov 15:106494. doi: 10.1016/j.tvjl.2025.106494. Online ahead of print.PMID: 41248799

Scalable purification enables high-quality virus-like particles for therapeutic translation.

Hołubowicz R, Gao F, Du SW, Menezes CR, Zhang J, Hołubowicz MW, Chen PZ, Armbrust N, Geilenkeuser J, Liu DR, Jeffery Truong DJ, Westmeyer GG, Palczewska G, Palczewski K.J Biol Chem. 2025 Nov 13:110946. doi: 10.1016/j.jbc.2025.110946. Online ahead of print.PMID: 41241097

Genomic insights into Bordetella pertussis evolution and macrolide resistance in Yiwu, China.

Xu W, Wei Q, Wu B, Zhu Z, Guan W, Chen G, Xu Z.BMC Genomics. 2025 Nov 17;26(1):1049. doi: 10.1186/s12864-025-12213-5.PMID: 41249897

Sexual Behavior, App Use, and Venue Comfort During COVID-19: A Global Study of Gay, Bisexual, and Other Men Who Have Sex with Men.

Jauregui JC, Hong C, Garner A, Howell S, Holloway IW.J Sex Res. 2025 Nov 17:1-7. doi: 10.1080/00224499.2025.2585071. Online ahead of print.PMID: 41248517

Leveraging optimized oligonucleotide-tagged antigen assemblies and single-cell sequencing for multiplexed proteogenomic profiling of human B cell reactivities.

Apps R, Polanco JJ, Lowman KE, Wang L, Cheung F, Kotekar A, Koroleva G, Mukherjee A, Ylade M, Crisostomo MV, Daag JV, Agrupis KA, Deen J, Gangler K, Cohen J, Law M, Aogo RA, Cherry J, Katzelnick LC, Douagi I.J Immunol. 2025 Nov 11:vkaf301. doi: 10.1093/jimmun/vkaf301. Online ahead of print.PMID: 41220068

Itaconate reduces viral endocytosis by targeting Cys128 of the adaptor-related protein complex 1 gamma 1 subunit in the host, providing a novel target for antiviral drug development.

Deng X, Chen H, Huang Z, He R, Rao Q, Xu L, Xu Z, Zhao N, Peng Y, Li M, Liu X, Ma T, Cui X, Wang C.Mol Biomed. 2025 Nov 10;6(1):105. doi: 10.1186/s43556-025-00348-6.PMID: 41212381

Awareness of HPV-related cancers and the HPV vaccination programme in Scotland: a cross-sectional study of gender, deprivation and knowledge gaps.

Nguyen-Thanh H, Marshall L, Wilson H, Stewart K, Kavanagh K, Sorensen A.J Public Health (Oxf). 2025 Nov 4:fdaf136. doi: 10.1093/pubmed/fdaf136. Online ahead of print.PMID: 41189120

Stimuli-responsive STING nanovaccine for systemic therapy of HPV-induced cancers.

Chen S, Ye S, Huang G, Sun Z, Feng Q, Wang M, Pantoja R, Sumer BD, Gao J.Proc Natl Acad Sci U S A. 2025 Nov 11;122(45):e2409570122. doi: 10.1073/pnas.2409570122. Epub 2025 Nov 3.PMID: 41183189

Preemptive Rituximab for Epstein-Barr Virus Reactivation after Hematopoietic Cell Transplantation: Necessary for All?

de Souza ABC, Simione AJ, Dos Santos ACF, Colturato I, Barbieri FR, do Prado Moreno JR, Zanetti LP, de Oliveira LCS, Delattre ERP, Santos JS, de Souza MP, Colturato VAR, Machado CM.Transpl Infect Dis. 2025 Nov 3:e70124. doi: 10.1111/tid.70124. Online ahead of print.PMID: 41178384

A protein G-based, antibody-free lateral flow assay for IgG detection.

Xiao Y, Dong H, Gu CM, Tian J, Wang H, Zhang K, Zhang F, Zhang J, Xu S, Gu L.Int J Biol Macromol. 2025 Nov 15:149031. doi: 10.1016/j.ijbiomac.2025.149031. Online ahead of print.PMID: 41248793

Alcaligenes lipid A as a sublingual adjuvant to augment protective immune responses in the respiratory and gastrointestinal tracts.

Yoshii K, Liu Z, Shimoyama A, Hirayama Y, Iemitsu K, Node E, Hosomi K, Kiyono H, Fukase K, Kunisawa J.Int Immunol. 2025 Nov 11:dxaf066. doi: 10.1093/intimm/dxaf066. Online ahead of print.PMID: 41216838

Kenyan men and cervical cancer prevention: Insights from a national survey.

Moucheraud C, Ochieng E, Golub G, Navario P, Sacks E, Abdillahi H, Hoffman RM.Cancer Epidemiol Biomarkers Prev. 2025 Nov 7. doi: 10.1158/1055-9965.EPI-25-0987. Online ahead of print.PMID: 41201262

Glioblastoma Immunotherapy Adjuvants for Glial Cell Polarization Regulation.

Park JS, Lee DG, Min DH, Lee SJ.Exp Neurobiol. 2025 Nov 4. doi: 10.5607/en25026. Online ahead of print.PMID: 41185538

Orf virus-based vectors induce potent germinal center B cell, Tfh cell, and CD8⁺ T cell responses.

Kastner AL, Müller M, Marx AF, Dimitrova M, Wagner I, Merkler D, Amann R, Pinschewer DD.Mol Ther. 2025 Nov 5;33(11):5383-5400. doi: 10.1016/j.ymthe.2025.08.037. Epub 2025 Aug 27.PMID: 40873034

Leveraging human precision cut lung slices for the study of human parainfluenza virus 3 infection.

Danov O, Vollmer Barbosa P, Obernolte H, Fuchs M, Guillon P, Dirr L, El-Deeb I, Kunz M, Hose L, Martin G, Röpken F, Zimmer A, Neubert L, Jonigk D, Fieguth HG, Dahlmann F, Wronski S, von Itzstein M, Tschernig T, Braun A, Sewald K.Respir Res. 2025 Nov 14;26(1):315. doi: 10.1186/s12931-025-03335-1.PMID: 41239423

Prevalence of Rotavirus Gastroenteritis and Its Associated Clinical and Sociodemographic Characteristics Among Hospitalized Children Aged Under 5 years in Hazaribagh, Jharkhand, India.

Singh BK, Yadav AP, Chaudhary VS, Kharat N, Machathi A, Varghese T, Lingam R.Indian J Pediatr. 2025 Nov 15. doi: 10.1007/s12098-025-05776-4. Online ahead of print.PMID: 41240251

Antibody responses to polymorphic Plasmodium falciparum merozoite antigens in Malawian children with severe and uncomplicated malaria.

Dobaño C, Rogerson SJ, Cavanagh DR, Taylor TE, McBride JS.Malar J. 2025 Nov 17;24(1):401. doi: 10.1186/s12936-025-05660-8.PMID: 41250165

Invasive Pneumococcal Disease at Eight Children's Hospitals in the United States, 2018-2023.

Kaplan SL, Barson WJ, Ling Lin P, Dahl S, Bradley JS, Pannaraj PS, Tan TQ, Bard JD, Ramirez K, Grant LR, Arguedas A, Tort MJ, Miller A, Cané A, Hulten KG.Pediatr Infect Dis J. 2025 Nov 7. doi: 10.1097/INF.0000000000005039. Online ahead of print.PMID: 41199435

"Just be honest with us": A qualitative analysis of Canadians' public trust during the COVID-19 pandemic.

Muhajarine N, Neudorf C, Braun F, Mehdiyeva K, Baudelaire K, Omot A, Bedard B, Entwistle K, Bandara T, Sadique S, Abraham N, Huyser K, Lavoie KL, Dubé È, Betker C.Can J Public Health. 2025 Nov 5. doi: 10.17269/s41997-025-01121-6. Online ahead of print.PMID: 41191293

Clinical Determinants of Unsuccessful Ultrasound-Guided Hydrostatic Saline Reduction in Children with Intussusception Post-Rotavirus **Vaccine** Introduction: Insights from a Tertiary Care Centre in Thrissur, Kerala, India.

Namboodiripad A, Xavier R, Chaudhary VS, Lingam R, George G, Thuruthiyath N, Alappat MM, Machathi A, Kharat N.Indian J Pediatr. 2025 Nov 3. doi: 10.1007/s12098-025-05778-2. Online ahead of print.PMID: 41182600

Integrating Human-Animal Care Through a Public Health-Driven One Health Clinic Model in Pima County, Arizona, October 2023-February 2024.

Mitchell CL, Ramirez V, Santos E, Noumeh D, VerSchave S, Escheman H, Goetz N, Figueroa M, Wagner K, Singletary M, Kohler LN, Ellingson KD, Wagner J, Pogreba-Brown K, Cullen TA.Public Health Rep. 2025 Nov 3:333549251367579. doi: 10.1177/00333549251367579. Online ahead of print.PMID: 41181916

A Cohort Study Characterizing the Outcomes Following an Acute SARS-CoV-2 Infection in Pregnancy.

Adeyemi C, Breuer L, Kodvawala R, Miller D, Powers-Fletcher MV.J Clin Med. 2025 Nov 6;14(21):7869. doi: 10.3390/jcm14217869.PMID: 41227265

Novel Maintenance Therapies for Chronic Obstructive Pulmonary Disorder.

Covert K, Brooks S, Burchette JE.Ann Pharmacother. 2025 Nov 5:10600280251382202. doi: 10.1177/10600280251382202. Online ahead of print.PMID: 41190453

Beyond the *emm*-type: fine-tuning Group A *Streptococcus* typing with Enn and Mrp.

Widomski C, Bruyns C, Schiavolin L, de Crombrugghe G, Smeesters PR, Botteaux A.Microbiol Spectr. 2025 Nov 14:e0204725. doi: 10.1128/spectrum.02047-25. Online ahead of print.PMID: 41236364

Adenovirus 40 and 41 antibodies associated with protection from infection in a Bangladeshi birth cohort.

Hendrick J, Ma JZ, Huynh V, Pablo JV, Teng AA, Oberai A, Campo JJ, Camerini D, Petri WA Jr.J Infect Dis. 2025 Nov 5:jiaf558. doi: 10.1093/infdis/jiaf558. Online ahead of print.PMID: 41206008

Identification of transiently produced IgG linear epitopes in Senecavirus A for differentiating infected from vaccinated animals.

Yang L, Meng F, Zhou H, Ma H, An T, Jiang N, Wang H, Cai X.Vet Microbiol. 2025 Nov 8;312:110789. doi: 10.1016/j.vetmic.2025.110789. Online ahead of print.PMID: 41218398

Impact of oral Bacillus Calmette-Guérin on B220 receptor expression in Peyer's patches of lactating mice: Analysis of receptor percentiles and cell frequencies.

de Mello Loureiro IV, de Araujo CAA.J Immunol Methods. 2025 Nov 5;545:113995. doi: 10.1016/j.jim.2025.113995. Online ahead of print.PMID: 41202870

Economic burden of invasive pneumococcal disease in hospitalized children in Zhejiang Province, China: A multicenter hospital-based study conducted from 2014-2024.

Lu ZJ, Zhou JS, Zhu YY, Yang JH, Fang C, Zhou MM, Li XY, Liu SS, Liu Y, Hua CZ.Hum Vaccin Immunother. 2025 Dec;21(1):2580757. doi: 10.1080/21645515.2025.2580757. Epub 2025 Nov 5.PMID: 41190690

Mycobacterium tuberculosis curli pili (MTP) facilitates pathogenicity by modulating oxidative phosphorylation and carbon flux during early infection of A549 epithelial cells.

Naidoo TJ, Ashokcoomar S, Truebody B, Mackenzie JS, Cumming BM, Steyn AJC, Pillay M.Metabolomics. 2025 Nov 15;21(6):173. doi: 10.1007/s11306-025-02366-5.PMID: 41241674

State-level progress and setbacks in influenza vaccination among adults ≥65: A fifteen-season analysis from 2009/10 to 2023/24.

Russo L, Farina S, Macri RA, Pentecost WA, Maio A, Villani L, Maio V, Boccia S, Ricciardi W.Vaccine. 2025 Nov 13;69:127983. doi: 10.1016/j.vaccine.2025.127983. Online ahead of print.PMID: 41237563

Risk of new-onset heart failure and heart failure exacerbations following COVID-19, influenza or respiratory-syncytial-virus hospitalisation.

Wee LE, Loy EX, Ngiam N, Lim JT, Chiew CJ, Li RJ, Chia YW, Lim SL, Yap J, Wong R, Yeo KK, Hausenloy DJ, Chan MYY, Lye DCB, Tan KB.Eur J Prev Cardiol. 2025 Nov 6:zwaf714. doi: 10.1093/eurjpc/zwaf714. Online ahead of print.PMID: 41206580

Socioeconomic deprivation and human papillomavirus vaccination inequities: evidence from Southern Italy.

Fiorilla C, Contarino F, Sorrentino M, Bella F, Leonforte F, Nicosia V, Mistretta A, Montuori P, Palladino R.Vaccine. 2025 Nov 11;69:127986. doi: 10.1016/j.vaccine.2025.127986. Online ahead of print.PMID: 41223688

Epidemiology and Burden of Rotavirus-Associated Acute Gastroenteritis Among Children Aged Under 5 Years in Gujarat, India, from 2020 to 2023.

Vyas B, Patel N, Chudasama R, Buch P, Mehta C, Vaishnav J, Surana A, Singh P, Chaudhary VS, Machathi A, Kharat N, Lingam R, Varghese T.Indian J Pediatr. 2025 Nov 7. doi: 10.1007/s12098-025-05769-3. Online ahead of print.PMID: 41199123

Protective effect of heat-inactivated Mycobacterium bovis applied intramuscularly is associated with enhanced lung immune response in caprine tuberculosis.

Agulló-Ros I, Muñoz-Fernández L, Roy Á, Bezos J, Sevilla IA, Moreno I, Garrido J, Rodríguez-Bertos A, Domínguez M, Juste R, Domínguez L, Gortázar C, Risalde MA.Vet Res. 2025 Nov 4;56(1):209. doi: 10.1186/s13567-025-01634-5.PMID: 41189022

Main-chain disulfide-linked cationic polycarbonates for local mRNA delivery.

Gong X, Yang Y, Wang Z, Zhang Q, Liu Y.Int J Pharm. 2025 Nov 10;684:126179. doi: 10.1016/j.ijpharm.2025.126179. Epub 2025 Sep 14.PMID: 40957542

Pediatric Antibiotic Use Associated With Respiratory Syncytial Virus and Influenza in the United States, 2008-2018.

King LM, Bruxvoort KJ, Tartof SY, Lewnard JA.J Infect Dis. 2025 Nov 14;232(5):e811-e823. doi: 10.1093/infdis/jiaf309.PMID: 40479527

Genomic surveillance reveals global spread of macrolide-resistant Bordetella pertussis linked to **vaccine** changes.

Xu Z, Huang Z, Yuan L, Wu H, Chen X, Chen M, Zhuang Y, Feng J.J Clin Microbiol. 2025 Nov 14:e0106425. doi: 10.1128/jcm.01064-25. Online ahead of print.PMID: 41236009

Increasing Vaccination Awareness for Italian Primary Care Pediatricians: Game Design and Usability Study.

Marchetti F, Barretta M, Di Mauro A, Bona M, Amerighi C, D'Avino A.JMIR Pediatr Parent. 2025 Nov 3;8:e70049. doi: 10.2196/70049.PMID: 41183381

Modulating antigen processing through metal-organic frameworks to bias adaptive immunity.

Cho E, Davis MA, Nowak JA, Izzo M, Ferrante AM, Sha F, Magdalenski JS, Farha OK, Teplensky MH.Proc Natl Acad Sci U S A. 2025 Nov 11;122(45):e2409555122. doi: 10.1073/pnas.2409555122. Epub 2025 Nov 3.PMID: 41183191

Transmission of SARS-CoV-2 between ferrets in presence of pre-existing immunity.

Wang C, Shuai L, Zhong G, Wen Z, Liu R, Liu Q, Wang J, Ge J, Zhang X, Guan Y, He X, Bu Z.J Virol. 2025 Nov 4:e0156625. doi: 10.1128/jvi.01566-25. Online ahead of print.PMID: 41186412

TLR9 signaling requires ligand-induced phosphorylation of two specific tyrosine residues by EGFR and Syk.

Veleeparambil M, Wang C, Kessler PM, Sengupta P, Das S, Chakravarti R, Willard B, Sen GC, Chattopadhyay S.mBio. 2025 Nov 12;16(11):e0027625. doi: 10.1128/mbio.00276-25. Epub 2025 Sep 22.PMID: 40980882

Understanding the Second Year of the COVID-19 Pandemic From a Nursing Perspective: A Multi-Country Descriptive Study.

Squires A, Dutton HJ, Casales-Hernandez MG, López JIR, Saldarriaga-Dixon P, Jimenez-Sanchez J, Lee SA, Lee T, Smichenko J, Lickiewicz J, Malinowska-Lipien I, Damiran D, Khatun S, Skela-Savič B, Anyorikeya M, Cheng HY, Rojas DM, Skipalska H, Yanjmaa E, Castillo TP, Zisberg A, Aborigo R, Burka L, Zhuo L, Engel P, Mobarki A, Jones S.J Adv Nurs. 2025 Nov 11. doi: 10.1111/jan.70380. Online ahead of print.PMID: 41217107

From zero-COVID to global alignment: transnational pressures and China's pandemic communication transformation.

Liu D, Mustafa SEB, Sarmiti NZB.Global Health. 2025 Nov 4;21(1):64. doi: 10.1186/s12992-025-01155-y.PMID: 41188889

Determination of immune responses in mucosal lymphoid tissues following infectious laryngotracheitis virus (ILTV) eye drop and vent brush vaccination of chickens.

Tran TT, Andronicos NM, Ketheesan N, Nazir S, Walkden-Brown SW, Gerber PF.Avian Pathol. 2025 Nov 3:1-28. doi: 10.1080/03079457.2025.2584351. Online ahead of print.PMID: 41178669

Association between seasonal influenza vaccination and neonatal outcomes in Shanghai, China.

Lei L, Yang L, Feng DM, Yan Y, Cai QQ, Pang H.Hum Vaccin Immunother. 2025 Dec;21(1):2583804. doi: 10.1080/21645515.2025.2583804. Epub 2025 Nov 14.PMID: 41236786

Human antibody targeting of coronavirus spike S2 subunit is associated with protection mediated by Fc effector functions.

Muthuraman K, Jackman M, Liang Y, Garrett ME, Cui H, Nguyen LVH, Ivanochko D, Ye C, Pino PA, Hicks A, Maingot B, Yusko E, Benzeno S, Martínez-Sobrido L, Torrelles JB, Gilbert AE, Rubin BER, Keitany G, Jetha A, Julien J-P.J Virol. 2025 Nov 12:e0152325. doi: 10.1128/jvi.01523-25. Online ahead of print.PMID: 41222229

Population-Based Viral Antibody Profiles of Preschool Children in Burkina Faso.

Chen C, Hinterwirth A, Ouattara M, Bountogo M, Coulibaly B, Sié A, Yan D, Liu Y, Abraham T, Yu D, Zhong L, Lebas E, Oldenburg CE, Lietman TM, Doan T.Am J Trop Med Hyg. 2025 Nov 6:tpmd250408. doi: 10.4269/ajtmh.25-0408. Online ahead of print.PMID: 41197137

Prevalence of human papillomavirus infection and its associations with metabolic risk factors in China: a nationwide population-based study.

Chen Y, Bao H, Man S, Sun Y, Huang Y, Luo Y, Yan L, Yu C, Lv J, Wang L, Wang B, Li L, Liu H.BMC Infect Dis. 2025 Nov 17;25(1):1599. doi: 10.1186/s12879-025-11791-9.PMID: 41250008

Hepatitis B vaccination coverage and associated factors among adults in Somalia: a cross-sectional study.

-Tuuryare SAH, Timothy KK, Mohamud MH.BMC Public Health. 2025 Nov 12;25(1):3917. doi: 10.1186/s12889-025-25171-0.PMID: 41225376

Impact of self-administered pulse oximetry among non-hospitalized patients at risk of severe COVID-19 in Honduras: A pragmatic, cluster-randomized trial with temporal clustering.

Roberts KW, Alvarez B, de St Aubin M, Diaz O, Garnier S, Schnorr CD, Cruz S, Pavon L, Ochoa A, See R, Medice S, Santos HM, Ochoa J, Solis S, Dumas D, Baldwin M, Martinez A, Hakim A, Nilles E.PLOS Glob Public Health. 2025 Nov 7;5(11):e0004618. doi: 10.1371/journal.pgph.0004618. eCollection 2025.PMID: 41202024

Design of messenger RNA vaccines based on lipid-polymer hybrid nanoparticles.

Baghel S, Lokras A, Dias BA, Landry M, Cerdá SL, Wadhwa A, Herrera-Barrera M, Thakur A, Rades T, Franzyk H, Hopkins C, Sun C, Christensen D, Pedersen GK, Sahay G, Foged C.J Control Release. 2025 Nov 3;388(Pt 2):114385. doi: 10.1016/j.jconrel.2025.114385. Online ahead of print.PMID: 41192518

Mortality following recovery from COVID-19 hospitalization: a long-term cohort study.

Ahmad WA, Wolff-Sagy Y, Battat E, Arbel R, Lavie G.Int J Infect Dis. 2025 Nov 13:108223. doi: 10.1016/j.ijid.2025.108223. Online ahead of print.PMID: 41241136

Racial and Ethnic Disparities in Meningococcal Vaccination Coverage and Disease Burden Among U.S. Adolescents.

Wells CR, Shoukat A, Shin T, Galvani AP, Moghadas SM.J Adolesc Health. 2025 Nov 12:S1054-139X(25)00459-8. doi: 10.1016/j.jadohealth.2025.09.030. Online ahead of print.PMID: 41222522

Cost-effectiveness of infant and maternal RSV immunization strategies, in British Columbia, Canada.

Taleshi J, Paramo MV, Watts A, Chilvers M, Wong JMH, Piszczek J, Separovic L, Hu J, Skowronski D, Lavoie PM, Sbihi H.Vaccine. 2025 Nov 10;68:127936. doi: 10.1016/j.vaccine.2025.127936. Online ahead of print.PMID: 41218303

Preliminary Genetic Characterization of Enteroviruses in Pediatric HFMD Cases: First Data from Jeddah, Saudi Arabia.

Alsulami AO, Al-Sharif HA, Habiballah S, Helaby HB, Ashshi AM, Qutub M, Alyazidi RM, Alandijany TA, Azhar EI.J Epidemiol Glob Health. 2025 Nov 17;15(1):133. doi: 10.1007/s44197-025-00477-9.PMID: 41247396

Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis **vaccine** candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial.

Wagner L, Obersriebnig M, Hochreiter R, Kadlecek V, Larcher-Senn J, Hegele L, Maguire JD, Murphy T, Derhaschnig U, Bézay N, Jaramillo JC, Eder-Lingelbach S, Messier M.Lancet Infect Dis. 2025 Nov 7:S1473-3099(25)00541-9. doi: 10.1016/S1473-3099(25)00541-9. Online ahead of print.PMID: 41213278

Parametric survival analysis of long COVID among hospitalized patients in Zambia: A retrospective cohort study on the time to symptoms resolving.

Malambo W, Sampa-Kawana M, Chanda D, Fwoloshi S, Kaonga P.PLOS Glob Public Health. 2025 Nov 6;5(11):e0004679. doi: 10.1371/journal.pgph.0004679. eCollection 2025.PMID: 41196899

Mutational dissection of HCMV gB and gH cytoplasmic tails highlights conserved and divergent features of fusion regulation.

Lee C, DiBella HK, Heldwein EE.mBio. 2025 Nov 12;16(11):e0190525. doi: 10.1128/mbio.01905-25. Epub 2025 Sep 22.PMID: 40981481

Postoperative delirium and delayed neurocognitive recovery in older adults with prior coronavirus disease: a prospective cohort study.

Cui K, Yao X, Tong Y, Li Y, Liang X, Zhang S, Fang B.Int J Surg. 2025 Nov 13. doi: 10.1097/JS9.0000000000003975. Online ahead of print.PMID: 41249009

Epidemiology: Temporal and spatial patterns of measles in Amhara Region, Ethiopia, 2019-2024: implications for targeted intervention.

Endalamaw D, Nibret E, Munshea A, Mekonnen F, Tadesse S, Zeru T, Tefera M, Yismaw G, Amsalu T, Amsalu A, Endaylalu K, Tesfa E.BMC Infect Dis. 2025 Nov 6;25(1):1516. doi: 10.1186/s12879-025-11950-y.PMID: 41199196

Maternal RSV vaccination for infant protection: A systematic review and meta-analysis of phase 3 trials with an integrated economic evaluation.

Torres-Torres J, Rojas-Zepeda L, Villafan-Bernal JR, Martinez-Portilla R, Espino-Y-Sosa S, Cerda-Flores P, Moreno-Verduzco ER, Monroy-Muñoz IE, Gonzalez-Guerrero AY, Solis-Paredes JM, Duran JP.Int J Gynaecol Obstet. 2025 Nov 4. doi: 10.1002/ijgo.70641. Online ahead of print.PMID: 41189343

COVID-19 antibody testing study: a nested substudy within Alberta's Tomorrow Project (ATP) in Alberta, Canada.

Nejatinamini S, Charlton C, Harman S, Kanji JN, Kellner JD, Lines K, Murdoch K, Powell W, Roberts J, Rosner W, Shen-Tu G, Tipples G, Xu JY, Vena JE.BMJ Open. 2025 Nov 13;15(11):e101336. doi: 10.1136/bmjopen-2025-101336.PMID: 41248356

Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.

Wong GL, Yuen MF, Lin B, Douglas MW, Hu P, Xie Q, Lv F, Tak WY, Leerapun A, Kim DJ, Tangkijvanich P, Lim YS, Dai CY, O'Beirne J, Weltman M, Khemnark S, Piratvisuth T, Manasirisuk W, Chen X, Liu CJ, Heo J, Lee J, Niu J, Kumar R, Kumar R, Zhu C, Cao K, Tian A, Chen X, Zhu Q, Margolis D, Jia J, Hong Z.Nat Med. 2025 Nov 7. doi: 10.1038/s41591-025-04049-z. Online ahead of print.PMID: 41203919

Long-term cardiovascular events in individuals hospitalised with COVID-19: a retrospective cohort.

Soares P, Ruivinho C, Silva J, Lobão MJ, Santos L, Paixão J, Ramalho AR, Henriques A, Simões I, Guimarães LE, Moça R, Costa A, Atanásio G, Nóbrega S, da Luz Brazão M, Goes AR, Leite A; LOCUS group.BMC Infect Dis. 2025 Nov 7;25(1):1525. doi: 10.1186/s12879-025-11762-0.PMID: 41204399

Unequal access in a universal health system: COVID-19 vaccination and health services utilization among international migrants in Brazil.

De Araújo JST, Ferezin LP, Moura HSD, Rosa RJ, Tártaro AF, Pinto IC, de Campos MCT, Arcêncio RA.BMC Public Health. 2025 Nov 11;25(1):3905. doi: 10.1186/s12889-025-25198-3.PMID: 41219690

A five-year retrospective evaluation of perinatal outcomes in Syrian refugee and Turkish citizen pregnant women and their newborns at a tertiary hospital.

Taşkıran D, Ay O.BMC Pregnancy Childbirth. 2025 Nov 7;25(1):1175. doi: 10.1186/s12884-025-08355-9.PMID: 41204160

Maternal and Neonatal Outcomes After Respiratory Syncytial Virus Prefusion F Protein Vaccination During Pregnancy: Analysis From the 2024-2025 Immunization Campaign in France.

Gabet A, Bertrand M, Jabagi MJ, Kolla E, Olié V, Zureik M.Obstet Gynecol. 2025 Nov 13. doi: 10.1097/AOG.0000000000006121. Online ahead of print.PMID: 41232114

A Comprehensive Review on Human Metapneumovirus.

Agarwal U, Paliwal S, Tonk RK.Curr Gene Ther. 2025 Nov 5. doi: 10.2174/0115665232389869251014055641. Online ahead of print.PMID: 41208068

Association between COVID-19 vaccination and atopic diseases in US adults: A retrospective cohort study.

Lu M, Bu Z, Xiang N, Yu J.PLoS One. 2025 Nov 13;20(11):e0336698. doi: 10.1371/journal.pone.0336698. eCollection 2025.PMID: 41231867

Differential immune profiles in elderly patients with non-severe versus severe SARS-CoV-2 omicron variant infection: dysregulation of antibody responses and B-cell subsets.

Li X, Li Y, Liu S, Zhou J, Yang X, Yang J, Xu W, Chen W.Immun Ageing. 2025 Nov 4;22(1):50. doi: 10.1186/s12979-025-00543-7.PMID: 41188857

Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): a 24-month prospective and retrospective cohort study.

Van Dijck C, Berens-Riha N, Zaeck LM, Kremer C, Verschueren J, Coppens J, Vanroye F, Willems E, Bosman E, De Cock N, Smekens B, Vandenhove L, Goovaerts O, Van Hul A, Wouters J, Jacobs BKM, Bracke S, Hens M, Brosius I, De Vos E, Bangwen E, Houben S, Tsoumanis A, Dantas PHLF, Rutgers J, Lipman A, Wijnans K, Soentjens P, Bottieau E, Kenyon C, van Griensven J, Reyniers T, Horst N, Ariën KK, Van Esbroeck M, Torneri A, Vercauteren K, Adriaensen W, de Vries RD, Mariën J, Liesenborghs L.Lancet Infect Dis. 2025 Nov 7:S1473-3099(25)00545-6. doi: 10.1016/S1473-3099(25)00545-6. Online ahead of print.PMID: 41213280

Patentes registradas en Patentscope

Estrategia de búqueda: (Vaccine) AND DP:([03.11.2025 TO 17.11.2025]) *as the publication date 62 records.*

1.2640725VACCINE

GB - 05.11.2025

Clasificación Internacional C12N 7/08Nº de solicitud 202406207Solicitante GENERA DIONICKO DRUSTVOInventor/a LANA LJUMA SKUPNJAK

An isolated infectious bronchitis (IB) virus (IBV) QX1285 strain under accession number DPS RE RSCIC 41 in the IZSLER biobank. A vaccine comprising the isolated infectious bronchitis virus and a carrier. The virus may be inactivated. The virus may alternatively be live and attenuated. The vaccine may be formulated for an avian. The avian may be a chicken. The vaccine may be administrated via drinking water. Also claimed is an isolated infectious bronchitis virus having an S1 protein encoded by SEQ ID NO: 1 or a sequence having at least 96% sequence identity thereto, for use as a vaccine against infectious bronchitis. Also claimed is a method of vaccinating an avian against infectious bronchitis, comprising administering the vaccine. Also claimed is a process for preparing a live infectious bronchitis vaccine comprising passaging the virus to reduce pathogenicity, harvesting the attenuated virus, and processing the virus to produce a vaccine. The virus may be passaged at least 50 times. The virus may be passaged by culturing in allantoic fluid of chicken embryos.

2.WO/2025/229688METHOD FOR PRODUCING ANTI-PHOSPHORYLCHOLINE ANTIBODIES AND VACCINE COMPOSITION THEREOF

WO - 06.11.2025

Clasificación Internacional A61K 31/685Nº de solicitud PCT/IN2025/050704Solicitante KUMAR SAMAL, ShaileshInventor/a KUMAR SAMAL, Shailesh

The present invention is related to a novel composition and vaccine formulation designed to elicit a specific immune response against phosphorylcholine (PC) epitopes, targeting chronic inflammatory conditions. The composition comprises an immunogenic conjugate of PC and CRM197, demonstrating enhanced immunogenicity and stability. The vaccine formulation, formulated for parenteral routes, and other routes such as cutaneous, nasal and mucosal, incorporates the immunogenic composition along with a pharmaceutically acceptable carrier or adjuvant, further enhancing efficacy. Additionally, the disclosure encompasses methods

for vaccine preparation and administration, including vaccine kits with reconstitution instructions. By immunizing subjects against chronic inflammatory conditions and monitoring anti-PC antibody levels, our invention offers a promising approach for treating and preventing diseases such as cardiovascular diseases, rheumatoid arthritis, autoimmune disorders, allergies, dementia, cancerous diseases and infections caused by virus, bacteria, parasites and other pathogens.

3.4644550IMPFSTOFF GEGEN RESPIRATORISCHE SYNZYTIALVIRUSINFEKTION

EP - 05.11.2025

Clasificación Internacional C12N 15/45Nº de solicitud 24773947Solicitante WESTVAC BIOPHARMA CO LTDInventor/a WEI XIAWEI

Provided is a vaccine against respiration syncytial virus infection. In view of the lack of effective prevention and treatment drugs for respiratory syncytial virus infection for the elderly, infants, and people with low immunity, a vaccine against respiratory syncytial virus infection is provided. The vaccine is based on adenovirus as a vector, and the antigen gene expressed is optimized based on the sequence of respiratory syncytial virus F protein. The adenovirus vector vaccine can help a host resists respiratory syncytial virus infection and has a good preventive and therapeutic effect.

4.WO/2025/230087ATTENUATED SARS-COV-2 VACCINE STRAIN INCLUDING N GENE TRANSCRIPTIONAL REPRESSION AND NSP1 PROTEIN MUTATION, AND USE THEREOF

WO - 06.11.2025

Clasificación Internacional C12N 7/00Nº de solicitud PCT/KR2024/096071Solicitante INDUSTRIAL COOPERATION FOUNDATION JEONBUK NATIONAL UNIVERSITYInventor/a MYOUNG, Jinjong

The present invention relates to an attenuated SARS-CoV-2 vaccine strain including nucleocapsid *N* gene transcriptional repression and a non-structural protein 1 (nsp1) protein mutation, and a use thereof. The attenuated SARS-CoV-2 vaccine strain according to the present invention has excellent safety and efficacy as a vaccine, and thus can be effectively used as an attenuated live vaccine for the prevention of coronavirus disease 2019.

5.20250345282EXTRACELLULAR VESICLE COMPRISING ANTIGENIC PROTEIN OR GENE ENCODING SAME PROTEIN, AND USES THEREOF

US - 13.11.2025

Clasificación Internacional A61K 9/50Nº de solicitud 18993289Solicitante EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATIONInventor/a Ki Hwan KWON

The present disclosure relates to an extracellular vesicle including an antigen protein or a gene encoding the antigen protein and use thereof, and more particularly, to: an extracellular vesicle including an antigen protein derived from a virus, a microorganism, or cancer cells, or a gene encoding the antigen protein; or a vaccine composition for the prevention or treatment of a viral infection, a microbial infection, or cancer, the vaccine composition including the extracellular vesicle. The extracellular vesicle or the vaccine composition including the extracellular vesicle, according to the present disclosure, is a platform that has stability and an excellent effect of inducing an antigen-specific immune response and can be applied

to various diseases, and thus is expected to be effectively used in the field of development of a vaccine for the prevention or treatment of various diseases, including microbial infections or cancer.

6.20250339507MRNA VACCINE FOR BANDAVIRUS DABIEENSE AND PREPARATION METHOD THEREOF

US - 06.11.2025

Clasificación Internacional A61K 39/12Nº de solicitud 19271871Solicitante NANJING MEDICAL UNIVERSITYInventor/a Xinjian LIU

A messenger ribonucleic acid (mRNA) vaccine for Bandavirus dabieense (DBV) and a preparation method thereof are provided. The provided mRNA molecule is an mRNA obtained by cloning an optimized DBV glycoprotein gonadotropins (Gn) sequence into a pGEM-3Zf (+) mRNA vaccine vector, linearizing a plasmid via enzyme digestion, and capping and adding a poly(A) tail through an in vitro transcription enzyme method. The mRNA is encapsulated using a lipid nanoparticle delivery system to obtain the mRNA vaccine.

7.WO/2025/227322BROAD-SPECTRUM ANTI-COVID-19 VACCINE IMMUNOGEN COMPOSITION, AND PREPARATION AND USE THEREOF

WO - 06.11.2025

Clasificación Internacional C07K 19/00Nº de solicitud PCT/CN2024/090634Solicitante SHANGHAI PUBLIC HEALTH CLINICAL CENTERInventor/a XU, Jianqing

Provided are a broad-spectrum anti-COVID-19 vaccine immunogen composition, and the preparation and a use thereof. Specifically, provided is an immunogen composition, comprising an RBD recombinant chimeric antigen, wherein the chimeric antigen comprises S protein RBD domains from two or more COVID-19 subtypes, or functional fragments thereof. The immunogen composition can further comprise a multimerization domain and a T-cell immunogen domain. Further provided are a use of the immunogen composition, a corresponding encoding molecule therefor, a vector, and/or a host cell in preparing an anti-COVID-19 vaccine. The vaccine can induce a broad-spectrum protective effect against a prototype strain and various currently prevalent variants, and can also elicit a potent cross-protective T-cell response, thereby achieving effective and broad-spectrum prevention against COVID-19 and achieving a protective effect against other coronaviruses.

8.20250339511NUCLEIC ACID VACCINE AGAINST MONKEYPOX VIRUS AND USE THEREOF

US - 06.11.2025

Clasificación Internacional A61K 39/275Nº de solicitud 19273107Solicitante INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCESInventor/a Fu GAO

Provided are a polynucleotide encoding a chimeric or mixed antigen of poxvirus multiple immunogens, a related nucleic acid product thereof, and the use thereof in the preparation of a vaccine for preventing and/or treating poxvirus (in particular monkeypox virus) infection. The chimeric or mixed antigen of the poxvirus multiple immunogens encoded by the polynucleotide comprises two immunogens: a monkeypox virus A35R protein or an antigenic fragment thereof (or an appropriate variant thereof) and a monkeypox virus MIR protein or an antigenic fragment thereof (or an appropriate variant thereof). The immunogen components of the chimeric or mixed nucleic acid vaccine based on the polynucleotide are clear, and the chimeric or mixed nucleic acid vaccine can efficiently stimulate specific immune responses (for example, generating a protective

antibody) against poxvirus (in particular monkeypox virus), can be used for preventing and/or treating poxvirus (in particular monkeypox virus), and has high clinical application prospects.

9.WO/2025/235990CANCER ONCOGENE MRNA VACCINE

WO - 13.11.2025

Clasificación Internacional A61K 39/00Nº de solicitud PCT/US2025/028892Solicitante METROHEALTH VENTURES LLCInventor/a LIU, Shujun

An mRNA vaccine composition is described. The vaccine composition includes an exosome comprising an expression cassette comprising mRNA encoding chimeric/fusion/hybrid oncogene (CFHON). Methods of treating or preventing cancer in a subject by administering a therapeutically effective amount of the mRNA vaccine composition are also described.

10.WO/2025/231007INFLUENZA VACCINE COMPOSITIONS AND METHODS OF MAKING AND USING SAME

WO - 06.11.2025

Clasificación Internacional A61K 39/12Nº de solicitud PCT/US2025/026852Solicitante CHILDREN'S HOSPITAL MEDICAL CENTERInventor/a TAN, Ming

Disclosed are vaccine compositions, in particular, polyvalent icosahedral compositions for presentation of an HA1 influenza antigen. The disclosed compositions may contain an S particle comprising a norovirus (NoV) S domain and an HA1 influenza antigen, which may be linked via a linker protein domain operatively connected to the norovirus S domain and an influenza antigen. Fusion proteins for producing the vaccine compositions, and methods of using the disclosed vaccine composition are also provided.

11.4643875IMPFSTOFFZUSAMMENSETZUNG MIT GOLD-NANOPARTIKELTRÄGER MIT DARAN GEBUNDENER DOPPELSTRÄNGIGER DNA

EP - 05.11.2025

Clasificación Internacional A61K 39/385Nº de solicitud 23912868Solicitante NES BIOTECHNOLOGY CO LTDInventor/a LEE KANGSEOK

The present invention relates to a vaccine composition including double-stranded DNA delivered into cells via gold nanoparticles, and more particularly, to a vaccine composition characterized in that the double-stranded DNA is derived from a viral, bacterial or cancer gene and expresses an antigen to induce an immune response.

12.20250345409COMPOSITIONS AND METHODS FOR THERAPEUTIC OR VACCINE DELIVERY

US - 13.11.2025

Clasificación Internacional A61K 39/12Nº de solicitud 19214942Solicitante GenVivo, Inc.Inventor/a Jacqueline FISCHER-LOUGHEED

Described herein are compositions for delivering a therapeutic or vaccine. Also described herein are methods for using the compositions described herein for delivering a therapeutic or a vaccine.

13.4642479MODIFIZIERTER BCG-IMPFSTOFF

EP - 05.11.2025

Clasificación Internacional A61K 39/04Nº de solicitud 24703869Solicitante UNIV JOHANNESBURG WITWATERSRANDInventor/a KANA BAVESH DAVANDRA

The present invention relates to a recombinant Mycobacterium bovis BCG strain comprising a plasmid having a short guide RNA (sgRNA) target sequence for knockdown of the Mb3739 gene. Also provided are vaccine compositions for eliciting an immune response against Mycobacterium tuberculosis comprising the recombinant Mycobacterium bovis BCG strain engineered to activate the NOD-1 pathway. The recombinant Mycobacterium bovis BCG strain or the vaccine compositions may be useful in methods of eliciting an immune response against Mycobacterium tuberculosis. The invention also relates to methods of obtaining the recombinant Mycobacterium bovis BCG strain.

14.WO/2025/231359A NOVEL METHOD TO TARGET PFGBP130 AS A VACCINE FOR P. FALCIPARUM MALARIA

WO - 06.11.2025

Clasificación Internacional A61K 39/015Nº de solicitud PCT/US2025/027490Solicitante BROWN UNIVERSITYInventor/a KURTIS, Jonathan

The present invention relates to a malaria vaccine composition designed to elicit an immune response against *Plasmodium falciparum* by providing proteins or amino acid sequences, including PfGBP130 or PfGBP130-A surface antigen sequences. Upon administration to a human subject, the vaccine composition induces the production of specific anti-malaria antibodies. These antibodies are configured to inhibit the invasion of red blood cells by *Plasmodium falciparum* parasites and/or the antibodies binding to the antigens can cause the death of the parasites within red blood cells, thereby offering a preventive and/or therapeutic effect against malaria. The composition aims to enhance the immune defense mechanism in humans, reducing the incidence and severity of malaria infections by targeting critical stages of the parasite's lifecycle.

15.WO/2025/232863ENGINEERED NUCLEIC ACID MOLECULE, MRNA VACCINE FOR HPV-RELATED DISEASES, AND USE THEREOF

WO - 13.11.2025

Clasificación Internacional C12N 15/62Nº de solicitud PCT/CN2025/093648Solicitante CSPC MEGALITH BIOPHARMACEUTICAL CO., LTD.Inventor/a DONG, Yunxia

The present invention relates to an engineered nucleic acid molecule, an mRNA vaccine for HPV-related diseases, and the use thereof. The obtained mRNA vaccine for the treatment of HPV can fully activate the in-vivo specific T-cell reaction, and has a potent tumor inhibition activity in an HPV-related mouse CDX tumor model.

16.WO/2025/231483IMMUNOGENIC PROTEINS AND NUCLEIC ACIDS ENCODING THE SAME

WO - 06.11.2025

Clasificación Internacional C07K 14/16Nº de solicitud PCT/US2025/027789Solicitante INTERNATIONAL AIDS VACCINE INITIATIVE, INC.Inventor/a COTTRELL, Christopher

The invention relates to proteins and nucleic acids for immunization regimens, in particular, immunogens that can prime rare bnAb precursor B cells and guide their maturation towards bnAbs capable of neutralizing diverse HIV strains, modifications thereof, and/or development of nanoparticles, and/or development of membrane-anchored immunogens, and methods of making and using the same. The invention also encompasses cell surface trimers that bind to the broadly neutralizing antibodies and/or nucleic acids encoding the same.

17.WO/2025/234450MODIFIED CANCER CELL AND CANCER VACCINE COMPOSITION CONTAINING SAME

WO - 13.11.2025

Clasificación Internacional C12N 5/10Nº de solicitud PCT/JP2025/016891Solicitante TEIKYO HEISEI UNIVERSITYInventor/a TATEBE Takuya

The purpose of the present invention is to provide a cancer vaccine composition effective for treating or preventing cancer. The present invention provides a genetically modified cancer cell comprising: a nucleic acid encoding a cytotoxic T cell-inducing antigen and a nucleic acid encoding IL-2. This genetically modified cancer cell can be used as an active ingredient of a cancer vaccine composition. The cytotoxic T cell-inducing antigen in this genetically modified cancer cell is preferably a pathogen-derived antigen or a virus-derived antigen.

18.20250339504CANCER VACCINE WITH USE OF COMMON CANCER ANTIGEN COCKTAIL, TCR/CAR-T CELL THERAPEUTIC, COMPANION DIAGNOSTIC METHOD, AND METHOD FOR DIAGNOSING RISK OF CANCER ONSET BY DETECTING CIRCULATING TUMOR CELLS

US - 06.11.2025

Clasificación Internacional A61K 39/00Nº de solicitud 18865980Solicitante National Cancer CenterInventor/a Tetsuya NAKATSURA

An object of the present invention is to provide a cancer vaccine with use of a common cancer antigen cocktail, a TCR/CAR-T cell therapeutic, a companion diagnostic method, and a method for diagnosing risk of cancer onset by detecting circulating tumor cells. The present invention provides a cancer vaccine comprising: (1) common cancer antigens comprising three or more selected from GPC3, ROBO1, EPHB4, CLDN1, and LAT1; (2) partial peptides of the three or more common cancer antigens with CTL inducibility; (3) a dendritic cell stimulated with the partial peptides; or (4) mRNAs encoding the common cancer antigens or the partial peptides.

19.WO/2025/231068COMPOSITIONS AND METHODS FOR ENHANCING SYSTEMIC AND MUCOSAL IMMUNE RESPONSES

WO - 06.11.2025

Clasificación Internacional A61K 39/39Nº de solicitud PCT/US2025/026980Solicitante THE REGENTS OF THE UNIVERSITY OF MICHIGANInventor/a WONG, Pamela

The disclosure provides compositions and methods for improving and enhancing systemic and mucosal vaccine immune responses. In particular, the disclosure provides mucosal adjuvant for vaccine delivery and methods of using the mucosal adjuvant in a vaccination regimen to induce sterilizing immunity in a vaccinated subject.

20.WO/2025/231293IN SITU TUMOR VACCINE TO PROMOTE ANTI-TUMOR IMMUNITY

WO - 06.11.2025

Clasificación Internacional A61N 5/10Nº de solicitud PCT/US2025/027376Solicitante THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventor/a ALLURI, Prasanna

Provided herein are methods and compositions for treating cancer by administering an in-situ cancer vaccine, such as comprising tumor directed radiation therapy and a Bromodomain and Extra-Terminal motif (BET) inhibitor.

21.20250339369NEOEPITOPE VACCINE DELIVERY VEHICLE AND METHODS OF MAKING THE SAME

US - 06.11.2025

Clasificación Internacional A61K 9/06Nº de solicitud 19271310Solicitante ImmunityBio, Inc.Inventor/a Philip T. Liu

Disclosed herein are mannan nanogels as a novel vaccine delivery platform as well as a novel method of making a self-assembling mannan nanogel for in vivo delivery of therapeutic agents.

22.WO/2025/235418VIRUS-LIKE PARTICLE, PREPARATION METHOD THEREOF, AND USE THEREOF IN PREPARING VACCINE

WO - 13.11.2025

Clasificación Internacional A61K 39/145Nº de solicitud PCT/US2025/027834Solicitante NATIONAL HEALTH RESEARCH INSTITUTESInventor/a LEE, Min-shi

A virus-like particle (VLP) includes: an extracellular domain of a hemagglutinin having an amino acid sequence, or the extracellular domain of a spike protein; a matrix protein 1 having an amino acid sequence; and a transmembrane-cytoplasmic domain of the hemagglutinin. A method for preparing the VLP includes: constructing a recombinant plasmid; generating a recombinant bacmid by transformating the recombinant plasmid into a competent cell; generating a recombinant baculovirus by transfecting the recombinant bacmid into a first cell; and harvesting the VLP by transfecting the recombinant baculovirus into a second cell. Also provided is the use of the VLP in preparing a vaccine.

23.20250345286COMPOSITE LIPID NANOPARTICLE AND PREPARATION METHOD THEREOF, RNA VACCINE, DRUG AND USE

US - 13.11.2025

Clasificación Internacional A61K 9/51Nº de solicitud 18950190Solicitante Bisheng (Beijing) Biotechnology Co., Ltd.Inventor/a Yuhong Cao

The present disclosure belongs to the technical field of lipid nanoparticle biological application, and discloses a composite lipid nanoparticle and a preparation method thereof, an ribose nucleic acid (RNA) vaccine, a drug and use. The composite lipid nanoparticle provided by the present disclosure includes a lipid composition and a recombinant antibody protein containing a streptavidin tag; and the lipid composition comprises an ionizable lipid, an auxiliary lipid, cholesterol, a polyethylene glycol lipid and a biotinylated polyethylene glycol lipid in a mass ratio of (40-90):(0.1-20):(20-50):(0.5-10):(0.5-10). Through strong interaction between the recombinant antibody protein with the streptavidin tag and the biotinylated polyethylene glycol lipid in the composite lipid nanoparticle, the composite lipid nanoparticle achieves safe, convenient, rapid, efficient, and stable linkage between a lipid nanoparticle (LNP) and a recombinant antibody protein, and the recombinant antibody protein can be adaptively replaced according to target cells and/or tissues, with high flexibility and applicability.

24.4642480ABGESCHWÄCHTER IMPFSTOFF GEGEN DAS PSEUDORABIESVIRUS BEI SCHWEINEN, DER EINE DELETION DES GENS UL23 UMFASST

EP - 05.11.2025

Clasificación Internacional A61K 39/12Nº de solicitud 23847729Solicitante ZOETIS SERVICES LLCInventor/a KONG YIBO

This disclosure provides an attenuated suid herpesvirus 1 (a Pseudorabies virus) wherein the TK, gl and gE genes thereof are modified relative to a parent field strain, such that the resultant virus is safe and effective for use as a live vaccine that protects swine animals from challenge with a virulent Pseudorabies virus.

25.20250345413SARS-COV-2 SUBUNIT VACCINE

US - 13.11.2025

Clasificación Internacional A61K 39/215Nº de solicitud 18282689Solicitante VIRAVAXX AGInventor/a Pia GATTINGER

An immunogenic subunit vaccine antigen which comprises at least two receptor-binding domains (RBDs) of the spike (S) protein of SARS-CoV-2 which are fused to a heterologous immunogenic carrier protein, wherein each of said at least two RBDs has a folded structure in an accessible conformation to bind the human angiotensin-converting enzyme 2 (ACE2) receptor protein.

26.20250339517LIPID NANOCARRIER VACCINE

US - 06.11.2025

Clasificación Internacional A61K 39/385Nº de solicitud 18869179Solicitante ROYAL MELBOURNE INSTITUTE OF TECHNOLOGYInventor/a Sampa SARKAR

The present disclosure relates to a lipid nanoparticle which is a carrier for an antigen. The present disclosure also relates to an immunogenic composition comprising the antigen. The immunogenic composition may be a vaccine composition. The present disclosure further relates to methods and uses of the carrier and immunogenic composition.

27.20250345407NUCLEIC ACID BASED VACCINE ENCODING AN ESCHERICHIA COLI FIMH ANTIGENIC POLYPEPTIDE

US - 13.11.2025

Clasificación Internacional A61K 39/108Nº de solicitud 18868888Solicitante CureVac SEInventor/a Roberto ADAMO

The disclosure is directed to a coding RNA encoding an antigenic polypeptide which is selected or derived from *Escherichia coli* FimH. The present disclosure is also directed to compositions and vaccines comprising said coding RNA. Further, the disclosure concerns a kit, particularly a kit of parts comprising the coding RNA, or the composition, or the vaccine. The disclosure is also directed to methods of treating or preventing a disorder caused by *E. coli.*

28.WO/2025/227519TUMOR VACCINE AND USE THEREOF

WO - 06.11.2025

Clasificación Internacional C07K 19/00Nº de solicitud PCT/CN2024/106849Solicitante BEIJING IMMUPEUTICS MEDICINE TECHNOLOGY LIMITEDInventor/a SHEN, Ning

A tumor vaccine for treating esophageal squamous cell carcinoma and other cancers, and a composition thereof. Specifically, provided is a polypeptide, which contains one or more antigen fragments selected from: ACTL8, BRDT, FOXI3, GNGT1, SMC1B, PLAC1, MAGEA1, MAGEA3, MAGEA4, MAGEA6, MAGEA10 and MAGEA11, wherein the one or more antigen fragments are linked via a linker peptide, and the antigen fragments contain one or more antigenic epitope peptides. Furthermore, provided are a linear epitope peptide, a nucleic acid encoding the polypeptide and the linear epitope peptide, and the use of the polypeptide or the linear epitope peptide in the preparation of a drug for preventing or treating cancers such as esophageal squamous cell carcinoma.

29.WO/2025/230957PORCINE ENDOGENOUS RETROVIRUS (PERV)-FREE PORCINE CIRCOVIRUS TYPE 2D-BASED VACCINES AND METHODS OF USE

WO - 06.11.2025

Clasificación Internacional A61K 39/12Nº de solicitud PCT/US2025/026773Solicitante ZOETIS SERVICES LLCInventor/a MARX, Jacqueline Gayle

The invention provides a vaccine composition for use in protecting a pig against infection with porcine circovirus type 2 (PCV2), comprising a PCV1-2d chimeric whole virus which comprises and/or expresses the ORF1 replicase of PCV1 and the ORF2 of PCV2d, wherein the vaccine composition is porcine endogenous retrovirus (PERV) negative.

30.WO/2025/231510A TRICHOMONIASIS VACCINE

WO - 13.11.2025

Clasificación Internacional C12N 1/10Nº de solicitud PCT/AU2025/050468Solicitante THE UNIVERSITY OF QUEENSLANDInventor/a TABOR, Ala

The present disclosure relates to a novel isolated protozoal strain of the species *Tritrichomonas foetus*. More particularly, this disclosure relates to the development of a vaccine for treating, preventing, or ameliorating infections caused by this protozoal species.

31.20250345414ADENOVIRAL VECTOR-BASED VACCINE FOR EMERGING VIRUSES

US - 13.11.2025

Clasificación Internacional A61K 39/215Nº de solicitud 18681226Solicitante THERAVAX, INC.Inventor/a Norberto Julián Maggini

Provided herein is an adenoviral vector-based vaccine for inducing immune responses against viruses, such as coronaviruses. The adenoviral vector comprises a hybrid promoter, a nucleic acid sequence encoding a viral antigen operatively linked to the hybrid promoter; a posttranscriptional regulatory element; and a modified fiber protein. Also provided is a method of inducing an immune response against a coronavirus using a composition containing the adenoviral vector.

32.20250345410VACCINATION IN NEWBORNS AND INFANTS

US - 13.11.2025

Clasificación Internacional A61K 39/155Nº de solicitud 19029252Solicitante CureVac SEInventor/a Karl-Josef KALLEN

The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

33.20250345372USE OF DOPAMINE PRODUCING PRODUCTS TO INCREASE VACCINE EFFICACY

US - 13.11.2025

Clasificación Internacional A61K 35/744Nº de solicitud 19233806Solicitante Iowa State University Research Foundation, Inc.Inventor/a Mark Lyte

The present disclosure is directed to dopamine producing probiotics to increase immune responses to vaccination and to provide increased immune protection. The present disclosure is further directed to dopamine producing synbiotic compositions, formulations, plants, and synthetic compounds and their use for targeted clinical and veterinary applications, for example, in promoting health and well-being and enhancing vaccine efficacy. The present disclosure also provides an approach for optimization of synbiotic delivery of a probiotic or other dopamine producing product with a dopamine precursor to beneficially aid in the use of such products for a variety of conditions and diseases, and particularly in the field of vaccines, whether prophylactic or therapeutic.

34.20250345411VACCINATION IN NEWBORNS AND INFANTS

US - 13.11.2025

Clasificación Internacional A61K 39/155Nº de solicitud 19280019Solicitante CureVac SEInventor/a Karl-Josef KALLEN

The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in

said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

35.202503454l6PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF HERPES SIMPLEX VIRUS ANTIGENS AND RELATED METHODS

US - 13.11.2025

Clasificación Internacional A61K 39/245Nº de solicitud 18833073Solicitante BioNTech SEInventor/a Ugur Sahin

The present disclosure provides pharmaceutical compositions for delivery of HSV antigens (e.g., an HSV vaccine) and related technologies (e.g., components thereof and/or methods relating thereto).

36.4647440IMMUNOGENES PEPTID TROP2

EP - 12.11.2025

Clasificación Internacional C07K 14/47Nº de solicitud 23914966Solicitante ASTON SCIENCE INCInventor/a JUNG HUN

The present invention relates to TROP2 immunogenic peptides and a use thereof. The TROP2 immunogenic peptide according to the present invention selectively binds to MHC class II to enhance only the immunogenicity of specific immune cells capable of killing cancer cells and thus can be advantageously used as an excellent cancer vaccine for the prevention and/or treatment of cancer by minimizing the immune escape mechanism of cancer cells.

37.WO/2025/229369SYNTHETIC NUCLEIC ACID MOLECULES AND USE THEREOF

WO - 06.11.2025

Clasificación Internacional C12N 15/67Nº de solicitud PCT/IB2024/000666Solicitante SAMSUNG BIOLOGICS CO., LTD.Inventor/a KWON, Oh Sung

The present invention relates to synthetic nucleic acid molecules and use thereof and to: a polynucleotide comprising an isolated 3'- UTR and/or 5'- UTR; synthetic nucleic acid molecules comprising the polynucleotide; and a pharmaceutical composition, a vaccine composition, or a gene therapy composition, comprising same.

38.WO/2025/230959METHODS OF MANUFACTURING PORCINE ENDOGENOUS RETROVIRUS (PERV) FREE ANIMAL HEALTH VACCINES

WO - 06.11.2025

Clasificación Internacional A61K 39/12Nº de solicitud PCT/US2025/026775Solicitante ZOETIS SERVICES LLCInventor/a MARX, Jacqueline Gayle

The invention provides a method of preparing a vaccine composition. The method includes infecting gene-edited porcine endogenous retrovirus (PERV) negative swine cells with a microorganism which expresses at least one protein antigen capable of inducing protective immunity in an animal against an infectious agent; culturing the infected cells in culture medium to propagate the microorganism; and harvesting the propagated

microorganism from the culture medium to obtain a fraction comprising a PERV free antigen for use in immunizing an animal against the infectious agent.

39.WO/2025/229609VACCINE

WO - 06.11.2025

Clasificación Internacional A61K 39/12Nº de solicitud PCT/IB2025/054609Solicitante GENERA DIONIČKO DRUŠTVOInventor/a SKUPNJAK, Lana Ljuma

A novel infectious bronchitis virus (IBV) serotype, to isolated attenuated IBV strains derived therefrom, and to live or inactivated vaccines against infectious bronchitis made using the isolated attenuated IBV strain.

40.20250342906EPITOPE AND IMMUNOGEN DESIGN FOR DEVELOPMENT OF VACCINES, DIAGNOSTICS, AND IMMUNOTHERAPEUTICS

US - 06.11.2025

Clasificación Internacional G16B 15/30Nº de solicitud 19183263Solicitante Iowa State University Research Foundation, Inc.Inventor/a Ratul Chowdhury

Workflows for the efficient identification of viral epitopes and/or host paratopes are provided. The workflows leverage artificial intelligence to quickly and reliably identify candidate epitopes for immunogen development thereby reducing the lead time of vaccine development. Immunogenic compositions for use in the treatment and/or prevention of porcine reproductive and respiratory syndrome virus (PRRSV) and Infectious Bronchitis Virus (IBV) are also provided, as are antibodies or antigen binding fragments.

41.20250339503PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ACUTE MYELOID LEUKEMIA (AML) AND OTHER HEMATOLOGICAL NEOPLASMS

US - 06.11.2025

Clasificación Internacional A61K 39/00Nº de solicitud 19202865Solicitante Eberhard Karls Universität Tübingen Medizinische FakultätInventor/a Juliane Walz

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular of hematological neoplasms, such as acute myeloid leukemia (AML). The present invention furthermore relates to tumor-associated T-cell peptide epitopes that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

42.4646564KÄLTESPEICHERVORRICHTUNG

EP - 12.11.2025

Clasificación Internacional F25D 3/06Nº de solicitud 24720520Solicitante B MEDICAL SYSTEMS SARLInventor/a BRUNO SIMONE

An RFID enabled cold storage device, notably a vaccine storage device, has a cold storage compartment separated from an ice lining by a thermal barrier. The thermal barrier comprises a layer of thermal insulation

material and a planar temperature distributing metal sheet, with the planar temperature distributing metal sheet providing an RFID antenna.

43.202503395 10POLYNUCLEOTIDE VACCINE FORMULATIONS AND METHODS OF USING THE SAME

US - 06.11.2025

Clasificación Internacional A61K 39/215Nº de solicitud 18854353Solicitante IMUNON, INC.Inventor/a Carlo IAVARONE

Disclosed herein are immune stimulatory compositions, pharmaceutical compositions, and vaccines comprising a polynucleotide comprising at least one antigen nucleic acid which encodes at least one pathogen protein or an antigenic fragment thereof, wherein the antigen nucleic acid is operably linked to a first promoter; a delivery component selected from the group consisting of a cationic polymer, a poly-inosinic-polycytidylic acid, a poloxamer, or derivative thereof; and an adjuvant comprising an aluminum or aluminum-salt based adjuvant, a stimulator of interferon genes (STING) agonist, or a combination thereof. Methods of production and therapeutic use of the same are also disclosed herein.

44.WO/2025/232734PORCINE CIRCOVIRUS TYPE 3 CAP PROTEIN AND RELATED PRODUCT THEREOF

WO - 13.11.2025

Clasificación Internacional C12N 15/34Nº de solicitud PCT/CN2025/092883Solicitante PULIKE BIOLOGICAL ENGINEERING, INC.Inventor/a TIAN, Kegong

The present application relates to the technical field of veterinary biological products, and particularly provides a porcine circovirus type 3 (PCV3) Cap protein and a related product thereof. The PCV3 Cap protein is an NLS region 8-16aa truncated Cap protein. The amino acid sequence of the Cap protein is as shown in SEQ ID NO: 2. The present application further provides a PCV3 virus-like particle antigen, which is the PCV3 Cap protein. The Cap protein is expressed at a higher level. A vaccine prepared from the antigen exhibits strong immunogenicity and provides excellent protective efficacy.

45.WO/2025/231288HSV VECTORS HAVING IMPROVED SAFETY PROFILES

WO - 06.11.2025

Clasificación Internacional C12N 15/00Nº de solicitud PCT/US2025/027368Solicitante VIRADIGM, INC.Inventor/a MULVEY, Matthew

Disclosed are improved Disabled Infectious Single Cycle (DISC) Herpes Simplex Virus (HSV) and their uses in the treatment of cancer or as a vaccine. Also disclosed are improved methods of making DISC HSV.

46.WO/2025/232927DIFFERENCE QUANTIFICATION COMPARISON METHOD FOR ADAPTIVE IMMUNE SYSTEM, AND USE THEREOF

WO - 13.11.2025

Clasificación Internacional C12Q 1/6883Nº de solicitud PCT/CN2025/095859Solicitante NANJING UNIVERSITY OF CHINESE MEDICINEInventor/a CAO, Peng

Provided are a difference quantification comparison method for an adaptive immune system, and the use thereof. The method comprises obtaining at least one of a BCR heavy chain sequence of a B cell, a BCR light chain sequence of the B cell and a TCR β chain sequence of a T cell of a sample to undergo comparison, and sequencing same; comparing the determined sequence with a gene sequence in the IMGT database to obtain sequence annotation information of the corresponding sequence, and further constructing a 3D graph displaying the adaptive immune condition of the sequence; then by means of using a minimum transformation cost method, quantifying an immune state difference between samples to be tested and between a sample to be tested and the database that has undergone the test. The method for quantifying immune differences can be used for evaluating the immune state of biological samples, and can also be used for evaluating influences of various therapy and intervention methods on the immune system, so as to judge the effects of the therapies and interventions, including but not limited to the drug efficacy, the vaccine efficacy, etc.

47.20250340580TETRASACCHARIDES FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF MELIOIDOSIS AND GLANDERS

US - 06.11.2025

Clasificación Internacional C07H 15/08Nº de solicitud 19209117Solicitante INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventor/a Charles GAUTHIER

A tetrasaccharide of formula I and a method of production thereof are provided. Furthermore, a conjugate comprising the tetrasaccharide and a molecule attached to the tetrasaccharide, preferably via its amine group, is also provided. Compositions, preferably immunogenic or vaccine compositions, comprising this tetrasaccharide or this conjugate are also provided. Such tetrasaccharides, conjugates, and compositions can be used for preventing or treating a disease caused by a *Burkholderia* infection in a subject, for inducing the production of anti-*Burkholderia* antibodies in a subject, or for diagnosing a *Burkholderia* infection in a subject. Preferably, the *Burkholderia* infection is an infection by *Burkholderia pseudomallei* (Bp) or *Burkholderia mallei* (Bm); the disease is melioidosis or glander; and/or the anti-*Burkholderia* antibodies are anti-*Burkholderia pseudomallei* (Bp) antibodies or anti-*Burkholderia mallei* (Bm) antibodies.

48.2025256140EIMERIA VACCINE

AU - 06.11.2025

Clasificación Internacional Nº de solicitud 2025256140Solicitante Eimeria Pty LtdInventor/a KOSARAJU, Sarika

49.20250345412CORONAVIRUS VACCINE

US - 13.11.2025

Clasificación Internacional A61K 39/215Nº de solicitud 18269108Solicitante The Univesity of Melbourne Grattan StreetInventor/a Dale Ian Godfrey

The present invention relates to chimeric and fusion proteins and their compositions, and the use of such proteins and compositions in the prevention and/or treatment of coronavirus infections, or respiratory diseases or conditions associated with coronavirus infections.

50.202503395125ELF-CLEAVING POLYPROTEINS AND USES THEREOF

US - 06.11.2025

Clasificación Internacional A61K 39/29Nº de solicitud 18294900Solicitante The University of MelbourneInventor/a Joseph Torresi

Disclosed herein are vaccine constructs for producing a virus-like particle (VLP) capable of raising an immune response to an immunogen, and uses thereof, wherein the constructs comprise nucleic acid sequences encoding an immunogen and a polyprotein, wherein the polyprotein comprises two or more viral structural proteins, wherein at least two of the two or more viral structural proteins are separated by a signal peptidase sequence such that, when the polyprotein is expressed in a host cell, the signal peptidase sequence undergoes host cell peptidase-dependent cleavage to liberate the two or more viral structural proteins, thereby allowing the liberated structural proteins to self-assemble into a VLP carrying the immunogen.

51.20250345408BCG VACCINATIONS FOR PREVENTION OF COVID-19 AND OTHER INFECTIOUS DISEASES

US - 13.11.2025

Clasificación Internacional A61K 39/04Nº de solicitud 18027696Solicitante The General Hospital CorporationInventor/a Denise L. FAUSTMAN

The invention relates, in part, to a method for the prophylactic treatment of a coronavirus infection in a human adult subject comprising administering at least two doses of a Bacillus Calmette-Guerin (BCG) vaccine to the subject, wherein the subject is a type I diabetic.

52.20250339458USES OF MODIFIED RNA ENCODING RETINALDEHYDE DEHYDROGENASE

US - 06.11.2025

Clasificación Internacional A61K 31/7115Nº de solicitud 19273379Solicitante President and Fellows of Harvard CollegeInventor/a Ulrich H. von Andrian

Some aspects of this disclosure provide modified mRNA (modRNA) encoding retinaldehyde dehydrogenase (RALDH) enzyme, in addition to methods of synthesis, administration, use, and treatment. In some embodiments, the modRNA may be used in a vaccine to treat infections (e.g., mucosal infections) and/or cancers (e.g., mucosal cancers).

53.4644552POLYNUKLEOTIDMOLEKÜL ZUR PRÄVENTION ODER BEHANDLUNG VON HPV-INFEKTIONSBEDINGTEN ERKRANKUNGEN

EP - 05.11.2025

Clasificación Internacional C12N 15/62Nº de solicitud 23910686Solicitante RINUAGENE BIOTECHNOLOGY CO LTDInventor/a CEN SHAN

The present application relates to a polynucleotide molecule that can be used for preventing or treatment HPV infection-related diseases, and a pharmaceutical product, a pharmaceutical composition, or an mRNA vaccine comprising said polynucleotide.

54.3040541ICE-LINED VACCINE REFRIGERATOR

ES - 03.11.2025

Clasificación Internacional A61J 1/16Nº de solicitud 19742747Solicitante B Medical Systems S.à r.l.Inventor/a RIES, Gilles

55.WO/2025/230306NOVEL PURINE DERIVATIVE AND USE THEREOF

WO - 06.11.2025

Clasificación Internacional C07D 473/16Nº de solicitud PCT/KR2025/005851Solicitante GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGYInventor/a AHN, Jin Hee

The present invention relates to a novel purine derivative compound and a composition for enhancing an immune response comprising same as an active ingredient. The compound of the present invention not only has a nanomolar EC_{50} value for TLR7, which is an intracellular membrane receptor of immune cells, but also has high selectivity for TLR7 compared to TLR8, which has a similar structure and is mainly distributed in the endoplasmic reticulum (ER), thereby being able to induce sustained immune activation. Therefore, the compound of the present invention can be effectively used as an efficient vaccine adjuvant composition against various RNA viruses including influenza virus, SARS-CoV-2, and hepatitis C virus.

56.20250348617SECURE MESSAGING IN A MACHINE LEARNING BLOCKCHAIN NETWORK

US - 13.11.2025

Clasificación Internacional G06F 21/62Nº de solicitud 19219930Solicitante LedgerDomain Inc.Inventor/a Victor Bovee Dods

Multi-layer ensembles of neural subnetworks are disclosed. Implementations can classify inputs indicating various anomalous sensed conditions into probabilistic anomalies using an anomaly subnetwork. Determined probabilistic anomalies are classified into remedial application triggers invoked to recommend or take actions to remediate, and/or report the anomaly. Implementations can select a report type to submit, or a report recipient, based upon the situation state, e.g., FDA: Field Alert Report (FAR), Biological Product Deviation Report (BPDR), Medwatch, voluntary reporting by healthcare professionals, consumers, and patients (Forms 3500, 3500A, 3500B, Reportable Food Registry, Vaccine Adverse Event Reporting System (VAERS), Investigative Drug/Gene Research Study Adverse Event Reports, Potential Tobacco Product Violations Reporting (Form 3779), USDA: APHIS Center for Veterinary Biologics Reports, Animal and Plant Health Inspection Service: Adverse Event Reporting, FSIS Electronic Consumer Complaints, DEA Tips, Animal Drug Safety Reporting, Consumer Product Safety Commission Reports, State/local reports: Health Department, Board of Pharmacy.

57.WO/2025/231560VACCINE TO MOBILIZE B CELLS FOR THERAPY

WO - 13.11.2025

Clasificación Internacional C07K 19/00Nº de solicitud PCT/CA2025/050669Solicitante THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTOInventor/a AUNG, Aereas

An antigen (Ag) that elicits a polyclonal T cell receptor like antibody response from endogenous B cells. The Ag comprises a single chain peptide MHCI (pMHCI) complex, that directs B cell responses to the displayed peptide without reactivity to the rest of the pMHCI molecule. Also, methods of using the Ag to induce polyclonal

T cell receptor like (TCRL) antibodies (Abs) and using the Ag to deliver the single chain peptide to a target cell.

58.20250345415SARS-COV-2 VACCINE CONSTRUCTS

US - 13.11.2025

Clasificación Internacional A61K 39/215Nº de solicitud 19277129Solicitante Rutgers, the State University of New JerseyInventor/a Stephen Anderson

The present disclosure describes, inter alia, fusion polypeptides comprising a SARS-CoV-2 Spike polypeptide fragment comprising at least a portion of the N-terminal domain, domains CD1, RBM, and CD2, and at least a portion of CTD1, wherein the N- or C-terminus of the Spike polypeptide fragment is fused to a heterologous N- or C-terminal tag comprising at least two, at least three, or at least four amino acids, as well as polynucleotides and vectors expressing such fusion polypeptides, pharmaceutical compositions comprising the polypeptides or polynucleotides encoding them, host cells for their production, and methods of using such pharmaceutical compositions as vaccines or for generation of antibodies.

59.4643850NUKLEINSÄUREFREISETZUNGSTRÄGER, HERSTELLUNGSVERFAHREN DAFÜR UND VERWENDUNG DAVON

EP - 05.11.2025

Clasificación Internacional A61K 9/16Nº de solicitud 23909780Solicitante CANSINO SHANGHAI BIOLOGICAL RES CO LTDInventor/a WANG HAOMENG

A lipid nanoparticle composition, a preparation method therefor, and use thereof in nucleic acid delivery. An mRNA drug or vaccine can be prepared on the basis of the lipid nanoparticle composition. The starting materials of the lipid nanoparticle composition comprise an ionizable cationic lipid, an auxiliary phospholipid, a sterol compound, a lipid polyethylene glycol conjugate, and a buffer.

60.3041285A VACCINE FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF A DISEASE

ES - 11.11.2025

Clasificación Internacional C07K 14/005Nº de solicitud 19765206Solicitante InProTher ApSInventor/a HOLST, Peter

61.2025904986A NOVEL APPROACH TO TREATMENT OF PERSISTENT & ASSOCIATED AUTOIMMUNE ILLNESS RELATING TO LONG COVID & POST ACUTE COVID19 VACCINE SYNDROME

AU - 06.11.2025

Clasificación Internacional Nº de solicitud 2025904986Solicitante Tal, MelissaInventor/a Tal, Melissa

62.20250339506COMPOSITIONS FOR USE IN TREATMENT OF CHLAMYDIA

US - 06.11.2025

Clasificación Internacional A61K 39/118Nº de solicitud 19046019Solicitante SANOFI PASTEURInventor/a Nadège ARNAUD BARBE

This invention relates to compositions (e.g., vaccine compositions) which can be used to immunise against *Chlamydia* infections. The compositions comprise *Chlamydia* sp. antigens and antigen combinations which can be used to immunise against *Chlamydia* sp., used in the form of nucleic acids (e.g., mRNAs) encoding antigenic proteins or in the form of recombinant protein antigens.

Patentes registradas en United States Patent and Trademark Office (USPTO)

Estrategia de búqueda: *vaccine.ti. AND @PD>="20251103"<=20251117 22 records*

Document ID	Title	Inventor	Applicant Name
US 20250345413 A1	SARS-COV-2 SUBUNIT VACCINE	GATTINGER; Pia et al.	VIRAVAXX AG
US 20250345412 A1	Coronavirus Vaccine	Godfrey; Dale Ian et al.	The Univesity of Melbourne Grattan Street
US 20250345414 A1	ADENOVIRAL VECTOR-BASED VACCINE FOR EMERGING VIRUSES	Maggini; Norberto Julián et al.	THERAVAX, INC.,FUNDACION INSTITUTO LELOIR,CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICET)
US 20250345372 A1	USE OF DOPAMINE PRODUCING PRODUCTS TO INCREASE VACCINE EFFICACY	Lyte; Mark	Iowa State University Research Foundation, Inc.
US 20250345409 A1	COMPOSITIONS AND METHODS FOR THERAPEUTIC OR VACCINE DELIVERY	FISCHER-LOUGHEED; Jacqueline et al.	GenVivo, Inc.
US 20250345407 A1	NUCLEIC ACID BASED VACCINE ENCODING AN ESCHERICHIA COLI FIMH ANTIGENIC POLYPEPTIDE	ADAMO; Roberto et al.	CureVac SE
US 20250345415 A1	SARS-CoV-2 Vaccine Constructs	Anderson; Stephen et al.	Rutgers, the State University of New Jersey

US 20250345286 A1	COMPOSITE LIPID NANOPARTICLE AND PREPARATION METHOD THEREOF, RNA VACCINE, DRUG AND USE	Cao; Yuhong et al.	Bisheng (Beijing) Biotechnology Co., Ltd.
US 12465634 B2	Use of trimanganese tetraoxide particles in preparation of vaccine adjuvant	Wang; Yaling et al.	Guangzhou Realbenefitspot Pharmaceutical Co., Ltd.
US 20250339509 A1	IMMUNOGENIC CONSTRUCTS AND VACCINES FOR USE IN THE PROPHYLACTIC AND THERAPEUTIC TREATMENT OF INFECTIOUS DISEASES	Fredriksen; Agnete Brunsvik et al.	Nykode Therapeutics ASA
US 20250339514 A1	SINGLE-AND MULTI-EPITOPE PEPTIDE AND MRNA VACCINES TO GENERATE TOLEROGENIC EFFECTS FOR ALLERGIC AND AUTOIMMUNE DISEASE BY TARGETING LIVER SINUSOIDAL ENDOTHELIAL CELLS	Nel; Andre E. et al.	The Regents of the University of California
US 20250339369 A1	Neoepitope Vaccine Delivery Vehicle and Methods of Making the Same	Liu; Philip T. et al.	ImmunityBio, Inc.
US 20250339510 A1	POLYNUCLEOTIDE VACCINE FORMULATIONS AND METHODS OF USING THE SAME	IAVARONE; Carlo et al.	IMUNON, INC.
US 20250339504 A1	CANCER VACCINE WITH USE OF COMMON CANCER ANTIGEN COCKTAIL, TCR/CAR-T CELL THERAPEUTIC, COMPANION DIAGNOSTIC METHOD, AND METHOD FOR DIAGNOSING RISK OF CANCER ONSET BY DETECTING CIRCULATING TUMOR CELLS	NAKATSURA; Tetsuya et al.	National Cancer Center

US 20250339517 A1	LIPID NANOCARRIER VACCINE	SARKAR; Sampa et al.	ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY
US 20250339511 A1	NUCLEIC ACID VACCINE AGAINST MONKEYPOX VIRUS AND USE THEREOF	GAO; Fu et al.	INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES
US 20250339507 A1	MRNA VACCINE FOR BANDAVIRUS DABIEENSE AND PREPARATION METHOD THEREOF	LIU; Xinjian et al.	NANJING MEDICAL UNIVERSITY,Pharmaceutical Industry Technology Research Institute of Nanjing Medical University
US 20250342906 A1	EPITOPE AND IMMUNOGEN DESIGN FOR DEVELOPMENT OF VACCINES, DIAGNOSTICS, AND IMMUNOTHERAPEUTICS	Chowdhury; Ratul et al.	Iowa State University Research Foundation, Inc.
US 20250340601 A1	RECOMBINANT FLAVOBACTERIUM COVAE PROTEIN VACCINES	LANGE; MILES D	The United States of America, as Represented by the Secretary of Agriculture
US 20250339505 A1	IMMUNOGENICITY OF PLASMODIUM VIVAX CIRCUMSPOROZOITE PROTEIN NANOPARTICLE VACCINES	NTUMNGIA; Francis et al.	UNIVERSITY OF SOUTH FLORIDA
US 12458690 B2	African swine fever virus vaccine	Willemsen; Petrus Theodorus Johannes et al.	Stichting Wageningen Research
US 12459990 B2	Anti-HIV vaccine antibodies with reduced polyreactivity	Sievers; Stuart A. et al.	California Institute of Technology,The Rockefeller University

***NOTA ACLARATORIA**: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.*

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.
Claudia Camejo Salas ccamejo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu

FINLAY EDICIONES